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Abstract 
 
Mucosal vaccines are attracting increasing amounts of attention because of 
their ability to stimulate immune responses mucosally at the site of pathogen 
entry as well as systemically. Bacillus subtilis produces spores that are ~1 µM in 
size and can be modified to carry antigens on the surface, either by binding 
directly or by genetic modification, and have previously been tested as a 
vaccine adjuvant. The aim of this thesis was to further investigate the suitability 
of B. subtilis spores as a mucosal vaccine adjuvant. As an adjuvant carrying 
Mycobacterium tuberculosis (MTB) antigens (MPT64 and Ag85B-Acr), B. 
subtilis spores were able to demonstrate immunogenicity by stimulating Th1 
cytokine production and provided some degree of protection against MTB 
challenge in the mouse model. The adjuvant behaviour of spores and initial 
interactions with host immune cells were investigated. Autoclaved spores were 
found to interact with different cells to live spores, which was hypothesised to be 
due to damage to the spore surface proteins prohibiting interactions with cell 
pattern recognition receptors. The cells that spores interacted with appeared to 
be dependent on tissue and dosing route and may highlight the differing roles of 
the lungs, gut and NALT in processing foreign material. The innate immune 
responses that were examined after nasal dosing demonstrated that spores 
could activate innate immune responses in the lungs and lymphoid tissue, and 
suggested that they were able to stimulate dendritic cells that could act as 
antigen presenting cells to activate adaptive immunity. In conclusion, the data 
generated provided further evidence on the utility of spores as a mucosal 
vaccine adjuvant and provided an insight into how they are able to stimulate 
immune responses.    
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Ig  Immunoglobulin 
IGRA  Interferon-gamma Release Assay 
IL  Interleukin 
IP  Intraperitoneal 
IPTG  Isopropyl β—D-thiogalactopyanoside 
KCl  Potassium Chloride 
kDa  Kilodaltons 
L  Litre 
L  Ligand 
LB  Luria Bertani 
LF  Lethal Factor 
LN  Lymph node 
LPS  Lipopolysaccharide 
Ly6G  Neutrophil marker 
LT  E. coli Labile Toxin 
M  Macrophage 
M cell  Microfold cell 
MAC  Membrane Attack Complex 
MALT  Mucosal associated lymphoid tissue 
MAPK  Mitogen-activated protein kinase 
MCP  Monocyte Chemoattractant Protein 
Laura Sibley                                                                                                                             Abbreviations 
22 
MDG  Millennium Development Goals 
MDR  Multi-Drug Resistant 
mg  Milligram 
ml  Millilitre 
MHC  Major Histocompatibility Complex 
MLN  Mesenteric lymph node 
MTB  Mycobacterium tuberculosis 
MVA  Modified Vaccinia Ankara 
Mwt  Molecular weight 
MyD88 Myeloid differentiation primary response gene 
N  Neuraminidase 
NaCl  Sodium Chloride 
NADPH Nicotinamide adenine dinucleotide phosphate 
NALT  Nasal associated lymphoid tissue 
NBF  Neutral Buffered Formalin 
NHP  Non-Human Primate 
NHS  National Health Service 
NIAID  The National Institute of Allergy and Infectious Diseases 
NK  Natural Killer 
OD  Optical density 
OVA  Ovalbumin 
p  Probability 
PAMP  Pathogen Associated Molecular Pattern 
PBS  Phosphate buffered saline 
PE  Phycoerythrin 
PerCP Peridinin chlorophyll 
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pET  Plasmid Expression vector, T7 promoter 
PDGF  Platelet-derived growth factor 
pg  Picogram 
pg  Page 
PGE  Prostaglandin 
PI  Propidium Iodide 
PLGA  Poly(lactic-co-glycolic acid) 
PMA  Phorbol 12-myristate 13-acetate 
PPD  Purified Protein Derivative 
PRR  Pattern Recognition Receptor 
psi  Pound per square inch 
PVDF  Polyvinylidene fluoride 
r  Recombinant 
r  Regression 
R  Receptor 
RAW264.7 Murine macrophage cell line 
RD  Region of Difference 
RER  Rough Endoplasmic Reticulum 
RHUL  Royal Holloway University of London 
RNA  Ribonucelic Acid 
ROS  Reactive Oxygen Species 
rpm  Rotations per minute  
RT  Room temperature 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
Rv  Tuberculosis genes identified and classified in strain H37Rv 
SD  Standard deviation 
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SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SFU  Spot forming units 
SGUL  St. Georges Medical School, University of London 
sIgA  Secretory IgA 
SPICE Simplified Presentation of Incredibly Complex Evaluations 
SSC  Side Scatter 
SWAN South-West Alliance Network 
TAP  Transporter Associated with Antigen Processing 
TB  Tuberculosis 
TBS  Tris buffered saline 
Tc  T cytotoxic lymphocyte 
TCR  T-cell Receptor 
Tfh  T follicular helper lymphocyte 
TGFβ1 Transforming growth factor beta1 
Th  T helper lymphocyte  
TLR  Toll-like receptor 
TNF  Tumour necrosis factor 
TO  Thiazole Orange 
Tregs  Regulatory T-cells 
TRITC Tetramethyl rhodamine iso-thiocyanate 
TSLP  Thymic stromal lymphopoietin 
TST  Tuberculin Skin Test 
TTFC  Tetanus toxin fragment C 
UK  United Kingdom 
USA  United States of America 
UV  Ultraviolet 
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v/v  Volume per volume 
VLP  Virus Like Particles 
vs  Versus 
WHO  World Health Organisation 
w/v   Weight per volume 
γδ  Gamma-delta: A subset of T-cells 
µg  Microgram 
µl  Microlitre  
%  Percent  
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Chapter 1: Introduction 
1.1. Tuberculosis 
A third of the world’s population is estimated to be infected with Tuberculosis 
(WHO 2014c) and the WHO reported almost nine million cases and two million 
deaths from TB worldwide in 2011 (WHO 2011). M. tuberculosis (MTB) is the 
primary cause of TB disease in humans, although other species such as M. 
bovis can cause disease occasionally. MTB is an aerobic bacillus, characterised 
by a waxy lipid rich outer coat and a very slow replication rate (16-20 hours) 
(Todar 2012).  
1.1.1. Diagnosing disease 
The traditional diagnostic methods for TB include X-ray and computerised 
tomography (CT) scanning of the lungs for tissue damage, and the sputum 
smear test where a sputum sample is stained with a Ziehl-Neelson acid fast 
stain and examined under the microscope (Todar 2012). Because of the lipid 
rich wall of MTB, the Gram stain used for basic bacterial strain identification is 
unable to stain MTB. The Tuberculin Skin Test (TST) uses a range of TB 
proteins injected subcutaneously to determine if the immune system is primed 
for TB, by looking for inflammation (Gideon & Flynn 2011). However, it does not 
distinguish between individuals infected with TB and those vaccinated with BCG 
but currently the tuberculin skin test is used to determine whether an individual 
requires a BCG vaccination. IFNγ release assays (IGRA) can also be used for 
diagnosis as they take advantage of the region of difference (RD1) between 
MTB and BCG using proteins ESAT-6 and CFP-10, which are not present in 
BCG to diagnose infection with MTB (Gideon & Flynn 2011). No assay is 
available yet that can differentiate between active and latent disease. 
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1.1.2. Disease 
There are three main outcomes of TB disease, which depend on the balance 
between host immune response and MTB replication; primary disease, latency 
and reactivation. Primary disease generally occurs within two years of 
encountering MTB but is relatively rare. Here, MTB multiplies and spreads 
through the lung causing tissue damage leading to the symptoms of weight loss 
and haemoptysis. During primary disease, induction of an inflammatory 
response and actively replicating MTB, mean that an individual is positive in the 
sputum smear test and IFNγ release assay (Gideon & Flynn 2011).  
Latent disease occurs when the primary immune response is unable to clear 
MTB resulting in encapsulation in a granuloma (also known as a tubercule) so 
as to isolate the bacteria. The granuloma consists of macrophages, T-cells, B-
cells, neutrophils and fibroblasts that wall off MTB and form a stratified structure 
to prevent disease spread (Gideon & Flynn 2011). However, there are several 
types of granuloma, including caseous, mineralised and non-necrotising, which 
are characteristic of either latent or active disease and are indicative of how well 
the immune system is coping to contain the infection. For example, the 
mineralised granuloma is associated with latent disease, whilst caseous is more 
characteristic of active TB (Lin et al. 2009). MTB is thought to enter a slow or 
non-replicating persistent phase of growth inside the granuloma (Hampshire et 
al. 2004). However, this is debated because Isoniazid, a drug that targets cell 
wall synthesis, is effective in reducing reactivation in latent cases, which 
suggests that some bacteria are actively replicating (Schechter et al. 2006). 
Live MTB has also been reportedly isolated from granulomas of autopsies of 
individuals that died from other causes (Loring et al. 1955). Individuals with 
latent disease have no symptoms and no bacteria are isolated from sputum 
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smears due to the bacteria being trapped in the granuloma, but they test 
positive in the TST or IGRA immunoassay as they have mounted a cellular 
immune response (Gideon & Flynn 2011).  
Reactivation, leading to post primary disease can occur many years after 
infection, and may be due to the individual subsequently becoming 
immunocompromised. Evidence for this comes from observations that 
individuals undergoing arthritis treatment using anti-TNFα antibodies and those 
with human immunodeficiency virus (HIV) are more likely to have reactivation of 
MTB disease (Keane 2004; Selwyn et al. 1989), which suggests that a 
sustained immune response is required to control MTB pathogenesis. After 
reactivation, the granulomas break down and cause cavitation and tissue 
damage that can then spread the bacteria to other organs and cause further 
injury (Nasser Eddine et al. 2006). 
Although disease can be characterised, the groupings are very heterogeneous 
and can be viewed as a dynamic spectrum of disease. Markers for 
distinguishing between active and latent disease have not been discovered, 
which makes monitoring persons at risk of developing disease and spreading 
MTB difficult (Gideon & Flynn 2011). 
1.1.3. Immune responses to Tuberculosis 
1.1.3.1. Primary infection and the innate immune response 
The innate immune response is non-specific and can be activated quickly to 
prevent infections. The innate immune system includes barriers such as the 
skin and mucous membranes, as well as phagocytes, antimicrobial proteins and 
inflammation.  
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MTB is spread by the aerosol route, in droplets exhaled from infected 
individuals (Todar 2012). Once MTB enters the lungs, the surface proteins 
interact with pattern recognition receptors (PRRs) such as toll-like receptors 
(TLRs). There are several types of TLRs that exist on host cells that have 
specificities for different ligands, for example TLR2 binds to peptidoglycan found 
in Gram positive bacteria. Once activated, transcriptional regulators that control 
cytokine production are upregulated and phagocytosis can be instigated. TLR2, 
TLR4 and TLR9 have been implicated in MTB infection, because knock-out 
mice were shown to be more susceptible to MTB infection (Korbel et al. 2008). 
Other PRRs include scavenger receptors, Fc receptors and mannose binding 
receptors (Aderem & Underhill 1999). 
Complement proteins are also part of the innate immune response and are 
constantly in circulation. Once activated, the complement cascade is activated 
that causes a series of hydrolysis reactions of other complement proteins, which 
can lead to the generation of a membrane attack complex (MAC) that forms a 
pore in the bacterial membrane causing lysis. Complement protein C3 can also 
bind bacteria and act as an opsonin to activate phagocytosis. Complement has 
been demonstrated to bind to MTB, which can initiate phagocytosis by 
macrophages (Ferguson et al. 2004). However, in C3 knock out mice, disease 
burden was the same as in control mice and it was hypothesised that alternative 
receptors would still be able to activate phagocytosis of MTB (Hu et al. 2000).  
Once the bacterium is inside the macrophage, the phagosome fuses with a 
lysosome to form the phagolysosome, where upon degradative enzymes can 
attack the bacteria. Macrophages also produce reactive oxygen species (ROS) 
that can cause damage to bacteria (Aderem 2003). However, MTB is able to 
avoid degradation and will actively proliferate inside macrophages (Ehrt & 
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Schnappinger 2009). MTB are able to resist successful phagocytosis through a 
number of mechanisms; i) MTB produces enzymes including superoxide 
dismutases, catalases and antioxidants that detoxify the reactive oxygen 
species within the macrophage phagolysosome, ii) MTB has DNA repair 
enzymes that fix any damage resulting from ROS (Ehrt & Schnappinger 2009), 
iii) MTB is able to arrest phagosome maturation and reduce acidity, therefore 
delaying killing. The host immune response is important here because IFNγ 
produced by T-cells can influence the phagosome to become acidic, iv) the 
thick waxy coat of MTB adds to its resistance against acidic conditions by 
preventing entry of protons into the cell (Ehrt & Schnappinger 2009), v) MTB 
can also inhibit antigen presentation and promote release of anti-inflammatory 
mediators to aid its escape (Andersen & Woodworth 2014).    
DCs are also activated by TLR interactions with MTB. They also phagocytose 
the bacteria, but the phagosome is less destructive than macrophages because 
the main role of DCs is as an antigen presenting cell (APC) (Savina & 
Amigorena 2007). The peptides from the bacteria are exposed on the surface of 
the cell via an MHCII complex, which can interact with T-cells after migrating to 
the lymph nodes and provides the bridge between the innate and adaptive 
immune systems(Andersen & Woodworth 2014). It takes between eight to ten 
days for delivery of MTB to the lymph nodes after aerosol infection (Blomgran & 
Ernst 2011).  
There is an influx of neutrophils to the lungs after MTB infection and these 
neutrophils will phagocytose MTB. The neutrophils will then be taken up by 
macrophages, which enhances the macrophages killing ability by utilising the 
neutrophil granules that contain degradative enzymes (Tan et al. 2006). 
Neutrophils can also enhance DC maturation because apoptotic neutrophils are 
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phagocytosed by DCs which can cross-present the antigens to stimulate the T-
cell response (Alemán et al. 2007). MTB can prevent cross presentation of 
antigens by DCs so as to delay the T-cell response, allowing MTB time to 
replicate and establish infection. This is achieved by inhibiting prostaglandin 2 
(PGE2) in the neutrophil, which is involved in mitochondrial membrane integrity 
and leads to necrosis of the infected neutrophil, preventing apoptosis, therefore 
decreasing uptake of apoptotic bodies containing MTB by DCs (Chen et al. 
2008).  
NK cells are another set of cells involved in the innate immune response, which 
act by directly killing infected cells by using perforin to make holes in the 
membranes and granzymes that cause lysis or apoptosis. NK cells recognise 
diseased cells by forming synapses with cells and can recognise changes in 
inhibitory ligands and MHCI expression. DCs at the site of infection produce IL-
12 and IL-18, which stimulate NK cells to release IFNγ that can activate 
macrophage phagocytic activity and improve killing of the bacteria (Andersen & 
Woodworth 2014). However, studies by Junqueira-Kipnis et al showed that 
although NK cells were recruited to the lungs after MTB infection in mice, but 
when NK cells were depleted there was no effect on disease progression 
(Junqueira-kipnis et al. 2003). 
1.1.3.2. Adaptive immunity 
The adaptive immune response is a specific immune response and takes longer 
to develop than the innate response. The adaptive response is important 
because memory can develop which means that a faster response can be 
mounted against a repeat exposure from the pathogen. The adaptive immune 
system is comprised of the cellular and humoral arms; T-cells are part of the 
cellular response and there are many different subtypes that have a variety of 
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different roles, including producing cytokines to activate other cell types. B-cells 
are part of the humoral immune response and responsible for the production of 
antibodies, that can recognise pathogens after a repeat exposure. 
1.1.3.2.1. T-cells 
It is widely recognised that a T-cell response is important in controlling MTB 
infection, especially T-helper cells (Th), although Tc, Th17 and Tregs have been 
implied to have a role. Th cells are characterised by the CD4+ ligand and 
circulate as naïve cells until activated, by interaction with antigen presented by 
an MHCII ligand on an APC. The two main Th subsets are Th1 and Th2 cells. 
Th1 cells are characterised by producing pro-inflammatory cytokines including 
IFNγ, TNFα and IL-2, whereas Th2 cells are anti-inflammatory and produce 
cytokines IL-4, IL-5 and IL-10 (Kidd 2003).  
Evidence for the importance of T-helper CD4+ cells comes in part from HIV 
infected individuals, who have a decreased number of CD4+ cells and are far 
more susceptible to TB. TB is the biggest killer among those with HIV (Kalsdorf 
et al. 2009) and it is reported that approximately 20% of individuals infected with 
MTB are co-infected with HIV, ranging from 6.2% in Europe to 40% in Africa 
(WHO 2014a). After retroviral therapy for HIV, CD4+ counts increase and 
susceptibility to TB decreases, which further supports the essential role of 
CD4+ T-cells in controlling TB infection (Gideon & Flynn 2011). Th1 cytokines 
such as IFNγ have been shown to be essential in controlling MTB disease 
progression, and IFNγ knock-out mice are very susceptible to TB (Di 
Pietrantonio & Schurr 2005). This is because IFNγ classically activates 
macrophages and influences formation of the granuloma structure to control the 
MTB infection (Ehrt & Schnappinger 2009). However, IFNγ production alone 
does not correlate with protection and may actually correlate better with 
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bacterial load (Abebe et al. 2006). Evidence for this comes from studies that 
showed that mycobacterial inhibition by BCG vaccinated individuals did not 
correlate with IFNγ production and that mice with depleted IFNγ could control 
TB by CD4+ cells using other mechanisms including reactive nitrogen species 
(Abebe 2012). Other Th1 cytokines that are considered to have a part in MTB 
control are IL-2 and TNFα. IL-2 is thought to enhance memory cell development 
(Malek & Castro 2010) and TNFα is a proinflammatory cytokine and those with 
arthritis taking treatment to inhibit TNFα production are more susceptible to TB 
(Lin et al. 2010). Polyfunctional T-cells, producing more than one cytokine 
(IFNγ, TNFα, IL-2) are supposedly better effector cells and are more long lived 
(Kaveh et al. 2011).  
Cytotoxic T-cells (Tc) are characterised by the CD8+ ligand, and interact with 
MHCI presented peptides. MHCI has the potential to be present on all cells, and 
when a cell is infected, pathogens peptides are presented by MHCI to the CD8+ 
T-cell. The Tc can then produce perforin and granzyme B, which enter the cell 
and activate apoptosis (Harty et al. 2000). Tc cells can also activate apoptosis 
by binding to the Fas receptor and stimulating apoptosis pathways (Harty et al. 
2000). Tc cells can produce Th1 cytokines that can activate macrophages and 
neutrophils. including IFNγ, IL-2 and TNFα (Lepone et al. 2010). The 
importance of  Tc cells in MTB control had been suggested by Chen et al that 
demonstrated that primates with depleted CD8+ cells had more severe disease 
than naïve animals (Chen et al. 2009). In adoptive transfer studies in mice, it 
was also demonstrated that when Tc was given to Rag1-/- mice (deficient in B-
cell and T-cells), they had lower bacterial burdens in the spleen when 
challenged with BCG, which suggested that they had a role in preventing 
dissemination of disease (Feng & Britton 2000). 
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Th17 cells are thought to be important in TB infection as it has been shown that 
their presence will accelerate the initial response because IL-17 recruits other 
leukocytes, such as neutrophils to the site of infection and can enhance Th1 
responses (Khader & Cooper 2008; Wareham et al. 2014).  
Tregs regulate inflammation and control the balance of the immune response by 
producing IL-10 and influences Th1 and Th2 cells (Sojka et al. 2008). In non-
human primates (NHP) it has been shown that Tregs are recruited to the 
airways soon after TB infection. It was also found that those NHPs that 
developed latent TB had higher numbers of Tregs before challenge compared 
to those that developed active TB (Gideon & Flynn 2011). This could indicate 
that a controlled, rather than solely proinflammatory response is important in 
modulating disease. 
γδ T-cells are a small T-cell subset that have a γδ T-cell receptor (TCR) rather 
than a conventional αβ TCR. The TCR is involved in antigen recognition when 
presented by the MHC complex. γδ T-cells are unrestricted and do not interact 
with the MHC complex, but instead are activated by microbial phosphoantigens. 
γδ T-cells have been implicated in TB because they increase after infection and 
produce IFNγ, but in knock-out mice studies, the disease progression has been 
similar. γδ T-cells are thought to have an immunoregulatory role and an 
involvement in granuloma formation (Boom 1999).   
1.1.3.2.2. Humoral response 
B-cells produce antibodies that are specific for particular pathogens. B-cells are 
activated in the lymph nodes, in what is known as the germinal centre reaction. 
Once an antigen is brought there by an APC, naïve B-cells proliferate and 
undergo somatic hypermutation to produce antibodies that are high affinity to 
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the antigen. The cells then differentiate into B-cells and plasma cells which 
circulate until activated by pathogen recognition. Antibodies are important for 
immune responses to extracellular pathogens because they recognise and bind 
the pathogen, which then can either activate the complement cascade or 
phagocytosis by opsonising the pathogen and interacting with Fc receptors. 
Since MTB is an intracellular pathogen the humoral response is not considered 
to have a significant role in TB protection and disease progression (Abebe & 
Bjune 2009). Although B-cells have been overlooked, there is some evidence to 
suggest that B-cells are important because B-cell knock out mice were shown to 
have higher bacterial burden than control mice in a study by Vordermeier et al. 
The IFNγ responses were unaffected, and when administered BCG, the 
infection was reduced, implying that the cellular immune response was not 
affected but that B-cells were required for control of infection (Vordermeier et al. 
1996). Passive immunisation using immune sera has also been shown to help 
SCID mice control infection when used as an immunotherapy (Guirado et al. 
2006). 
To summarise, the immune response towards MTB is complex and not 
completely understood. Studies analysing biomarkers of active disease have 
provided clues to what components characterise immune responses to TB 
(Joosten et al. 2013), but what a protective immune response comprises of has 
not been defined, which makes vaccine development difficult.   
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1.1.4. TB vaccines 
1.1.4.1 BCG 
BCG is an attenuated form of M. bovis, which was developed in the early 20th 
century by Calmette and Guérin at the Pasteur Institute in Paris (Behr & Small 
1999). It is the only licensed vaccine for TB and has been in use since the 
1920’s. The use of BCG is promoted by the WHO and 157 countries worldwide 
vaccinate with BCG at birth (Zwerling et al. 2011). There are several different 
strains of BCG in use across the world because they have diverged over time 
from the original stock (Behr & Small 1999).  
BCG appears to be effective in preventing serious disease in children, including 
tubercular meningitis and miliary TB, but whilst BCG can be an effective vaccine 
and is able to induce Th1 responses, the immunity is not sterilising, and only 
helps to control disease (Andersen & Woodworth 2014). Protective ability is 
reduced in adults and appears to decrease over 10-15 years. This is thought to 
be because BCG preferentially stimulates production of terminally differentiated 
effector T-cells rather than memory T-cells (McShane et al. 2012). BCG efficacy 
also varies according to geographical location; in the UK the effectiveness is 
reported to be 80%, whereas in Malawi it is as low as 0% (Black et al. 2002). 
The reasons for this are unclear, but could be due to increased exposure to 
environmental Mycobacteria species in some areas (McShane et al. 2012). 
Other factors that could contribute to this difference geographical efficacy are 
the variation in BCG strain used, and at what age vaccination is given. One 
other reason why BCG shows poor efficacy could be because it is attenuated 
and missing a large number of MTB antigens, which could be important in 
stimulating a relevant immune response (Andersen & Woodworth 2014).  
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BCG is a live vaccine and is generally safe, but for immunocompromised 
persons it can cause disease (Hawkridge & Mahomed 2011). This is particularly 
a problem in areas where AIDS is prevalent and HIV co-infection with TB is an 
issue. 
1.1.4.2. TB Vaccine formulations 
The WHO initiated the ‘Stop TB’ Strategy, which aims to eradicate TB by 2050, 
and one of the goals is to develop novel TB vaccines (WHO 2010). As a result, 
there are many new vaccines under clinical evaluation (Table 1-1), many of 
which are either based on BCG or use BCG in a prime-boost regimen because 
BCG does show some efficacy and is widely used. BCG is able to generate 
cells that are responsive to mycobacterial antigens, but its ability to limit MTB 
growth in the lungs is poor (Cooper 2009). The immune responses to BCG are 
not well understood, so it is unclear how a protective immune response is 
generated, which makes vaccine development in this area difficult (McShane et 
al. 2012).  
BCG has been in use for a long period of time so it is likely that BCG will be 
involved in a new TB vaccination strategy, either as a recombinant form, or 
used in a prime-boost regimen (Figure 1-2). Any completely novel vaccine 
would have to be proven to be more efficacious than and as safe as BCG 
therefore replacing BCG would be challenging. It is estimated that 85% of the 
world are vaccinated with BCG (McShane et al. 2012) and it would be difficult to 
assess what effect a new vaccine would have without the interaction with BCG.  
Many vaccines focus on using a particular MTB antigen to stimulate a specific 
response. The choice of MTB antigen is challenging, and can be based on 
immunogenicity, functional role of the antigen or expression stage during MTB 
infection (Andersen & Woodworth 2014). However, these characteristics do not  
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Table 1-1. Vaccines in clinical trials as reported by the ‘Stop TB’ Partnership (2011). 
 
Phase I Phase II Phase IIb Phase III 
AdAg85A 
McMaster University 
M72-A501 
GSK, Aeras 
MVA85A/AERAS-
485 
OETC, Aeras 
Mw (M. indicus 
pranii (MIP) 
Dept of Biotechnology 
(India), M/s. Cadila 
Hybrid I+CAF01 
SSI, TBVI 
VPM 1002 
Max Plank, Vakzine, 
Projekt Mgmt, TBVI 
AERAS-
402/Crucell Ad35 
Crucell, Aeras 
 
 
Hyvac 4/AERAS-
404+IC31 
SSI, Sanofi Pasteur, 
Aeras, Intercell 
 
Hybrid-1+IC31 
SSI, TBVI, EDCTP, 
Intercell 
  
 
AERAS-422 
Aeras 
 
RUTI 
Archivel Farma, SL 
  
 
TB Vaccines and the companies that are producing and testing them. Phase I trials involve 
small numbers of healthy volunteers to test the safety, Phase II is larger and measures positive 
outcomes in the target group, whereas Phase III are large scale trials and compare the drug or 
vaccine to a placebo and best available treatment (NHS 2014b).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Strategies under investigation to improve BCG immunity. The main strategy is 
to boost Th1 responses (purple). BCG could also be supplemented with other antigens that are 
missing from BCG that would improve the ability of T-cells to recognise MTB (green). 
Supplementation of the T-cell response by enhancing T central memory cells (TCM), Th17 or 
CD8+ cells or improving antibody production could improve the early immune response and 
long-term memory (blue). Adapted from (Andersen & Woodworth 2014) 
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always correlate with the generation of a successful protective immune 
response and it is difficult to find a single antigen, which provides consistent and 
comparable protection to BCG. There are several formats for subunit vaccines 
delivering antigens including DNA vaccines, protein vaccines and viral vectors 
(e.g. adenovirus and MVA) (Checkley & McShane 2011). Other strategies for 
novel TB vaccines are investigating the delivery route of TB antigens and the 
use of mucosal vaccination because TB is a pathogen that primarily affects the 
lungs and stimulating specific immune responses here could be key (White et 
al. 2013; Stylianou et al. 2013). 
One of the major difficulties in TB vaccine discovery is that there is no 
biomarker of protection, which means that TB vaccines require clinical trials to 
assess efficacy in the field because there is no other way of testing protection 
(Hawkridge & Mahomed 2011). However, considerable investigation is being 
undertaken into the immune response to TB, as discussed above and to 
discovering what characterises a defensive memory response. The MVA85A 
boost vaccine, which was developed at Oxford University, has been shown to 
stimulate the production of polyfunctional T-cells, which are considered to be 
important for disease control (Odutola et al. 2012). This vaccine has reached 
Phase IIb clinical trials, but the current study showed no significant benefit in the 
vaccine (Tameris et al. 2013). This illustrates the difficulties of working with TB, 
even after animal studies (Sharpe et al. 2010; White et al. 2013) and clinical 
trials, the vaccine still may not provide significant protection. Clinical studies are 
also long because it can take years for disease to develop and therefore are 
also costly.  
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1.2. Bacillus subtilis  
B. subtilis is a spore forming Gram-positive bacterium from the Bacillus genus. 
The Bacillus genus comprises around 69 species, which can be clustered into 
three or four groups. B. subtilis, B. lichenformis, B. coagulans, B. cereus, B. 
thuringiensis and B. anthracis are all part of one group, and are similar to one 
another according to 16S ribosomal typing (Oggioni et al. 2003). B. subtilis is a 
well characterised Bacillus species and is used as a model prokaryote to 
understand gene regulation of other spore forming bacteria (Nicholson & Setlow 
1990).  
B. subtilis is not a pathogen and is used as a probiotic in animal feed. Probiotics 
are defined as “live microbial feed supplement which beneficially affects the 
animal host by improving its intestinal microbial balance” (AFRC 1989). The 
beneficial outcome of B. subtilis as a probiotic has prompted investigation into 
its positive effects on the immune system and use as a vaccine adjuvant.  
1.2.1. B. subtilis life cycle and spore formation 
B. subtilis exists is a vegetative form when conditions are favourable and 
appears as a rod shaped organism, which can exist in various niches including 
soil, and the mammalian and insect gut (Nicholson 2002; Huynh A. Hong et al. 
2009). During vegetative growth, B. subtilis replicates by binary fission (Figure 
1-3) whereby the chromosomes replicate and the cell grows and divides in the 
middle (Angert 2005). 
Sporulation of B. subtilis is initiated under nutrient limited conditions. The spores 
enter into a dormant phase of the life cycle and develop a proteinaceous coat 
that makes them resistant to heat and chemical assault. In brief, the steps that 
the bacteria undergo to form spores are as follows (Figure 1-3); two copies of  
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Figure 1-2.Schematic of the life cycle of B. subtilis  Binary fission of the vegetative cell by 
replication of the chromosome and division.  Sporulation in nutrient limited conditions. The 
chromosomes stretching between poles, creation of forespore and mother cells and engulfment 
of forespore. Creation of spore and lysis of mother cell to release spore. Germination of spore in 
favourable conditions. Based on (Angert 2005).  
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the chromosome stretch between the poles of the bacteria but cell division 
occurs only at one end of the cell. Part of one chromosome is trapped by the 
division septum, and is packaged into a smaller cell called the forespore. This is 
then engulfed by the larger mother cell, which nurtures and prepares the 
forespore for dormancy. This requires the DNA to be protected, the cell 
cytoplasm to be mineralised and the protective coat to be produced (Angert 
2005). The spore coat itself is created by the forespore and the mother cell. The 
inner coat produced by the forespore has two layers consisting of a germ cell 
wall and the cortex, which is responsible for the dehydrated state of the spore. 
The mother cell creates the outer coat, which also has two layers. Once the 
spore coat has been created, the mother cell lyses to release the spore. The 
creation and assembly of the spore coat is under the regulation of sigma 
factors, which control the timing of the creation and release of the spore. 
Sporulation takes approximately eight hours to complete (Driks 1999). When 
spores return to favourable conditions, they germinate and become vegetative 
cells again (Angert 2005). 
1.2.2. Immune responses to spores and their use as a vaccine adjuvant 
B. subtilis spores have been shown to have adjuvant properties both as killed 
microparticles and as live delivery vehicles (L. H. Duc et al. 2003; Song et al. 
2012). The use of spores as a vaccine was first demonstrated with heat 
attenuated B. anthracis spores to protect against anthrax infection in animals, in 
the 1880’s. B. anthracis spores were found to be protective, but formulations 
gave variable protection and so were discontinued and replaced with an 
acellular vaccine (Turnbull 1991). 
Other particles such as liposomes and nanoparticles have also been 
investigated as vaccine and drug delivery vehicles and adjuvants. The 
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advantage of using microparticles is that they are of a similar size to pathogens 
so they are readily processed by the immune system using the same 
mechanisms. Spores have an advantage over nanoparticles because they are 
bioparticles and their safety is well characterised because of their use as a 
probiotic (Hong et al. 2005; Cutting et al. 2009), whereas nanoparticles are not 
natural and their deposition and pharmacokinetics is not fully understood (Cho 
et al. 2009; Moghimi et al. 2012). Spores would also be an attractive vaccine 
adjuvant because they are heat stable, and therefore would be convenient to 
transport and store (L. H. Duc et al. 2003; Amuguni & Tzipori 2012).  
Spores can be used as a non-recombinant or recombinant antigen delivery 
microparticle. As a non-recombinant vaccine, hydrophobic and electrostatic 
interactions between the B. subtilis spore and antigen of choice provide a stable 
delivery vehicle. Both live and dead spores can be used for this purpose, with 
little difference to the stability or effect (Huang, Hong, et al. 2010; Song et al. 
2012; de Souza et al. 2014). Spores carrying H5N1 Influenza particles have 
been tested in mice and have been found to confer full protection to challenge 
with H5N1 (Song et al. 2012). 
Spores can also be genetically modified to carry heterologous antigens (Duc et 
al. 2004). Antigens can be fused to coat proteins (CotB and CotC are commonly 
used) so that they are surface expressed (Mauriello et al. 2004).  Tetanus Toxin 
Fragment C (TTFC) has been successfully expressed and tested in the mouse 
model and found to provide protection against challenge with tetanus toxin (Le 
H. Duc et al. 2003).  
Although B. subtilis is a model organism and is well characterised genetically, 
the immune responses to B. subtilis are not well known because it is non-
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pathogenic, therefore there has been little interest in its interactions with the 
mammalian immune system. However, B. anthracis is the causative agent of 
anthrax infection, which can be highly pathogenic, so there has been much 
investigation into how B. anthracis causes disease. Because B. anthracis is 
related to B. subtilis, the mechanisms may be similar and information about B. 
anthracis could be used as a guide for B. subtilis interactions. B. anthracis 
spores are taken up by alveolar macrophages (AM) that produce 
proinflammatory cytokines but later in infection, lethal factor (LF) toxin 
production causes immunosuppression and IL-10 is produced by the host which 
then downregulates TNFα and IL-1β (Shetron-Rama et al 2010). The 
macrophages lyse and the bacteria are released into the bloodstream (Guidi-
Rontani et al. 1999), where they cause bacteraemia, leading to oedema, 
haemorrhage and death. DCs containing B. anthracis move to the lymph nodes 
(LN) within five to twelve hours of infection, and this migration is dependent 
upon DCs since DC knockout mice had no bacteria in the lymph nodes 
(Shetron-Rama, et al 2010). Although information about infection with B. 
anthracis can provide some useful guidance as to potential interfaces of B. 
subtilis with the host, they are quite different organisms, as B. anthracis 
produces toxins and has an exosporium, which are thought to be important in 
their adherence and persistence, which could mean that there are differences in 
host interactions between B. anthracis and B. subtilis.   
B. subtilis has been shown to interact with macrophages in vitro (Huang, 
Ragione, et al. 2008; Duc et al. 2004; Ceragioli et al. 2009). B. subtilis spores 
have also been shown in vitro and in vivo to cause maturation of DCs, which 
may also affect the DCs antigen presenting capacity (Song, H. A. Hong, et al. 
2012, de Souza et al., 2014). When delivered orally, Rhee et al (Rhee et al. 
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2004) reported that B. subtilis spores in the appendix of rabbits were taken up 
by M cells, so they could then be presented to underlying tissues and 
leukocytes.  
Several studies using B. subtilis spores as vaccines in the murine model have 
indicated that spores induce a Th1 response. IFNγ, a classic Th1 cytokine has 
been shown to be increased after vaccination along with other proinflammatory 
cytokines (Song et al. 2012; Huang, La Ragione, et al. 2008; Duc et al. 2004). 
However, other papers have shown that spores are able to illicit a balanced 
Th1/Th2 response (Andrew G. C. Barnes, Vuk Cerovic & Peter 2007).  
Antigen-specific antibody production has been demonstrated in numerous 
studies (Table 1-2). The increases in IgG1 and IgG2a, which are subclasses of 
IgG that indicate Th2 or Th1 responses in mice, respectively, also add to 
evidence that the spores elicit a balanced immune response (Song et al. 2012; 
Huang, Hong, et al. 2010; L. H. Duc et al. 2003). Protection against infection 
has also been demonstrated in several studies in different animal models with 
different delivery routes (Table 1-2).  
If the vaccine is for a mucosal pathogen such as MTB, a successful vaccine 
should elicit production of mucosal associated IgA. Secretory IgA has been 
demonstrated to be increased when mice were dosed with spores in several 
studies (L. H. Duc et al. 2003; Uyen et al. 2007; Huang, Hong, et al. 2010; 
Permpoonpattana et al. 2011; Isticato, Sirec, Treppiccione, et al. 2013; 
Amuguni et al. 2011).   
The innate immune response was implicated in protection against influenza 
challenge when spores with no associated influenza antigen were dosed to 
mice and there was 100% protection after challenge (Song et al. 2012). In the  
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Table 1-2. Examples of some of the studies that have demonstrated antigen-specific 
increases in antibody production and/or protection after immunisation with B. subtilis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathogen Vaccine 
delivery 
route 
Model 
organism 
Antibody 
detected 
% 
Protection 
Publication 
C. difficile Oral Hamster Yes 75 (Permpoonpattana et 
al., 2011) 
Influenza Nasal Mouse Yes 100 (Song et al. 2012) 
Tetanus Sublingual 
Oral  
Oral 
Nasal 
Oral and 
Nasal 
Oral 
Mouse 
Mouse 
Mouse 
Mouse 
Mouse 
Mouse 
Yes 
Yes  
Yes 
Yes 
Yes 
Yes 
100 
100 
- 
- 
- 
90 
- 
(Amuguni et al. 2011) 
(L. H. Duc et al. 
2003) 
(Ciabattini et al. 
2004) 
(Uyen et al. 2007) 
(Huang, Hong, et al. 
2010) 
(Mauriello et al. 
2004) 
B. anthracis Injection Mouse Yes 100 (Duc et al. 2007) 
White spot 
syndrome 
virus 
Oral 
Oral 
Shrimp 
Crayfish 
N/A 
N/A 
65 
50 
(Nguyen et al. 2014) 
(Ning et al. 2011) 
C. sinensis Oral 
Oral 
Rat 
Mouse 
Yes 
Yes 
45 
- 
(Zhou et al. 2008) 
(Qu et al. 2014) 
E. coli LT Nasal Mouse Yes - (Isticato, Sirec, 
Treppiccione, et al. 
2013) 
Helicobacter 
acinonychis 
Oral Mouse Yes - (Hinc et al. 2014) 
HIV Injection Mouse Yes - (de Souza et al. 
2014) 
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same study, the innate immune mechanisms were examined further. It was 
found that there was an infiltration of NK cells to the lungs 24h after 
immunisation and that spores increased DC maturation in vitro (Song et al. 
2012). Interestingly, TLR expression was upregulated in vitro (Song et al. 2012). 
An earlier study also supported that TLR2 and TLR4 were up regulated in vitro 
by live spores in macrophages following 6h cell culture as measured using RT-
PCR (Huang, La Ragione, Nunez, & Cutting, 2008).  
Work by de Souza et al has investigated the adjuvant properties of B. subtilis 
spores when delivered subcutaneously (de Souza et al. 2014).  They tested live 
vs heat inactivated spores, to identify whether this had an effect on the immune 
responses stimulated. de Souza et al used a HIV antigen; gag p24 either 
adsorbed to the spore surface or in recombinant form and found that 
recombinant and adsorbed were both able to generate antibody responses, and 
that there was little difference between live and dead spores. However, live 
spores were better at enhancing DC maturation, which could affect cellular 
responses. de Souza et al found that TLR2 was important for the generation of 
antibody responses by spores using knockout mice. This adds evidence that 
spores are an immune-potentiator class of adjuvant. The work by de Souza et al 
is also important because it characterised responses using two strains of 
mouse: BALB/c and C57BL/6, which are said to have a Th2 and Th1 bias 
respectively, and showed that the spores generated similar immune responses 
in both strains and were unaffected by the genetic background of the host (de 
Souza et al. 2014). 
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1.3. Aims 
The central objective of this project was to further investigate the potential use 
of B. subtilis spores as a mucosal vaccine adjuvant. The first project aim was to 
investigate how B. subtilis spores carrying antigens Ag85B-Acr and MPT64 
could protect against infection with MTB in mice. Two different strategies were 
tested. One scheme used heat killed spores carrying Ag85B-Acr or MPT64, or 
both proteins bound to the surface of the spores. The second approach was to 
use recombinant spores expressing MPT64 that were inactivated using 
formaldehyde.  
The second project aim was to examine how spores, when delivered mucosally 
were initially taken up by the host. A comparison of sublingual, oral and nasal 
administration routes were used, and the lungs, NALT and gut tissues were 
investigated as the prime target sites. The cells that were monitored were M 
cells, DCs, macrophages and neutrophils. The final project aim was to profile 
the innate immune response to spores after intranasal dosing. The cells chosen 
for analysis were macrophages, DC, neutrophils and NK cells and TLR2 and 
TL4 expression was investigated. Cytokine production and complement killing 
was also monitored. 
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1.4. Hypotheses 
 
1. Can B. subtilis spores carrying TB antigens protect against challenge 
with MTB in the murine model? 
2. Will the quantity of spores that are able to enter the lung, gut and NALT 
vary between nasal, sublingual and oral dosing? 
3. Will the types of cells that initially interact with spores vary depending on 
location and dosing route? 
4. Will the interactions be different between live and autoclaved spores? 
5. After nasal dosing, will certain cells and innate immune characteristics be 
activated in the mucosal and systemic immune system compartments? 
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Figure 1-3. Diagram to illustrate the hypotheses. 1) Mice were dosed nasally with non-
recombinant (with spikes) or recombinant (red outline) spores and challenged with MTB (green) 
to see whether the spores provided protection, 2) Mice were dosed nasally, orally and 
sublingually and distribution of spores in the NALT, lungs and gut examined to determine 
differences, 3) Mice dosed nasally, orally and sublingually and determined differences in cell 
interactions in the NALT, lungs and gut, 4) Mice dosed nasally, orally or sublingually with either 
live or autoclaved spores to determine difference in cell interactions, 5) Mice dosed nasally and 
followed for seven days to assess the effect on the cell populations, cytokine production, TLR 
expression and complement killing ability assessed in different tissues (gut, lungs, spleen).   
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Chapter 2: Materials and Methods 
 
2.1. Bacillus subtilis strains 
HU58 is a non-domesticated strain of B. subtilis isolated from the human GI-
tract (Huynh A Hong et al. 2009) and to which proteins were adsorbed to the 
spore surface. PY79 is a laboratory strain that is isogenic to the 168 strain 
(Zeigler et al. 2008). HU58 (cotB-MPT64) (rHU58(MPT64)) is a genetically 
modified strain of HU58 expressing the protein MPT64 on the spore surface via 
chimeric fusion to the coat protein CotB and was created at Cobra Biologics Ltd 
(Keele, UK) by Dr David Radford. This strain has resistance to erythromycin 
and lincomycin. DS127 (cotC-GFP) is the strain described by Isticato (Isticato et 
al. 2007) and expresses GFP on the spore surface by fusion with CotC. This 
strain has chloramphenicol resistance and is derived from PY79. 
2.2. Culturing and purification of Bacillus subtilis spores 
For spore production of all strains, strains were grown overnight on plates 
containing relevant antibiotics. A single colony was then used to inoculate Difco 
sporulation media (DSM) and incubated at 37 °C for 5-6 h. DSM agar was then 
inoculated with the culture and incubated at 30 °C for two days. Spores were 
then harvested, washed, and treated with lysozyme (Sigma-Aldrich, UK), 
followed by sequential washes with NaCl and KCl and then heat treatment 
(68 °C, 30 min) (Nicholson & Setlow 1990). The salt washes help clean the 
spores of residual membrane integuments while heat treatment kills any 
residual vegetative cells ensuring a preparation of pure spores. Aliquots were 
stored at -20 °C until use. For preparation of ‘killed’ spores, HU58 was 
autoclaved (121 oC, 15 psi, 30 min) before use. 
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2.3. MPT64 protein production and purification (Chapter 3) 
MPT64 (26 kDa) expressed in E.coli BL21 carrying a pET28b expression vector 
(Novagen, USA) where MPT64 was fused to an N-terminal polyhistine (Yu & 
Cutting 2009). Cultures were grown in LB media and protein expression 
induced by Isopropyl β-D-1-thiogalactopyranoside (IPTG) and the cell free 
lysate passed through a nickel affinity binding column to bind poly-His-tagged 
recombinant MPT64 using the ÄKTA Prime system (GE Healthcare, UK). Purity 
was checked using SDS-PAGE electrophoresis and fractions were dialysed 
using PBS. Protein concentration was determined using the Bradford assay. 
Protein was concentrated further using VivaSpin20 columns (Sartorius, 
Germany) by centrifugation at 4500 g for 30 min – 3 h at 4 °C.  
2.4. Ethics statement 
Mice were housed and used in studies according to the Animals (Scientific 
Procedures) Act 1986, issued from the Home Office, UK. Studies at Royal 
Holloway University of London (RHUL) were carried out under licence number 
70/7025 and those that were performed at St. George’s Medical School (SGUL) 
using licences 70/6625 and 70/7490. 
2.5. Production of antisera (Chapter 3) 
C57BL/6 mice from Charles River (UK) were immunised by intraperitoneal 
injection three times with 2 µg protein over a period of six weeks. After a further 
two to eight weeks, mice were culled and terminally bled. Serum was separated 
from the blood by centrifugation at 10,000 g for 20 min. Antisera was purified 
using Protein G Spin Trap columns (GE Healthcare, UK).  
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2.6. Adsorption of protein onto spore surface (Chapter 3) 
2x109 HU58 spores were aliquoted into eppendorfs and washed using PBS of 
the appropriate pH. 10 µg of protein was added and mixed gently. The mixture 
was incubated at room temperature (RT) for 30 min. The sample was then 
washed three times using the pH7 PBS. Detection of protein bound to the 
spores was detected using Western immunoblotting and immunofluorescence. 
2.7. Spore coat extraction (Chapter 3) 
2x109 spores were pelleted at 16,000 g for 2 min and spore coat extraction 
buffer added. Samples were incubated at 68 °C for 80 min. Spores were 
centrifuged for 10 min at 12,000 g and the supernatant collected.  
2.8. Western blot of spore coat extracts (Chapter 3) 
Spore coat was extracted for use in Western blot to detect bound protein and 
run on an SDS-PAGE gel at 200 V for 60 min. The fractionated samples were 
transferred to nitrocellulose membranes and probed with appropriate mouse 
anti-sera (anti-MPT64 or anti-Ag85B-Acr) diluted in 5 % milk in TBS buffer and 
incubated for 1 h at RT. Mouse anti-IgG-HRP conjugate was added diluted in 
5 % milk in TBS buffer and incubated for 1 h at RT. Membrane developed using 
ECL membrane developing reagents (GE Healthcare, UK) and captured onto 
Amersham Hyperfilm ECL (GE Healthcare, UK).  
2.9. Whole spore ELISA (Chapter 3)  
Spores were diluted to 1x106 spores/ml in PBS with 4% formaldehyde and used 
to coat a high binding ELISA plate for 2h at RT. The plate was washed with 
PBS and blocked with 4% BSA for 1h at 37°C. 1% BSA with 0.05% Tween20 
and 4% FCS was added to the plate. MPT64 antisera at a 1/50 concentration 
was added to the top row and serially diluted 1:2 down the plate. Incubated for 1 
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h at 37 °C. Washed with PBS + 0.05 % Tween20.  Anti-mouse IgG-HRP diluted 
1:200 in 1 % BSA with 0.05 % Tween20 and 4 % FCS. Incubated for 1 h at 
37 °C. Washed with PBS with 0.05 % Tween20 and colour developed for 5-15 
min using 3,3’,5,5’-tetramethylbenzidine (TMB) and reaction stopped using 2 M 
H2SO4 (both Sigma-Aldrich, UK). 
2.10. Immunofluorescence of purified spores (Chapter 3)  
Spores were washed with PBS and 20 µl aliquoted onto coverslips coated with 
0.01 M poly-l-lysine (Sigma-Aldrich, UK) and incubated for 5 min. Excess liquid 
was removed and spores were left to dry. Spores were washed with PBS, then 
blocked with 2 % BSA (Sigma-Aldrich, UK) for 15 min and washed nine times 
with PBS. Primary antibody (antisera MPT64 or Ag85B-Acr) was added (1:500) 
and incubated at room temperature for 45 min. Slips were washed three times 
with PBS, then anti-mouse IgG-TRITC (1:200) (Sigma-Aldrich, UK) was added 
and incubated at room temperature for 45 min. Cover slips were washed three 
times with PBS and mounted onto slides and read with the Nikon Eclipse 
fluorescent microscope (Nikon, Japan) using the Cy3 laser (530-560 excitation) 
with 100 millisecond exposure.     
2.11. Inactivation of spores with formaldehyde (Chapter 3) 
Formaldehyde was supplied in a 37 % w/v solution (Sigma-Aldrich, UK) and 
was diluted to 4 % formaldehyde using sterile water. Spores were aliquoted into 
tubes, centrifuged (12,000 g, 2 min), supernatant discarded and resuspended in 
a formaldehyde solution. Samples were then incubated in a roller at either 37 °C 
for 24 h. Before dosing, spores were washed with PBS to remove 
formaldehyde. 
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2.12. Measurement of formaldehyde content using the HACH test    
(Chapter 3) 
The supernatant from spores that had been inactivated with formaldehyde were 
tested for their formaldehyde content after washing with PBS. To wash, the 
spores were centrifuged at 12,000 g for two min, supernatant removed and 
replaced with new PBS and this was repeated twice. Formaldehyde 
concentrations were measured using the HACH formaldehyde detection kit 
(HACH, USA) according to the manufacturer’s instructions. The ‘formaldehyde 1 
reagent powder pillow’ was added to 1 ml of the sample diluted in dH2O and 
swirled for 20 seconds. Two drops of thymolphthalein was added and mixed 
and the solution turned blue if formaldehyde was present. To assess the 
concentration of formaldehyde present 1.9 N sulphuric acid was added using a 
dropper and the drops counted until the solution turned clear. Each drop 
accounted for 0.5 % formaldehyde. For solutions from 0-1 %, 10 ml of solution 
was used and each drop of sulphuric acid accounted for 0.05 % formaldehyde.  
2.13. Experimental design of TB Study (Chapter 3) 
C57BL/6 mice (Charles River, UK) were used to test the efficacy and 
immunogenicity of MPT64 and Ag85B-Acr. At week zero, mice receiving BCG 
(groups B, G and I) were vaccinated with 5x105 CFU of BCG Pasteur (from 
Rajko Reljic at SGUL). At week three, the groups that had not received BCG, 
were administered their first dose of protein/spores intranasally. All mice were 
anaesthetised using isoflurane for dosing. The amount of protein in the doses 
was 10 µg. The number of spores per dose was 2x109. At week six, all groups 
received a second dose and at week nine, all groups received their third 
immunisation. Two mice from each group were culled by CO2 for 
immunogenicity experiments. Eight mice from each group were transferred to 
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SGUL to be challenged intranasally with 5x105 CFU H37Rv MTB. After four 
weeks, all mice were culled and lungs and spleen homogenised and plated onto 
7H11 agar (Difco, BD, UK) and grown at 37 °C for 28 days to estimate the 
bacterial burden in the organs. 
2.14. IFNγ ELISPOT (Chapter 3) 
IFNγ ELISPOT was carried out using a kit and used according to the 
manufacturers recommendations (Mabtech, Sweden). Polyvinylidene fluoride 
(PVDF) 96-well plates were coated with coating antibody in PBS and incubated 
at 4 °C overnight. 5x105 splenocytes were added to wells along with antigens 
MPT64 (10 µg/ml), Ag85B-Acr (10 µg/ml), PPD (purified protein derivative) (20 
µg/ml) (Statens Serum Institute, Denmark) or positive control mitogens PMA 
(phorbol 12-myristate 13-acetate (Sigma-Aldrich, UK)) (10 µg) and Ionomycin (1 
µg) (Sigma-Aldrich, UK) in 100 µl DMEM media supplemented with 20 % FCS, 
penicillin, streptomycin, 2-mercaptoethanol and L-glutamine (all Sigma-Aldrich, 
UK). Plates were incubated at 37 °C in a CO2 incubator overnight. Plates were 
washed and primary antibody added (1:1000) and incubated at RT for 2 h, 
washed and Streptavidin-ALP (1:1000) added and incubated for 1h at RT. 
Plates were washed and developed using BCIP/NBT (5-bromo-4-chloro-3-
indolyl-phosphate/nitro blue tetrazolium) for 25 minutes until spots developed. 
Plates were counted using CTL reader (CTL, Germany). Media only wells were 
subtracted from antigen stimulated wells and Spot Forming Units (SFU) were 
calculated per 106 cells using Microsoft Excel (Microsoft, USA). 
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2.15. DS127 spores detection of fluorescence (Chapter 4) 
Approximately 1x108 DS127 spores were added to a cover slip coated with 
0.01 % poly-l-lysine, incubated at RT for 45 minutes and washed seven times 
with PBS. The coverslip was mounted onto a microscope slide and observed 
using the FITC band pass filter (475 – 490 excitation) on a Nikon Eclipse Ti 
fluorescent microscope.  
2.16. Experimental design  – DS127 spores intranasal dosing (Chapter 4) 
Studies were performed using six to eight week old C57BL/6 mice (Charles 
River, UK). Mice were sedated using isoflurane and immunisations were given 
by the intranasal route. DS127 spores were given at a concentration of 2x109 
spores/dose. Mice were euthanized using CO2 and lungs were fixed in 10% 
neutral buffered formalin (NBF) and sent to TUPI Ltd for histological processing 
and half were stained with haematoxylin and eosin (H&E) stain. The stained 
samples were examined using a Nikon microscope at 100 x magnification to 
look for spores in the tissue. The unstained samples were read using a confocal 
microscope at SGUL, by Dr Andreas Hoppe (from Kingston University, London).  
2.17. Infection of RAW267.4 macrophages with DS127 spores (Chapter 4) 
RAW267.4 macrophages were grown for two days on coverslips coated with 
0.01 % poly-l-lysine until confluent. Wells were then infected with approximately 
1x106 DS127 freeze dried spores and incubated at 37 °C for 30 min. 
Supernatant was then removed, cells washed with PBS and fixed with 4 % 
formaldehyde. 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, UK) was 
used to stain the macrophage nuclei. Slips were mounted onto slides and read 
using the EVOS fluorescent microscope (Life Technologies, UK) using the blue 
and green laser blocks.  
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2.18. Experimental design of localisation of spores after different routes of 
dosing with spores (Chapter 4) 
Studies were performed using six to eight week old Balb/c mice (Charles River, 
UK). Mice were sedated with isoflurane before dosing. All mice were given 
2x109 HU58 spores, but the volumes varied for the dosing routes. Nasal 
immunisation spores were in 30 μl, sublingual dosing in 9 μl and oral dosing 
using 100 μl. 6 h and 24 h after dosing, six mice were culled using CO2 and the 
lungs, gut and NALT removed from each mouse. The set of lungs and gut from 
one mouse per group were incubated with 10 % (v/v) NBF at room temperature 
for 48 h. The other tissues were used for flow cytometric analysis. 
2.19. Isolation of single cells from the mouse spleen and lymph nodes 
 
Spleen was removed from mice culled by CO2 and placed in DMEM 
supplemented with 10 % FCS, penicillin/streptomycin and L-glutamine. The 
spleen was pushed through a 70 µm cell sieve and the cells collected and 
centrifuged at 400 g for 10 min. Spleen cells were resuspended in red blood cell 
lysis solution (Sigma-Aldrich, UK) and incubated at room temperature for 5 min. 
Cells were washed with media and then resuspended for counting. Cells were 
diluted 1/10 in media for counting with the Millipore Sceptre cell counter 
(Millipore, Germany).  
2.20. Isolation of single cells from the mouse lungs and gut 
 
The lungs and gut were removed from mice culled by CO2 and placed in DMEM 
supplemented with 10 % FCS, penicillin/streptomycin and L-glutamine. Tissues 
were homogenised using the GentleMACS (Miltenyi Biotec, Germany). 
Collagenase and DNAse (both Sigma-Aldrich, UK) were added and tissues 
were incubated for 37 ºC in the gyrorotarory shaker for 30 min. The tissues 
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were homogenised again with the GentleMACS and then the cells were put 
through a 70 µm cell sieve and the cells collected and centrifuged at 400 g for 
10 min. Lung cells were resuspended in red blood cell lysis solution (Sigma-
Aldrich, UK) and incubated at room temperature for 5 min. Cells were washed 
with media and then resuspended for counting. Cells were diluted 1/10 in media 
for counting with the Millipore Sceptre cell counter. 
2.21. Experimental design of innate immunity study (Chapter 5) 
Studies were performed using six to eight week old Balb/c mice (Charles River, 
UK). Mice were sedated with isoflurane before dosing. All mice were given 
2x109 HU58 spores suspended in 30 µl water for dosing. The experiment was 
carried out twice. The first time, at days one, two, three, four and seven after 
immunisation, three mice were culled, plus one naïve mouse using CO2 
asphyxiation and the lungs, gut and spleen were removed and placed in DMEM 
10 % FCS ready for processing. In the second experiment, six mice were culled 
on days one, two, three, four, and seven and the lungs, gut, spleen, peripheral 
lymph nodes (axillary, inguinal, thymus) and the NALT tissue was removed. The 
NALT tissue was washed in DMEM 10 % FCS media and then each NALT was 
put into a well of a 24-well plate in 250 µl media and incubated at 37 °C 5 % 
CO2 for 48 h before collecting the supernatant for detecting cytokines. The other 
tissues were homogenised and single cells isolated as described elsewhere in 
the methods (2.20, 2.21) and used for flow cytometry staining. 5x105 
splenocytes from each mouse were also used to seed a 96-well plate and 
incubated at 37 °C 5 % CO2 for 48h to collect supernatants for detecting 
cytokines. 
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2.22. Flow cytometric analysis of samples from experiment of localisation 
of spores after different routes of mucosal immunisation (Chapter 4) 
After isolation of single cells from the lungs, gut and NALT, 1x106 cells were 
used for staining. Cells were centrifuged at 200 g for 10 min and washed in 
10 % FCS. Cells were resuspended in 10 % FCS and antibodies added 
according to titration results. Two panels were used i) Macrophage F4/80-
PerCP (clone BM8, Biolegend, UK) and Dendritic cells CD11c-APC (clone 
N418, Miltenyi, Germany) and ii) Neutrophils Ly6G-APC (clone 1A8, Miltenyi, 
Germany) and M cell (clone NKM 16-2-4-PE, Miltenyi, Germany). The cells 
were then incubated with Cytofix (BD Biosciences, UK), washed and then 
incubated with PermWash (BD Biosciences, UK). All further wash steps used 
PermWash solution. The spores were detected using anti-spore rabbit antibody 
(generated at RHUL) followed by a secondary antibody, anti-rabbit IgG-FITC 
(Sigma-Aldrich, UK). Samples were then analysed using the BD Accuri C6 flow 
cytometer (BD Biosciences, UK). The populations of lymphocytes and 
monocytes were gated using FSC-A vs SSC-A and single cells gated using 
FSC-A vs FSC-H. DCs were gated as cells that were CD11c+, Macrophages 
were F4/80+, Neuutrophils were Ly6G+ and M cells were NKM 16-2-4+. All cell 
populations were plotted against anti-spore+ events. Double positive samples 
that included FITC showed populations that contained spores. Free spores 
were identified by using FSC-A vs SSC-A to gate on the spore population. 
Using information from the optimisation experiment anti-spore antibody and 
anti-IgG-FITC was used to positively identify spores. The results were analysed 
using Microsoft Excel. The percentage of total population was used for 
calculation and the unstained samples were subtracted from the stained 
samples. 
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2.23. Flow cytometric analysis of samples from the innate immunity study 
(Chapter 5) 
After isolation of single cells from the lungs, gut and NALT, 1x106 cells were 
used for staining. Cells were centrifuged at 200 g for 10 min and washed in 
10 % FCS. Cells were resuspended in 10 % FCS and antibodies added 
according to the titration results. Three panels were used i) Macrophage F4/80-
PerCP (clone BM8, Biolegend, UK) and Dendritic cells CD11c-APC (clone 
N418, Miltenyi, Germany), ii) Neutrophils Ly6G-APC (clone 1A8, Miltenyi, 
Germany) and NK cell CD49b-PE (clone DX5, Miltenyi, Germany) and iii) TLR2 
CD282-PE (clone REA109, Miltenyi, Germany) and TLR4 CD284-APC (clone 
MTS510, Miltenyi, Germany). After incubation, cells were washed with 10 % 
FCS and samples analysed using the BD Accuri C6 flow cytometer (BD 
Biosciences, UK). The data was analysed using the BD Accuri C6 software by 
gating on the lymphocytes, monocytes and granulocyte populations and gating 
on single cells. To determine DCs, M1 and M2 macrophages, the cells were 
analysed using CD11c-APC vs F4/80-PerCP. Those cells that were CD11c+ 
F4/80- were classified as DCs, CD11c+ F4/80+ were M1 macrophages and 
CD11c- F4/80+ were M2 macrophages, as described in other works (Li et al. 
2010; Fujisaka et al. 2009). NK cells were CD49b+, neutrophils were Ly6G+, 
TLR2 were CD282+ and TLR4 were CD284+.  
2.24. Embedding of tissues for histology and immunofluorescence 
(Chapter 4 and 5) 
Tissues taken from mice were incubated at RT for 24 – 48 h in 10 % NBF. 
Tissues were then put into individual cassettes and immersed in 70 % ethanol, 
followed by 90 % ethanol and 100 % ethanol with four changes of solution. The 
ethanol was displaced by immersing the tissue in three changes of xylene 
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(Sigma-Aldrich, UK). The tissue was then submerged in molten paraffin wax 
(Leica, Germany) for three changes. The tissue was then embedded in wax in a 
mould and the wax allowed to solidify. The tissues were processed using a 
Bright 3500 Microtome (Bright, UK) to a thickness of either 5 µM or 10 µM and 
heat fixed onto microscope slides (65 ºC, 20 min). To rehydrate the sections for 
staining, the slides were incubated with three changes of xylene, followed by 
two changes of 100 % ethanol and two changes of 95 % ethanol. Slides were 
washed twice with dH20 and once with PBS before incubating in 5 % BSA for 1 
h at RT. Primary antibody was then added in 1 % BSA (1:500 anti-spore (rabbit) 
(RHUL) 1:100 anti-M cell (Miltenyi, Germany) or 1:100 MHCII (Miltenyi, 
Germany and 1:500 CD3 (Biolegend, UK)) and incubated overnight at 4ºC. 
Slides were washed with PBS three times and then incubated with secondary 
antibody diluted in 1% BSA (anti-rabbit-IgG-FITC and anti-mouse-IgG-TRITC 
both 1:500 and incubated for 1h at RT). Slides were washed with PBS three 
times, mounting media added and coverslip added. Slides were read using an 
EVOS fl digital microscope (Life Technologies, UK).  
2.25. Cytokine bead array (Chapter 5) 
Mouse splenocytes were isolated and 5x105 cells were aliquoted into a 96-well 
plate in duplicate, with a positive control incubated with PMA and Ionomycin 
and incubated in DMEM media containing L-glutamine, penicillin, streptomycin, 
Hepes Buffer and 10 % FCS for 48 h at 37°C. The supernatants were then 
collected and stored at – 20 °C until used in the assay. The BD cytokine bead 
array mouse inflammation kit was used (BD Biosciences, UK), which measures 
the cytokines IL-6, IL-12, TNF, IL-10, IFNγ and MCP-1. This kit was chosen 
because a lot of these cytokines are implicated in the innate immune response. 
The method was followed according to the manufacturer’s instructions. The 
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lyophilised standards were reconstituted in 2 ml assay diluent for 15 min at 
room temperature and then diluted 1:2 in assay diluent with a final dilution of 
1:256 achieved. The capture beads were vortexed and for the master capture 
bead mix 10 µl of each cytokine capture bead x (number of standards and 
samples) was added to a tube (e.g. 10 µl of IL-6 cytokine bead x 50 samples = 
500 µl x 6 cytokines = 3000 µl total). 50 µl of the master capture bead mix was 
added to each sample tube. 50 µl of either a dilution of standard or unknown 
sample was added to each tube followed by addition of 50 µl of the PE 
detection reagent. Samples were incubated in the dark for 2 h and then 1 ml of 
wash buffer was added to each tube and centrifuged at 200 g for 5 min. The 
supernatant was discarded and the pellet was resuspended in 300 µl of wash 
buffer and read on the BD Accuri C6 using a CBA template from the BD website 
(BD Biosciences 2014). Each cytokine capture bead fluoresces differently in the 
FL4 channel and the quantity of cytokine is measured using the FL2 channel. 
The results, once obtained, were analysed using the BD FCAP Array v3 
software, which calculates the standard curves for all the cytokines and then 
calculates the pg/ml of cytokine per sample.        
2.26. Complement killing assay (Chapter 5) 
The method for the assay was developed by Virta et al (Virta et al. 1998).  
1x106 HU58 spores in dH20 were incubated with 20 µl of sera from immunised 
mice and incubated at 37 °C for 90 min, not shaking. The samples were then 
put on ice for 10 min to stop the reaction. After treatment, the spores were 
serially diluted 1:10 and plated out on DSM agar and incubated at 37 °C 
overnight. The total number of spores was calculated and percentage of dead 
spores calculated against the no sera control.  
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2.27. Infection of mice with MDR-TB after therapy with spores or IL-4D2 
(Chapter 5) 
Ten C57BL/6 mice per group were used. One group was given PBS as a 
control. One group was dosed with 2x109 autoclaved HU58 spores, one with 
IL4-D2 and other with both autoclaved HU58 spores and IL4-D2. All groups 
were given doses by the intranasal route three days prior to infection with MDR-
TB (Peru strain) and treated with doses every other day for three doses (Figure 
2-1). The strain of MTB was isolated from a Peruvian patient who was enrolled 
on a clinical trial (strain number: 10094G), which was resistant to Rifampicin 
and Isoniazid. Four weeks after treatment, the mice were culled and the lungs 
homogenised and plated out onto 7H11 media and incubated for 28 days at    
37 ºC to examine bacterial burden in the lungs. Work carried out by Dr Rajko 
Reljic and Gil Reynolds Diogo at SGUL. 
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Figure 2-1. Study design of stimulating the innate immune response to protect against 
MTB. N=10 Balb/c mice were dosed intranasally with either HU58 spores, IL4D2, or HU58 + 
IL4D2. Three days later they were challenged with MTB (Peru strain) and three further doses 
were administered. 28 days later, the mice were culled and the lungs were plated out to 
examine bacterial burden.  
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Chapter 3: Spores as a Vaccine Adjuvant for Tuberculosis 
 
3.1. Introduction 
The current TB vaccine, BCG, is widely used and is able to prevent serious 
disease in children (Trunz et al. 2006). However, efficacy is variable, and the 
use of live vaccines is problematic because they are considered to be 
unsuitable for immunocompromised individuals (Hawkridge & Mahomed 2011). 
This is a particular problem for TB, where there are large numbers of people co-
infected with HIV (43% of TB cases are co-infected with HIV in Africa in 2012 
(WHO 2014a)). The ‘STOP TB’ campaign, organised by the WHO aims to 
eradicate TB by 2050 (WHO 2001) and one of the approaches is to develop 
novel vaccines. Some of the strategies being tested for novel TB vaccines is to 
use an adjuvant carrying a TB antigen, for example MVA85A (Ibanga et al. 
2006) is a virus (modified vaccinia Ankara (MVA)) expressing Ag85A, and is 
used as a booster vaccine after priming with BCG. The benefits of using the 
prime-boost strategy are that many people are already vaccinated with BCG (it 
has been estimated that four billion doses of BCG have been given in total 
(Kaufmann & Gengenbacher 2012)) and that a booster would build on the 
protection that BCG confers. Boosting BCG with BCG is carried out in some 
countries and administered to teenagers (Zwerling et al. 2011) but it does not 
appear to significantly improve protection (Orme 1999). Other novel TB vaccine 
strategies include modifying BCG to include extra antigens, for example, Aeras-
422, is based on BCG but overexpresses antigens Ag85A, Ag85B and Rv3407 
(Kaufmann & Gengenbacher 2012). 
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Vaccine development for TB is difficult because of the lack of biomarkers and 
correlates of protection. IFNγ, a Th1 cytokine, and initiation of the Th1 immune 
response is important, because individuals with HIV, who have a reduction in 
CD4+ T-cells, are far more susceptible to MTB infection (Kalsdorf et al. 2009). 
Therefore, a new TB vaccine should activate Th1 immune responses. BCG 
does not completely eradicate MTB, but is able to help control the infection, so it 
is possible to still be latently infected with MTB after BCG vaccination. Any TB 
vaccine needs to reduce bacterial burden and enhance control of disease to the 
same degree or better than BCG.  
B. subtilis spores have been tested as vaccine adjuvants for diseases including 
anthrax (Duc 2007) and influenza (Song 2012). Work investigating their use as 
a vaccine adjuvant using TB antigens was initiated at RHUL. Three 
immunogenic antigens from MTB were tested; Ag85B (Rv1886c) (30kDa); a 
secretory mycolyl transferease protein involved in cell wall synthesis that is 
common in novel TB vaccines (Eddine 2006), Acr (Rv2031c, HspX) (16kDa); a 
stress protein important in latency and rMPT64 (Rv1980c) (26kDa); another 
secretory protein found in actively dividing MTB cells and used in diagnostics 
(Galliard 2011).  
All three antigens have been previously tested in various vaccine formats. 
MPT64 has been tested at RHUL by Huang et al in a Salmonella vector, which 
showed MPT64 to be immunogenic and stimulating an IFNγ response, but the 
reduction in MTB CFU in the lungs was not comparable to BCG (Huang, Sali, et 
al. 2010). Ag85B has been tested in DNA vaccines (Kamath et al. 1999), with 
nanoparticles (Stylianou et al. 2013) and in recombinant BCG (Kaufmann & 
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Gengenbacher 2012). Acr has been tested as an immune complex (Pepponi et 
al. 2013) and DNA vaccine (Khera et al. 2005) formats. 
In an experiment carried out by Jen Min Huang at RHUL using spores that 
carried either rMPT64 or rAg85B-Acr, and recombinant spores expressing 
rMPT64, protective efficacy was measured by CFU isolated from the lungs and 
spleen (unpublished). MTB found in the spleen is evidence of dissemination of 
MTB. The results to date show a reduction in CFU in the lungs comparable to 
BCG in groups given spores with rMPT64 or rAg85B-Acr (Figure 3-1). 
Reduction was better with spores rather than protein only, with and without 
BCG. Recombinant spores expressing rMPT64 after a BCG prime also showed 
a reduction in CFU in the lungs. Reduction in CFU in the spleen was seen in 
groups that had BCG followed by a booster vaccination with spores and 
antigens. 
Immunogenicity of the vaccines was tested by IFNγ release and IgG subclass 
ELISA. IFNγ release from cells was observed in groups given spores with MTB 
antigens, which meant the immunisations were able to stimulate an antigen-
specific Th1 response. Total IgG, IgG1 and IgG2a were also measured. Total 
IgG increased after administration of spores alone and also BCG with boosts of 
spores and antigens (Huang, unpublished). 
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Figure 3-1. Log reduction in CFU counts of MTB in lung and spleen samples from mice 
challenged with MTB after immunisations. Mice were immunised with HU58 spores, spores 
with rMPT64 adsorbed to the surface, rMPT64 protein alone, spores with rAg85B-Acr and 
rAg85B-Acr protein alone. The different vaccine preparations were also tested after a BCG 
prime. The BCG primed groups showed the greatest reduction in CFU in comparison to the 
naïve group. Spores with either rMPT64 or rAg85B-Acr had a lower bacterial burden in the 
lungs in comparison to protein alone, demonstrating spores can enhance the immunogenicity of 
the antigens. JM Huang, R Reljic, S Cutting unpublished data. 
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3.1.1. Aims 
The aim of this chapter was to continue to test the efficacy and immunogenicity 
of rMPT64 and rAg85B-Acr using B. subtilis spores as an adjuvant. HU58 
spores with rMPT64 or rAg85B-Acr were tested to confirm previous results and 
further characterise immune responses. rMPT64 and rAg85B-Acr were also 
combined, and were named ‘SWAN’ (after ‘South West Alliance Network’ who 
funded the study) to assess whether; a) more than one antigen could be 
adsorbed to the surface of the spores and b) whether the antigens could have a 
synergistic effect on inducing an immune response. SWAN was tested as 
protein alone, as well as adsorbed to spores and in a prime-boost regimen with 
BCG. 
The recombinant spores expressing MPT64 (rHU58(MPT64)) were further 
characterised. They were used alone, and in a prime-boost regimen with BCG. 
These spores were inactivated with formaldehyde before dosing because they 
were genetically modified and by inactivating them they pose less risk to the 
environment since they carry antibiotic resistance genes that could be 
transferred to other bacteria.  
C57BL/6 mice were challenged intranasally with MTB to assess how well 
protected they were following immunisation by examining the bacterial burden 
in the lungs and spleen. The immune responses were assessed after 
immunisations by IFNγ ELISPOT and IgG subclass ELISAs.  
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3.2. Results 
3.2.1. Protein 
rAg85B-Acr (1–2mg/ml) was supplied by Dr Illaria Pepponi and Dr Rajko Reljic 
(SGUL). Ag85B (30 kDa) was co-expressed with Acr (16 kDa) in E. coli DH5α. 
rMPT64 (26 kDa) was expressed in E. coli BL21 and expression induced using 
IPTG and the clone was created by Jen Min Huang (RHUL) as described by 
Huang et al (Huang, Sali, et al. 2010). The protein was purified using the ÄKTA 
purification system and checked for purity using SDS-PAGE electrophoresis, as 
described in the methods (Figure 3-2). The concentration of protein was 
measured using the Bradford assay and the concentration ranged from 0.6–
1.3mg/ml. Figure 3-3 illustrates the expression and purity of rMPT64 obtained. 
The rMPT64 and rAg85B-Acr proteins were mixed together when used for 
dosing, or adsorbed to the surface of autoclaved HU58 spores.  
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Figure 3-2. Coomassie blue stained SDS-PAGE electrophoresis gel of purified rMPT64 
protein (26kDa). Lane 1. His-tagged rMPT64 expressed in E. coli LH22 grown to OD 0.5-0.7 
and protein expression induced by IPTG.  Bacteria were sonicated, filtered and run on the 
AKTA His-tag purification programme.  Suitable fractions were dialysed and concentrated. 
Ladder indicates kDa of protein. 
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3.2.2. Adsorption of spores with proteins rMPT64 and Ag85b-Acr  
To deliver the antigenic proteins, they need to be bound to the surface of the 
spore. The adsorption of proteins onto the spore surface is dependent on pH, 
which is affected by the isoelectric point (pI) of each protein. The optimum 
binding conditions for rAg85B-Acr and rMPT64 were tested. PBS was prepared 
at pH4, pH7 and pH10 and used for the various wash steps involved in binding 
protein to spores. Spore coats were extracted and fractionated by SDS-PAGE 
followed by Western electroblotting to detect the bound protein. rMPT64 and 
rAg85B-Acr bound to autoclaved HU58 at pH4 and pH7 but not at pH10 (Figure 
3-3, Figure 3-4). Both proteins were able bind to spores together and neither 
was affected by the presence of the other as demonstrated by the ability to 
detect both proteins on the Western blot.   
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Figure 3-3. Western blot transfer and 12% SDS-PAGE gel showing binding of rMPT64 
(26kDa) to autoclaved HU58 spores at different pH’s. Western blot protein detected with anti-
rMPT64 antibody. rMPT64 (2µg) or in conjunction with rAg85B-Acr (2µg) and 2x10
9
 HU58 
spores combined for 30 minutes using PBS at different pH’s. Lanes 1-3 HU58 with rMPT64; 
Lane 1; pH4 PBS, Lane 2; pH7, Lane 3; pH10, Lanes 4-6 HU58 with rAg85B-Acr and rMPT64; 
Lane 4;  pH4, Lane 5; pH7, Lane 6; pH10,  Lane 7; rMPT64 protein alone,  Lane 8; rAg85B-Acr 
with HU58 at pH7, Lane 9; rAg85B-Acr protein. Ladder indicates kDa of protein. 
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Figure 3-4, Western blot transfer and 12% SDS-PAGE gel of the binding of rAg85B-Acr 
(45kDa) to autoclaved HU58 spores at different pH’s. Western blot detected with anti-
rAg85B-Acr antibody. rAg85B-Acr (2µg) or in conjunction with rMPT64 (2µg) and 2x10
9
 HU58 
spores were combined for 30 minutes using PBS at different pH’s.  Lanes 1-3 HU58 with 
rAg85B-Acr Lane 1; pH4 PBS, Lane 2; pH7 PBS, Lane 3; pH10, Lanes 4-6 HU58 with rAg85B-
Acr and rMPT64; Lane 4;  pH4, Lane 5; pH7, Lane 6; pH10, Lane 7; rAg85B-Acr protein alone,  
Lane 8; rMPT64 with HU58 at pH7, Lane 9; rMPT64 protein. Ladder indicates kDa protein. 
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3.2.3. Kinetics of protein binding to spores 
The interactions between the protein and autoclaved HU58 spores was 
characterised by how readily the protein bound to HU58 over time. Protein was 
incubated with spores for 5, 10, 20 and 30 minutes. Binding was seen at 5 
minutes for rMPT64 and 20 minutes rAg85B-Acr (Figure 3-5, Figure 3-6). 
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Figure 3-5, Western blot transfer and 12% SDS-PAGE gel showing binding of rMPT64 to 
autoclaved HU58 over time detected using anti-rMPT64 antibody. Lane 1; 5 min, Lane 2; 10 
min, Lane 3; 20 min, Lane 4; 30 min, Lane 5; 0.25 µg rMPT64, Lane 6; 0.125 µg rMPT64, Lane 
7; 0.065 µg rMPT64, Lane 8; 0.03 µg rMPT64, Lane 9; rAg85B-Acr + HU58, Lane 10; rAg85B-
Acr. Ladder indicates kDa protein. 
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Figure 3-6, Western blot transfer from 12% SDS-PAGE gel showing binding of rAg85B-
Acr to autoclaved HU58 over time detected using anti-rAg85B-Acr antibody. Lane 1; 5 
min, Lane 2; 10 min, Lane 3; 20 min, Lane 4; 30 min, Lane 5; rAg85B-Acr, Lane 6; rMPT64. 
Ladder indicates kDa protein. 
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3.2.4. Stability of protein bound to spores 
Spores with protein bound to the surface were stored at different temperatures 
for 24h, to assess whether the protein would dissociate from the spores over 
time, an attribute which would have implications for storage if they were used as 
vaccines. At 4°C and -20°C, there seemed to be less protein bound than in the 
original preparation. However, in both storage conditions protein was still bound 
which showed that spores can be stored, but the dose may be affected (Figure 
3-7). 
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Figure 3-7. Spores with MTP64 bound to the surface stored at different temperature.  
1; rAg85B-Acr protein, 2; rMPT64 protein, 3; rAg85B-Acr and spores incubated 30 min RT, 4; 
rMPT64 and spores incubated 30 min RT, 5; rAg85B-Acr and HU58 stored at 4°C overnight, 6; 
rMPT64 and HU58 stored at 4°C overnight, 7; rAg85B-Acr and HU58 stored at -20°C overnight, 
8; rMPT64 and HU58 stored at -20°C overnight.  
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Figure 3-8. Spores with Ag85B-Acr bound to the surface stored at different temperature. 
1; rMPT64 protein, 2; rAg85B-Acr protein, 3; rMPT64 and spores incubated 30 min RT, 4; 
rAg85B-Acr and spores incubated 30 min RT, 5; rMPT64 and HU58 stored at 4°C overnight, 6; 
rAg85B-Acr and HU58 stored at 4°C overnight, 7; rMPT64 and HU58 stored at -20°C overnight, 
8; rAg85B-Acr and HU58 stored at -20°C overnight. Ladder indicates kDa protein. 
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3.2.5. Immunofluorescence of proteins adsorbed to spores 
To provide additional confirmation that protein had been bound to the spores, 
and to validate the fluorescence microscope method, immunofluorescence of 
rAg85B-Acr and rMPT64 bound to the spores was evaluated. Fluorescence was 
brighter on the spores with protein bound compared to HU58 samples (Figure 
3-9). 
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Figure 3-9. Immunofluorescence of autoclaved HU58 spores with protein adsorbed to the 
surface. A) HU58 no protein adsorbed, detected using anti-rAg85B-Acr primary antibody and 
TRITC conjugated anti-mouse IgG secondary antibody  B) HU58 with rAg85B-Acr adsorbed to 
the surface, detected using anti-rAg85B-Acr primary antibody and TRITC conjugated anti-
mouse IgG secondary antibody, C) HU58 no protein adsorbed, detected using anti-rMPT64 
primary antibody and TRITC conjugated anti-mouse IgG secondary antibody  D) HU58 with 
rMPT64 adsorbed to the surface. Detected using anti-rMPT64 primary antibody and TRITC 
conjugated anti-mouse IgG secondary antibody. 1s exposure.  
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3.2.6. rHU58(MPT64) expression of rMPT64 
The rHU58(MPT64) strain was created by COBRA Bio-manufacturing Plc (UK) 
and expressed the rMPT64 protein in the spore coat of the HU58 spores 
because it was fused to a spore coat protein (CotB) (unpublished). rMPT64 
expression was confirmed by extracting the spore coat proteins and using 
Western blotting to detect rMPT64 using anti-rMPT64 antibody. Bands were 
seen at around 60 kDa which indicated that rMPT64 (26 kDa) was expressed 
fused to CotB (42 kDa) (Figure 3-10).  Another measure of rMPT64 expression 
was to use ELISA to detect MPT64 on the intact spores and in the extracted 
spore coat proteins (Figure 3-11). ELISA plates were coated with either spores 
of HU58 or rHU58(MPT64), spore coat extract or spores after spore coat 
extraction and then detected using anti-rMPT64 antibody. These results showed 
that rMPT64 could be detected in the spore coat extract, but only a small 
amount was present on the surface of spores and no rMPT64 could be detected 
on spores after extraction. Therefore the results suggested that rMPT64 was 
expressed in the spore coat, but may not be surface exposed.  
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Figure 3-10. Western blot from and 12% SDS-PAGE of recombinant HU58 (cotB-rMPT64) 
spores probed with anti-rMPT64 antisera and anti-mouse IgG-HRP secondary antibody. 
Lane 1; rHU58(MPT64) spore coat extract 2;  rHU58(MPT64) spore coat extract 1:2 dilution, 3; 
rHU58(MPT64) spore coat extract 1:4 dilution, 4; rHU58(MPT64) spore coat extract 1:8 dilution, 
5; HU58 spore coat extract. Protein measured in kDa according to ladder. 
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Figure 3-11. ELISA results showing rMPT64 detection. HU58 and rHU58(MPT64) spores 
(1x10
6
), spore coat extracts and spores after the coat was extracted were used to coat the 
plate, and anti-rMPT64 antibody followed by anti-mouse IgG-HRP secondary antibody used to 
detect rMPT64 expression.  
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3.2.7. Inactivation of rHU58(MPT64) with formaldehyde 
rHU58(MPT64) is a genetically modified (GM) organism, and as such there are 
potential safety concerns about using it as a live vaccine. Inactivation with 
formaldehyde would inactivate the spores thus alleviating any potential danger 
because they would be unable to replicate and spread in the environment. 
Vaccines including polio vaccine are inactivated using formaldehyde (Martin 
2003). According to the literature, formaldehyde activity is affected by time and 
temperature (Salk & Salk 1984), therefore rHU58(MPT64) spores were 
subjected to different concentrations of formaldehyde for different lengths of 
time at a variety of temperatures. Aliquots were plated onto DSM media and 
colony counts recorded as an indication of survival. Spores were washed after 
treatment with PBS to minimise the percentage of formaldehyde left in the 
sample, which could be toxic in the preparation. The residual formaldehyde was 
measured in the supernatants after washing using a formaldehyde testing kit. 
The greatest reduction in CFU was seen at 4% formaldehyde after incubation at 
37°C for 24h (Figure 3-12). 
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Figure 3-12. rHU58(MPT64) CFU after exposure with concentrations of 0%, 1% or 4% 
formaldehyde, and PBS washes after incubations at various times and temperatures. 
After treatment, spores were washed by centrifugation and PBS and plated out onto DSM 
media and incubated at 37°C overnight to measure recovery. The largest decrease in CFU was 
after 24h at 37°C and 4% formaldehyde.  
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3.2.8. Detection of formaldehyde in samples 
Formaldehyde is toxic and classed as a probable carcinogen and so the levels 
of formaldehyde in the vaccine preparation had to be reduced before 
administration to mice. The guidelines state that the maximum amount of 
formaldehyde permitted in a vaccine preparation is 0.2g/L (Pharmacopeia 
2014). Reducing the formaldehyde content was achieved by washing the 
inactivated spore preparation with PBS. The percentage of formaldehyde 
decreased over time and after two washes with PBS, the level of formaldehyde 
in the preparation was reduced to <0.05 % as detected using a formaldehyde 
test kit (HACH, USA) (Figure 3-13).  
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Figure 3-13. Graph depicting % formaldehyde present in inactivated rHU58(MPT64) 
samples after PBS washes using centrifugation. -1 indicated starting concentration of 
formaldehyde, 0 indicates % formaldehyde after 24h at 37°C prior to washing, 1 and 2 indicate 
the number of PBS washes and % formaldehyde detected. % formaldehyde was reduced to 
<0.05% after 2 washes.  
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3.2.9. TB Study  
After determining the conditions for binding the MTB antigens to the spores and 
inactivating the recombinant spores, the spores were assessed in vivo and mice 
were dosed as described in (Figure 3-14). Groups included: naïve (Group A), 
BCG (Group B), HU58 + rMPT64 (Group C), HU58 + rAg85B-Acr (Group D), 
SWAN proteins (Group E), HU58 + SWAN (Group F), BGG with a booster 
vaccine of HU58 + SWAN (Group G), rHU58(MPT64) (Group H) and BCG with 
a booster of rHU58(MPT64) (Group I). The aim of the study was to i) asses the 
safety of the regimens, ii) measure the immunogenicity of the different regimens 
using ELISA and ELISPOT and iii) efficacy by measuring bacterial burden in the 
lungs and spleen as a marker of protection. 
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Figure 3-14. Study plan for immunisations and challenge. Mice (n=10) in groups C, D, E, F 
and H were immunised intranasally at weeks 3, 6 and 9. Mice (n=10) in groups G and I were 
dosed with BCG subcutaneously, followed by intransal dosing with spores at weeks 6 and 9. 
Group A received PBS at dosing time points. Group B had a single dose of BCG delivered 
subcutaneously. n=8 from each group were challenged with MTB at week 17, and four weeks 
later were culled and the lungs and spleens used to examine bacterial burden. 
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3.2.10. TB Study – Weight changes  
After the mice were administered with the relevant doses, the weights were 
monitored throughout the study as a marker of animal health and assess the 
safety of the dosing regimens (Figure 3-15). The mice all put on weight, which 
would indicate no adverse effect due to the immunisations.  
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Figure 3-15. Median weights of groups of mice recorded throughout the study. Weight 
increased until week 7, and then plateaued. Timing of doses indicated by dotted lines. BCG 
was given by subcutaneous injection. Spores and protein vaccinations were given intranasally. 
A; groups naïve (Group A), BCG only (Group B), HU58 + rMPT64 (Group C), B; groups HU58 + 
rAg85B-Acr (Group D), SWAN (Group E) and HU58 + SWAN (Group F), BCG + HU58 + SWAN 
(Group G), rHU58(MPT64) (Group H) and BCG + rHU58(MPT64) (Group I)  
A 
B 
C 
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3.2.11. TB Study dose verification 
Western blot analysis was carried out on the leftover doses (as an excess was 
originally made) for the groups after the doses were administered to verify that 
they had received the antigens. rMPT64 was identified in the HU58 + rMPT64 
dose, SWAN protein dose and HU58 + SWAN dose. rAg85B-Acr was identified 
in the HU58 + rAg85B-Acr dose, SWAN protein dose and HU58 + SWAN dose 
(Figure 3-16). 
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Figure 3-16, Western blot transfer and 12% SDS-PAGE electrophoresis using anti-
rAg85B-Acr and anti-rMPT64 antisera of the doses for TB Study. After dosing the mice, 
10µl of what remained of the doses was used for Western blot analysis to confirm that the mice 
had received correct doses (i.e. protein had bound to spores). Lane 1; rAg85B-Acr protein , 
Lane 2; HU58 + rAg85B-Acr (10 µg), Lane 3; HU58 + rMPT64 (10 µg), Lane 4; SWAN (10 µg 
each), Lane 5; HU58 + SWAN (10 µg each). 
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3.2.12. Antibody subclass ELISA 
To assess the immunogenicity of the vaccination regimens, serum was taken 
from tail bleeds before the study began and from terminal heart bleeds from two 
representative mice per group at the end of the immunisations (week 16) 
(Figure 3-14). The sera was used to measure rMPT64 and rAg85B-Acr specific 
total IgG, IgG1 and IgG2a (Figure 3-17, Figure 3-18). IgG1 is indicative of a 
Th2 response and IgG2a of a Th1-biased response.  
The antibody levels appear highest in the SWAN protein only group (Group E) 
across the MPT64 IgG subtypes. In the MPT64 coated plates, only HU58 + 
SWAN (Group F) has a higher than baseline response on the IgG1 plate, and 
HU58 + MPT64 (Group D) and HU58 + SWAN (Group F) in the IgG2a ELISA. 
The total IgG levels have a high background level on the MPT64 coated plates, 
which may mask the total IgG levels in the samples. This could be an assay 
problem and the antibodies may not be specific enough to MPT64.  
The Ag85B-Acr coated plates are more variable, with only one mouse in certain 
groups making a response, suggesting that the induction of systemic immune 
responses by the nasal route is variable.  
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Figure 3-17. IgG subclass ELISA of serum samples on plates coated with rMPT64 
(5µg/ml). Serum samples taken after immunisations (week 17) (Figure 3-2). Serum was diluted 
1:50 and then serially diluted down the plate. Anti-mouse IgG, IgG1 and IgG2a secondary 
antibodies were all HRP conjugates. The OD at 450 wavelength shown. Each dot represents 
and individual sample and the line shows the mean. White – pre immune, black – naïve, navy – 
BCG, brown – HU58 + Ag85B-Acr, dark red – HU58 + MPT64, orange – SWAN protein, purple 
– HU58 + SWAN, green – BCG + HU58 + SWAN, red – rHU58(MPT64), blue – BCG + 
rHU58(MPT64), dark green – MPT64 protein as a positive control. 
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Figure 3-18. IgG subclass ELISA of serum samples on plates coated with rAg85B-Acr 
(5µg/ml). Serum samples taken after immunisations (week 17) (Figure 3-2). Serum was diluted 
1:50 and then serially diluted down the plate. Anti-mouse IgG, IgG1 and IgG2a secondary 
antibodies were all HRP conjugates. Each dot represents an individual sample and the line 
represents the mean. White – pre immune, black – naïve, navy – BCG, brown – HU58 + Ag85B-
Acr, dark red – HU58 + MPT64, orange – SWAN protein, purple – HU58 + SWAN, green – BCG 
+ HU58 + SWAN, red – rHU58(MPT64), blue – BCG + rHU58(MPT64), dark green – Ag85B-Acr 
protein as a positive control. 
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3.2.13. IFNγ ELISPOT 
Splenocytes were isolated from two mice from each immunisation group as a 
representative sample of the cellular immunogenicity induced by the 
immunisations. Splenocytes were stimulated overnight with rMPT64, rAg85B-
Acr and PPD MTB antigens and then IFNγ production calculated per 106 cells 
(Figure 3-20).  
There does appear to be some MPT64 specific IFNγ production in splenocytes 
from the HU58 + MPT64 group (Group D), HU58 + SWAN (Group F) and BCG 
+ rHU58(MPT64) (Group I). Mice in the following groups show some Ag85B-Acr 
specific immune responses; BCG (Group B), HU58 + Ag85B-Acr (Group C), 
HU58 + SWAN (Group F) and BCG + HU58 + SWAN (Group G). PPD is used 
as a general stimulation for MTB specific cells but only animals in the BCG 
boosted groups show any responses to PPD (Group G and Group I). Only two 
mice were used in the ELISPOT assay, therefore there was a significant 
amount of variation and the induction of an IFNγ immune response seems to be 
inconsistent. If the study was repeated with more mice, it would give a clearer 
picture as to the reliability of the vaccines to induce a Th1 response. 
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Figure 3-19. Graph of IFNγ ELISPOT results of SFU/10
6
 splenocytes from two 
representative mice from each group. Spleens were taken from representative mice at week 
16 after immunisations (Figure 3-2). Cells were isolated from the spleen and 5x10
5
 cells were 
stimulated overnight with either rMPT64 (10µg), rAg85B-Acr (10µg) or PPD (20µg) at 37°C on 
an ELISPOT plate coated with anti-IFNγ capture antibody. The ELISPOT was developed 
according to manufacturer instructions and spot forming units (SFU) were measured using a 
CTL ELISPOT reader. Media only wells were subtracted from antigen stimulated wells and 
results were calculated to SFU/10
6
 cells. Dots show individual samples and lines represent the 
mean. White – pre immune, black – naïve, navy – BCG, brown – HU58 + Ag85B-Acr, dark red – 
HU58 + MPT64, orange – SWAN protein, purple – HU58 + SWAN, green – BCG + HU58 + 
SWAN, red – rHU58(MPT64), blue – BCG + rHU58(MPT64). 
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3.2.14. Protection data 
Following the immunisation regimens, eight of the ten mice were challenged 
intranasally with MTB at week 17 and followed for four weeks by Dr Rajko Rejlic 
(SGUL) (Figure 3-14). At the end of the four weeks, the mice were culled and 
the lungs and spleens were plated out and colony counts used to estimate 
bacterial load (Figure 3-20, Figure 3-21). Mice with no recoverable MTB were 
excluded from calculations because it could indicate that they were not 
successfully challenged with MTB. However, this means that strong conclusions 
cannot be made from the resulting data because the reliability of the challenge 
method cannot be verified. Bacteria in the lungs would indicate active disease, 
and bacteria in the spleens were a characteristic associated with dissemination.  
BCG (Group B) was used to compare the vaccine preparations against, as this 
is the current vaccine so any future vaccine would need to perform at least as 
well or better than BCG. Spores with rAg85B-Acr (Group C) showed the 
greatest reduction in comparison to PBS (Group A). In the lungs, the spores 
with rMPT64 (Group D) in general showed a reduction in bacterial burden, but 
two mice returned higher MTB counts than PBS, so protection seems to be 
inconsistent. SWAN protein alone (Group E) did not reduce the bacterial burden 
greatly. It was improved with spores (Group F), but the median reduction was 
not better than rAg85B-Acr (Group C), so there appears to be no additive effect 
of using all proteins (Ag85B-Acr and MPT64 in the SWAN preparation). The 
responses to rHU58(MPT64) (Group H) were mixed as there were clear groups 
that were protected and not protected. rHU58(MPT64) with BCG (Group I) 
showed a lower bacterial burden in comparison to the recombinant spores 
alone. The greatest reduction in bacterial burden in the lungs were in the BCG 
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(Group B), spores with rMPT64 (Group D), BCG with HU58 + SWAN (Group G) 
and rHU58(MPT64) spores booster (Group I).  
Overall, it would seem that both proteins separately in conjunction with spores 
(Groups C and D) were able to reduce bacterial burden after challenge with 
MTB, and were much better than protein alone (Group E). However, when both 
proteins were used together with the spores (Group F), there appeared to be no 
further decrease in CFU. The recombinant spores rHU58 (MPT64) (Group H) 
were not as successful as the protein adsorbed to spores, but when used with 
BCG (Group I), they did reduce the bacterial burden in the lungs and spleen to 
lower levels than BCG alone (Group B). 
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Figure 3-20. Lung CFU data. Four weeks after MTB challenge of mice that had been 
immunised according to the schedule with spores/protein (Figure 3-2) the lungs were 
homogenised and plated out on 7H11 agar and incubated for four weeks to measure MTB CFU.  
Median data shown and Mann-Whitney test performed (p=0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-21. Spleen CFU data. Four weeks after MTB challenge of mice that had been 
immunised according to the schedule with spores/protein (Figure 3-2) the spleen was 
homogenised and plated out on 7H11 agar and incubated for four weeks to measure MTB CFU.   
Median data shown and Mann-Whitney carried performed (p=0.05). 
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3.3. Discussion 
3.3.1. Vaccine formulations 
3.3.1.1. Protein bound to the surface of the spores 
B. subtilis spores have been used as a vaccine adjuvant carrying protein 
previously, including one experiment where whole virus was adsorbed to the 
spore surface (Song et al. 2012). In general, spores have been used to carry 
one protein only but in this work, it has been demonstrated that the spores were 
able to bind two proteins at the same time, and that one protein did not affect 
the binding of the other. This could be useful in the future for spore vaccines 
because more antigens may improve the diversity of the immune response 
since the immune system would be able to recognise more than one antigen. In 
the TB field, vaccines are being produced that carry more than one antigen to 
improve the range of the immune response (Khera et al. 2005). For example, 
vaccine H56, which carried early antigens Ag85B and ESAT6, as well as 
latency antigen Rv2660c showed an enhanced level of protection in comparison 
to BCG against TB challenge in mice, and protection was longer-lasting 
(Aagaard et al. 2011). The optimum pH of binding of rAg85B-Acr and rMPT64 in 
this case was similar, but this would need to be taken into account when adding 
more or different proteins to the vaccine. In terms of practical use as a vaccine, 
it was demonstrated that the protein remained bound to the spores after storage 
at 4°C and -20°C, but that the concentration of protein was reduced. A method 
for stabilising the protein on the surface to guarantee dose would need to be 
optimised, or the reduction taken into account when dosing. 
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3.3.1.2. Recombinant spores 
Recombinant spores have been used previously against C. difficile 
(Permpoonpattana et al. 2011) and anthrax (Duc et al. 2007). One of the 
advantages of using recombinant spores is that the expression of antigen is 
more uniform than protein bound to the surface. We demonstrated here that the 
spores could express rMPT64 in the spore coat and were weakly expressed on 
the surface. Other spore vaccine preparations have used CotB as a fusion 
protein because it is abundant in the spore coat, and have detected the antigen 
using confocal microscopy (Permpoonpattana et al. 2011; Duc et al. 2007). In 
this experiment, the fusion of MPT64 to CotB could not be detected on the 
surface strongly using ELISA, immunofluorescence or flow cytometry (data not 
shown) but this could be because these techniques depend on the antigen 
being surface exposed whereas confocal microscopy can examine interior 
structures. The results here are supported by data from Hinc et al that showed 
that when UreA was expressed fused to CotB, CotC and CotG, the 
fluorescence was weakly detected with CotB when using immunofluorescence 
(Hinc et al. 2010). Isticato et al also demonstrated that CotB could be detected 
using flow cytometry, but when CotB-TTFC was expressed, the antigen-specific 
fluorescence was very weak (Isticato et al. 2001a). Isticato et al hypothesised 
that the low surface expression was due to the full-length CotB also being 
present (Isticato et al. 2001a). Imamura et al have examined the localisation of 
different spore proteins using immunofluorescence and have found that whilst 
CotB is in the outer spore coat, it is not on the outside of the spore, and 
therefore it could be that the antigen is covered by the spore crust (Imamura et 
al. 2011). Other researchers have investigated using spore crust proteins; CotZ 
and CgeE as fusion proteins for surface display of enzymes or antigens instead 
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(Mascher et al. 2012; Negri et al. 2013).Despite the antigen possibly not being 
surface expressed, the MPT64 antigen was confirmed to be expressed in the 
spore coat using Western blotting and the spores expressing CotB-MPT64 still 
provided some protection against TB challenge. This could be because the 
spores are phagocytosed and degraded and therefore the digested spore coat 
proteins and antigens can still be presented by APCs to provoke the production 
of antigen-specific antibodies.  
There are several vaccines that use formaldehyde to inactivate active 
components before delivering the vaccine. Examples include; Polio (Salk & Salk 
1984) and Hepatitis A (Pellegrini et al. 1993) vaccines. Recombinant Bacillus 
spores need to be inactive because they carry antibiotic resistance genes that 
could be potentially transferred to other bacteria. The levels of formaldehyde 
have to be reduced to a safe level before administration, as formaldehyde is a 
likely carcinogen and relatively toxic. In this experiment, recombinant spores 
were able to be significantly inactivated by formaldehyde. The formaldehyde 
was removed effectively with washing so that it did not affect the health of the 
animals. The main problem with this method of inactivation was that not all of 
the spores were inactivated, so there is a chance some of them could proliferate 
in the host. However, the method is being further optimised by other lab 
members as part of the CDVAX project, which is developing the spore based 
vaccine described by Permpoonpattana et al for use in a human clinical trial 
(Permpoonpattana et al. 2011, www.CDVAX.org). An alternative method for 
using recombinant spores is also being investigated in the Cutting lab is to 
clone antigens into B. subtilis without using antibiotics, therefore removing the 
risk of antibiotic resistance transmission (unpublished).  
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Figure 3-22. Schematic of the organisation of the spore coat proteins. Adapted from 
(Imamura et al. 2011) 
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3.3.2. Immune responses and protection 
3.3.2.1. Antibody ELISA 
 
The antibody titres after vaccination were very low, apart from the SWAN 
protein alone samples. The SWAN protein was delivered intranasally using 
Alum, which is an adjuvant that is known to stimulate Th2 biased immune 
responses (Marrack et al. 2009), which could account for why the antibody titres 
were higher. The dosing route may also have affected the systemic immune 
responses. White et al has shown in NHPs that the antibody titres were much 
lower when aerosol BCG was compared to BCG delivered subcutaneously 
(White et al. 2013). 
In previous studies carried out at Royal Holloway by Huang et al, three doses of 
spores were given, the last dose on day 43 and the serum taken for ELISA on 
day 63 (Huang, Hong, et al. 2010). In this study there was an eight week gap 
(approximately 56 days) between the last dose and taking the samples for 
immunogenicity experiments because we wanted to see what the state of the 
immune system was around the time of MTB challenge. However, this could 
mean that the antibody titre could have waned by this point.  The study should 
be repeated and serum taken earlier after vaccination to detect antibody 
responses and more animals should be used. 
 
3.3.2.2. IFNγ ELISPOT 
There appeared to be some antigen specificity in the IFNγ ELISPOT immune 
responses, and together with the IgG ELISA data, the spores appear to promote 
cellular immune responses over antibody responses. However, the ELISPOT 
responses are low overall in comparison to some studies (Kamath et al. 1999) 
but are comparable to those reported by Esparza-Gonzalez et al, who also used 
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B. subtilis spores to deliver MTB antigens ESAT-6 subcutaneously (Esparza-
Gonzalez et al. 2014) and Kaveh et al also showed ELISPOT results of 
between 100-500 SFU/million cells in splenocytes after BCG vaccination 
(Kaveh et al. 2011). Picking an earlier time point after vaccination may have 
shown stronger responses. Santosuosso et al has shown that there was a high 
level of IFNγ production two weeks after vaccination intramuscularly with 
AdAg85A, which had declined by week eight (Santosuosso et al. 2006). 
Therefore, due to the immunological analysing being undertaken 17 weeks after 
BCG and 8 weeks after the other vaccination regimens, the peak IFNγ 
ELISPOT response may have been missed. 
The route of immunisation is also important as although in some studies, 
mucosal dosing has shown comparable systemic immune responses to 
injection routes (Cuburu et al. 2007), other studies have shown that there are 
poor systemic antigen specific T-cell responses after intranasal dosing in 
comparison to injectable delivery of vaccine, although the responses in the 
lungs and BAL were higher (Santosuosso et al. 2006; White et al. 2013).  
The study could be improved by using more animals, changing the time that 
immune responses were monitored to be earlier after vaccination and analysing 
responses in mucosal tissues as well as splenocytes. 
3.3.2.3. Protection 
 
The data suggested that the spores that carried MPT64 and Ag85B-Acr proteins 
did cause a reduction in bacterial burden below that of PBS. However, because 
some animals did not appear to be infected with MTB, as demonstrated by the 
lack of CFU from some of the tissues, strong conclusions cannot be drawn from 
the data. Either the animals were able to fight off the TB infection completely or 
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the nasal dosing of MTB was not consistently able to cause disease, which 
means that the dose of MTB could be variable for all animals. The study needs 
to be repeated to get more consistent infection.  
3.4. Conclusions  
Although there was a lack of strong immune responses seen in the test animals, 
there does appear to be some reduction in bacterial burden after nasal dosing 
with spores. In the literature, it has been shown that Adenovirus carrying Ag85A 
delivered nasally had poor systemic immune responses in mice, but provided 
better protection than when delivered intramuscularly (Santosuosso et al. 2006) 
so a lack of peripheral immune response may not necessarily mean that no 
protective immune responses have been mounted. It would be important in the 
future to use lung samples and BAL washes to assess mucosal immune 
responses, as done by others in the field (Redford et al. 2010; Algood & Flynn 
2004; White et al. 2013). 
Vaccine development for TB is difficult because of the lack of correlates of 
protection. IFNγ is known to be important because IFNγ knock-out mice are 
much more susceptible to TB (Cooper et al. 1993). IFNγ activates 
macrophages, which are important in the initial infection by MTB (Ehrt & 
Schnappinger 2009). The problem with IFNγ is that it is required for protection, 
but high levels do not guarantee protection. This was also observed by Sharpe 
et al in a non-human primate (NHP) study, where primates who had high post-
vaccination levels of IFNγ succumbed to infection quickly after challenge 
(Sharpe et al. 2010).   
In this study, a reduction in bacterial burden in the lungs and spleen in mice in 
test groups compared to PBS was observed. The mouse model is useful 
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because there is the capacity to measure the immune response. However, 
disease progression in mice is very different to human disease as they do not 
form granulomas in the lungs and control the disease differently. The mouse 
model also does not develop latent disease, but has chronic disease instead, 
and host-to-host transmission has not been successfully mimicked (Korbel et al. 
2008). The other rodent model that is utilised for TB research is the guinea pig 
because it is sensitive to TB and forms granulomas (Williams et al. 2009). 
However, there are not many immunological reagents developed for the guinea 
pig so it is useful for looking at survival, but not at immune responses. The non-
human primate (NHP) model is the best animal model for TB because disease 
is much closer to the human disease, there are reagents available to monitor 
the immune response and multiple and relatively large blood samples can be 
taken at intervals to monitor the immune response over time (Sharpe et al. 
2010). However, the NHP model is expensive and specialist facilities are 
required to house NHPs at containment level 3 (CL3) because MTB is an 
ACDP3 organism. Other general problems with animal models are that the 
immune system does differ to humans; for example in mice, the antibody 
subclasses are different, and therefore it can be difficult to relate the results 
back to humans. This was important in the TGN1412 clinical trial. The TGN1412 
treatment was for autoimmune diseases and was safe in primate studies, but 
caused severe life-threatening illness in primary clinical trials. The cause of this 
was that there was a difference in the structure of the CD28 receptor the 
antibody recognised between primates and humans, which explained why they 
saw no adverse effects in primates (Attarwala 2010). 
The lack of correlates of protection makes research into novel vaccines difficult 
and relies on big clinical trials with large cohorts of patients to see any 
Laura Sibley Chapter 3: Spores as a Vaccine Adjuvant for Tuberculosis 
 
113 
protective effects. Clinical trials are expensive and time consuming, as TB is a 
slow infection and it can take years for active TB disease to develop so long 
follow up times with patients are required. Research is underway to investigate 
in vitro tests that can be used to validate biomarkers and vaccines. For 
example, continuous culture of MTB has been used to mimic conditions of 
oxygen limitation and latency, which has provided gene expression data that 
could yield useful targets for vaccine development (Bacon & Marsh 2007). 
Another approach is to find early correlates of protection after vaccination to 
reduce the length of time of clinical trials. A mycobacterial inhibition assay is 
showing some promise and can show that BCG vaccinated individuals inhibit 
MTB growth better than unvaccinated persons (Marsay et al. 2013; Fletcher et 
al. 2013). 
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Chapter 4: Localisation of Spores after Dosing by 
 
Different Mucosal Routes 
 
4.1. Introduction 
 
There is considerable interest in mucosal vaccines as an alternative to 
injectable vaccines for many reasons including ease of use and needle-free 
administration which reduces the risk of transmission of blood-borne diseases. 
A major advantage of mucosal vaccines is that the mucosa is the major portal of 
entry for many pathogens and therefore immune cells active at mucosal sites as 
more relevant (Neutra & Kozlowski 2006) and in some cases are able to 
stimulate systemic immune responses as well. For example, Kowolski et al 
demonstrated that after nasal, rectal and vaginal immunisation with cholera 
toxin, IgG in the sera could be detected (Kozlowski 2002).  There is evidence 
that suggests that injectable vaccines are less able to elicit mucosal immune 
responses, as demonstrated by Santusuosso et al that after intramuscular 
vaccination with AdAg85A there were fewer CD4+ and CD8+ cells in the BAL 
and lungs in comparison to intranasal vaccination in mice (Santosuosso et al. 
2006). However, Kaveh et al showed IFNγ ELISPOT responses in the lung after 
intradermal BCG vaccination in mice (Kaveh et al. 2011).  
There are three main routes for mucosal vaccination; nasal, oral and sublingual 
(Holmgren & Czerkinsky 2005; Czerkinsky et al. 2011). The MALT tissues are 
linked and immunisation via each route should be able to stimulate specific 
immune responses at other mucosal locations (Holmgren & Czerkinsky 2005). 
One of the challenges of using oral dosing is that the gut is specialised to 
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tolerate foreign entities such as food and commensal bacteria, which means 
that it can be difficult to induce an immune response and for the gut to not 
develop tolerance to the antigens. The immunosuppressant environment of the 
gut is regulated by Tregs and Th3 cells producing IL-10 and TGFβ. DCs in the 
gut default to Th2/Th3 cell stimulation in comparison to Th1 biased spleen DCs, 
and so produce anti-inflammatory cytokines including IL-4, IL-5, IL-10 and TGFβ 
that reduce potential immune stimulation (Iwasaki & Kelsall 1999). Despite the 
problems associated with oral dosing, there are licenced oral vaccines against 
polio, cholera and typhoid (Holmgren & Czerkinsky 2005). 
Nasal dosing can directly access the lungs and so would be suitable for 
respiratory pathogens, such as TB. There is a nasal vaccine licensed for 
influenza (Van Kampen et al. 2005) and aerosol vaccines are also under 
investigation for TB (White et al. 2013). Safety concerns exist for nasal 
vaccination, most notable of which is that it could cause Bell’s palsy, which is a 
form of facial paralysis (Czerkinsky et al. 2011), as has been the case after 
nasal administration of cholera toxin and E.coli labile toxin as adjuvants in the 
flu vaccine ‘Nasalflu’ (Rath et al. 2007). After investigation, it was found that the 
toxicity was due to the toxins binding to neuronal cells. ‘Flumist’, a nasal flu 
vaccine that does not contain any toxins, has had no cases of Bell’s palsy 
associated with it (Rath et al. 2007). Therefore, the risk of Bell’s palsy after 
nasal administration is small, and is dependent on the adjuvant used.  
Sublingual dosing is administered under the tongue, and for example, glyceryl 
trinitrate medication for angina is administered by this route (NHS 2014a) since 
the drug can access the bloodstream faster because the sublingual mucosa is 
highly vascular. The other advantages are that sublingual dosing avoids 
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destruction by the acid in the stomach and avoids metabolism in the liver that 
could affect the vaccine formulation and potency. Sublingual dosing is attracting 
more attention as a vaccine delivery route because they have been used for 
allergy treatments with no adverse effects and show good humoral and cellular 
immune responses (Shim et al. 2013). The sublingual mucosa is packed with 
DCs, which are mobilised on immunisation, so that large proteins can be 
disseminated to lymphoid tissue (Amuguni et al. 2012). A comparison of the 
different routes of mucosal vaccination by Czerkinsky et al indicated that 
systemic antibody responses were highest after sublingual and nasal 
vaccination with ovalbumin and cholera toxin adjuvant. Secretory IgA (sIgA) 
was detected in the respiratory tract, stomach, small intestine, genital tract and 
blood after sublingual dosing, respiratory tract and blood after nasal dosing and 
in the stomach, small intestine, colon, rectum and blood after oral dosing 
(Czerkinsky et al. 2011).  
B. subtilis spores have been shown to be efficacious in oral (Permpoonpattana 
et al. 2011), sublingual (Amuguni et al. 2011) and nasal (Song et al. 2012) 
dosing regimens, but the mechanism of how the spores cross mucosal barriers 
to be able to generate responses is not well defined. M cells, the specialised 
epithelial cells that are able to transport antigens across the epithelium to 
immune cells are a target in the development of mucosal vaccines because if 
uptake by M cells can be increased, then the presentation of the antigen to the 
immune cells would also be improved. The uptake of spores by M cells has 
been shown in the appendix of rabbits (Rhee et al. 2004), but in this chapter, 
lung and NALT M cells have also been investigated as M cells are present in all 
epithelium. MTB has been demonstrated to be able to enter lung tissue via M 
cells (Teitelbaum et al. 1999) and Group A Streptococci can translocate M cells 
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of the NALT (Park et al. 2003), therefore providing some evidence that certain 
bacteria translocate into tissues via M cells in these locations.  
Macrophages have been shown to phagocytose spores in vitro (Huang, La 
Ragione, et al. 2008; Duc et al. 2004), but how much of a role they play in vivo 
is less well understood. DC maturation, which is an indication that DCs are 
presenting antigen and are capable of migration, was demonstrated with spores 
in vitro by Song et al (Song et al. 2012) and in vivo by de Souza et al (de Souza 
et al. 2014). DCs may be important in activation of the immune system after 
delivery of spores because of their ability to sample the lumen outside of the 
epithelial layer. Macrophages and DCs, as APCs are important immune cells for 
vaccine research because of their ability to prime T-cells and develop the 
memory response. Neutrophils were also examined because they are usually 
the first phagocyte to reach the site of infection and are responsible for bacterial 
clearance. Identifying the phagocytes responsible for clearance of spores could 
be advantageous because it would provide evidence that the spores were 
cleared and would not induce inappropriate immune responses.  
The epithelium in the mucosa is an important barrier to keep pathogens from 
entering tissues and causing infections, but this also means it is a barrier to 
mucosal vaccines. It is important for the spores to be able to cross the 
epithelium so that they can elicit immune responses. In this chapter, the 
distribution of spores, ability to enter the lung tissue and the clearance of spores 
in the lungs after nasal dosing was examined to provide some preliminary 
information about how well the spores could enter the lungs and the length of 
time before they were cleared. The information from this study informed the 
following experiment, where the nasal route was compared to the oral and 
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sublingual routes to investigate the distribution of spores to the lungs, gut and 
NALT tissue. The distribution of spores after dosing by each route is also 
important as it may dictate where the strongest immune responses will be. 
Spores were also characterised by flow cytometry. Flow cytometry uses light 
scattering to determine relative size and granularity of cells and is commonly 
used in haematological analysis to determine granulocytes, monocytes and 
lymphocyte populations. Flow cytometry is not as frequently used in 
microbiology as in the immunology field, but there are applications for it to be 
used; i) in identifying bacteria (Holm et al. 2004), ii) analysing cell cycles, iii) 
sporulation, iv) taxonomy (Cronin & Wilkinson 2010) and v) biofilm formation 
(Garcia-Betancur et al. 2012) in bacteria. Some previous publications have 
described evaluating spores on the flow cytometer to detect antigen expression 
(Isticato et al. 2001b; Kim et al. 2005), GFP expression when fused to CotG 
(Kim et al. 2007) or live/dead populations (Virta et al. 1998) however this has 
not been done using the BD Accuri C6 nor were the populations of spores and 
vegetative cells described. Analysis of the FSC-SSC profile of Paenibacillus 
polymyxa, (a spore former)  was able to identify vegetative cells and two types 
of spores, which was confirmed using electron microscopy (Comas-Riu & Vives-
Rego 2002) and demonstrated that flow cytometry is a useful and sensitive tool 
for characterising spore forming bacteria. 
The method for intracellular staining of spores inside mammalian cells was 
optimised prior to the in vivo experiments. Examining uptake of particles using 
the flow cytometer has been described by Byersdorfer and Chaplin (Byersdorfer 
& Chaplin 2001) using stained beads and tracking their temporal movement to 
from the lungs to the lymph nodes. Trouillet et al described a method for 
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staining Staphylococcus aureus inside cells in vitro after invasion and detecting 
these on the flow cytometer using saponin to permeabilise the cells so as to 
allow entry of the antibody into the cell interior to label the bacteria (Trouillet et 
al. 2011). The method is not dissimilar to intracellular cytokine staining used in 
Chapter 3 and described by Beveridge et al (Beveridge et al. 2007).  
Live and autoclaved spores were used for the experiments because both states 
could potentially be used in vaccine preparations. The advantage of using 
autoclaved spores is that they will not germinate and therefore will present the 
antigen for longer because the antigen is on the surface of the spore. 
Autoclaved spores have been shown to be able to carry antigens and elicit 
antibody responses (Song et al. 2012; Huang, Hong, et al. 2010), but there is 
evidence to suggest that they are less immunogenic, as de Souza 
demonstrated that heat-killed spores induced lesser amounts of IL-4, IFNγ, 
TNFα, IL-12, IL-1β and there was lower expression of MHC I and MHC II on 
DCs in comparison to live spores (de Souza et al. 2014). Therefore, the initial 
interactions of live and autoclaved spores with host cells were examined to see 
whether it could be responsible for the differences in adaptive immune 
responses later on. 
4.1.1. Aims 
The overall aim of this chapter was to compare oral, nasal and sublingual routes 
of immunisation and their ability to deliver spores to different tissues. The 
capability of spores to cross the mucosal barrier is important as it might affect 
dosing and could imply where the strongest immune responses could be 
generated. The cells that phagocytose the spores are also important and will 
have downstream implications for the adaptive immune responses. Live and 
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autoclaved spores were compared to see whether there was a difference in 
uptake dependent on the physiological state of the spore. 
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4.2. Results 
4.2.1. Detection of fluorescent spores, DS127 
 
A strain of B. subtilis, DS127 (amyE::cotC-GFP), that expresses Green 
Fluorescence protein (GFP) on the spore surface was used and has been 
described elsewhere (Isticato et al. 2001b). GFP is fused in frame to the 
carboxy-terminus of the outer spore coat protein CotC. Spores of DS127 were 
purified and GFP expression confirmed by fluorescence microscopy using a 
FITC laser and green fluorescent spores were observed. PY79 spores, which 
are isogenic to DS127 and do not express GFP were used as the negative 
control in parallel and PY79 spores were found to exhibit little background 
fluorescence (Figure 4-1). Background fluorescence is caused by the natural 
autofluoresence of biological material and can be due to certain proteins and 
molecules. In the case of spores autofluorescence is hypothesised to be due to 
the dityrosine proteins that crosslink coat proteins and pigments present 
(Magge et al. 2009). The poles of DS127 exhibited greater fluorescence, which 
corresponds with data from Isticato et al that demonstrated that CotC was 
localised here (Isticato, Sirec, Giglio, et al. 2013). 
4.2.2. Analysis of infection of RAW267.4 macrophages with DS127 spores 
 
Macrophages have previously been shown to phagocytose spores in vitro (Duc 
et al. 2004), and was confirmed here to determine whether DS127 spores could 
be identified in cell culture. RAW267.4 macrophages were infected with DS127 
spores. After thirty minutes co-infection with spores, the cells were fixed and the 
nuclei stained with DAPI. Slides were examined using an EVOS microscope at 
100x magnification. Large clumps of spores were evident in the cytoplasm of 
some of the macrophages (Figure 4-2). This demonstrates that macrophages 
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are indeed capable of engulfing spores and that DS127 can be detected inside 
RAW267.4 cells in culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Fluorescence microscope images showing DS127 spores expressing GFP. 
Spores were grown and purified as outlined in the methods (Chapter 2) and ~1x10
8
 aliquoted 
and dried onto coverslips. Slides were examined using a Nikon fluorescent microscope with a 
FITC laser. Panel A, DS127 spores expressing GFP; panel B, PY79 spores. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. Immunofluorescence images of DS127 spores inside the cytoplasm of 
RAW267.4 macrophages. Macrophages were grown as a monolayer for 48h and then 
incubated with 1x10
8
 spores for 30 min at 37°C. Green (spores). Macrophage nuclei were 
stained for 5 min at RT with DAPI (blue). Examined at 100x magnification using an EVOS fl 
microscope. 
A B 
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4.2.3. Analysis of lung tissue samples infected with DS127 spores 
 
C57BL/6 Mice (n=4) were dosed intranasally with 2x109 DS127 spores and 
culled at 2, 6, 24 or 48h post-immunisation. The lungs were removed and fixed 
in 10% (v/v) neutral buffered formalin (NBF). Embedding, tissue sectioning and 
staining was carried out at TUPI Ltd. Some lung section slides were left 
unstained and other tissue section slides were stained using haematoxylin and 
eosin stain (H&E) so that the lung tissue structure could be observed.  
Although the spores were not stained, they were identified in the H&E sections 
by i) relative size in comparison to the cells and ii) being phase-bright, a 
characteristic of spores (Figure 4-3). At 2h, spores were seen in the lungs, and 
were in general found to cluster in the bronchiolar regions and in the airways. 
This confirmed that spores administered intranasally could enter the lungs, but 
after 2h, did not penetrate the tissues to any great extent. After 6h, spores could 
still be identified in the bronchioles and had moved into the alveolar regions of 
the lung. There were changes in the tissue and there was an infiltration of cells 
and some phagocytosis could be observed. Spores were rarely identified in the 
24h and 48h samples, but there was a change in the cell populations in the lung 
tissue. Cellular infiltration was identified and monocytes/macrophages were 
observed with many phagosomes in the cytoplasm. Confocal images were 
taken by Dr Andreas Hoppe (Kingston University, London). Spores could be 
identified in the airways, but the spores were not bright enough to be able to 
distinguish them from the natural autofluorescence of the lung tissue.  
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Figure 4-3. Representative images of H&E stained lung sections from mice that had been 
dosed intranasally with 2x10
9
 DS127 spores and culled at time points after dosing. 
Samples from C57CL/6 mice at 0, 2, 6, 24 and 48h after intranasal dosing with 2x10
9
 
DS127spores. Arrows indicate spores.  
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4.2.4. Detecting spores using a flow cytometer 
 
Before dosing the mice for the next study, DS127 spores were grown in liquid 
DSM at 37°C for 48h and samples were taken at intervals and compared to 
purified spores to i) characterise the populations of vegetative cells and spores 
in the medium, and ii) determine how these populations changed over time, so 
that they would be easier to identify in mouse tissue samples after dosing using 
the flow cytometer. 
Forward Scatter (FSC) and Side Scatter (SSC) were used to characterise how 
the different cells appeared on the flow cytometry plot. There was a distinct 
difference in the FSC between actively growing vegetative cells and purified 
spores (Figure 4-4). After 6h growth, only one population of cells could be 
detected and it was confirmed under the microscope that these were vegetative 
cells. After 24h, two distinct populations were apparent, one under 20,000 FSC 
units, and the other over 20,000 FSC units (Figure 4-4). These populations 
became more distinct over time. After purification of spores, there was only one 
population which was above 20,000 FSC units and this was confirmed by 
microscopy as spores. Vegetative cells of B. subtilis are longer (1-2 µm) than 
spores (~1 µm) but are of smaller relative size as measured using FSC in the 
flow cytometer. This might be because FSC-A (forward scatter area) was used 
and the distance across the vegetative cell is smaller than that of a spore. 
These results were confirmed with spores of various other strains (HU58, 
PP108) and species such as C. difficile 630 by other lab members. 
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Figure 4-4. Spore development characterised on the flow cytometer. DS127 was grown in 
liquid DSM and 1ml samples taken at intervals and ~100µl run on the flow cytometer to 
determine how the populations of vegetative cells and spores appeared on the flow cytometer. 
Plots show two distinct populations separated by SSC and FSC on the density plot and by FSC 
on the histogram.  
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4.2.5. Detection of fluorescent spores 
 
DS127 spores express GFP, but the fluorescence needed to be detectable on 
the flow cytometer to be able to identify them in the mouse dosing experiment. If 
the fluorescence could not distinguish between wild-type spores and DS127 
then an antibody-based method would be required. Spores harvested at 
different days were also tested, but none of the DS127 batches expressing GFP 
had sufficient fluorescence to distinguish them from PY79 spores that did not 
express GFP. Anti-spore primary antibody was therefore used, followed by a 
secondary antibody conjugated to FITC, whereupon the spores were 
successfully shown to be fluorescent (Figure 4-5). 
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Figure 4-5. Detection of fluorescence using anti-spore and anti-FITC antibodies. Spores 
were blocked with BSA for 10 min and incubated with anti-spore primary antibody for 10 min, 
washing and using anti-rabbit IgG-FITC before washing with PBS and running on the BD Accuri 
C6. A; PY79 without antibodies, B; DS127 without antibodies, C; DS127 with antibodies, D, 
overlay of plots with and without antibodies; Black; PY79 wild-type spores with no antibodies, 
Green; DS127 with no antibodies. Red; DS127 with antibodies, showing a distinct shift in 
fluorescence.  
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4.2.6. Comparison of the morphology of live and autoclaved spores 
 
Live and autoclaved spores were aliquoted onto a microscope slide to visually 
compare them and observe any obvious morphological differences that could 
account for potential differences observed in later experiments when used for 
dosing. The live HU58 spores were uniformly shaped, scattered and phase-
bright (Figure 4-6). In comparison, autoclaved spores were more clumped, less 
phase-bright and somewhat smaller. However, the spores did retain their 
shape. Therefore, even at the level of light microscopy, morphological 
differences can be observed between live and autoclaved spores. 
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Figure 4-6. Phase contrast images of live HU58 and autoclaved HU58 spores. 1µl of each 
spore suspension added to slide with 5µl water and examined using oil immersion and phase-
contrast microscope. Panel A; live HU58 spores, Panel b; autoclaved HU58 spores. Pictures 
taken at 100x magnification using Nikon Ti Eclipse microscope. 
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4.2.7. Spore coat extracts of live and autoclaved spores 
 
To investigate the damage to the spore coat following autoclaving, the spore 
coats were extracted and run on an SDS-PAGE gel to look at whether the 
surface proteins were denatured after autoclaving. Anti-spore, anti-CotB and 
anti-CotC antibodies were used in a Western blot of the spore coat extracts to 
determine whether the antibodies could detect autoclaved spores and whether 
the coat proteins were damaged beyond antibody recognition. The results 
showed that no spore coat proteins could be seen in the SDS-PAGE gel and 
CotB and CotC spore coat proteins could not be detected by Western blot in 
autoclaved spores (Figure 4-7). However, anti-spore antibody still was able to 
detect the autoclaved spores, so there must be some proteins that had 
remained intact for the antibody to bind to (Figure 4-7). 
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Figure 4-7. Spore coat extract analysis of live and autoclaved HU58 spores. Spore coats 
extracted from 2x10
9
 live and autoclaved HU58 spores were run on a 4-12% gradient SDS-
PAGE gel and stained with coomassie blue and ladder shows kDa. Lane 1; live HU58, lane 2; 
autoclaved HU58. The gel was then transferred to a membrane and anti-spore, anti-CotB or 
anti-CotC antibodies (both 1:4000) used to detect spore coat proteins. Lane 3; live HU58, lane 
4; live HU58 diluted 1:2, lane 5; autoclaved HU58 with anti-spore antibody, lane 6; live HU58, 
lane 7; autoclaved HU58 with anti-CotB antibody, lane 8; live HU58, lane 9; autoclaved HU58 
with anti-CotC antibody. Anti-spore detected using anti-rabbit IgG-HRP, anti-CotB and anti-CotC 
detected with anti-mouse IgG-HRP. 
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4.2.8. Demonstration of fluorescent antibody binding to live and 
autoclaved spores 
 
Anti-spore and anti-rabbit IgG-FITC antibodies were used to identify live and 
autoclaved spores using the flow cytometer. Autoclaved spores were able to 
bind the antibodies and showed a similar fluorescence intensity to live spores 
(Figure 4-8).  
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Figure 4-8. Detecting live and autoclaved spores using flow cytometry. ~1x10
8
 live and 
autoclaved spores were incubated with anti-spore antibody for 10 min, followed by washing and 
anti-rabbit IgG-FITC antibody for 10 min. Samples washed and run on the flow cytometer. 
Black; HU58 without antibodies, Red; HU58 with antibodies. A; live HU58, B; autoclaved HU58. 
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4.2.9. Localisation of spores after intranasal, sublingual and oral dosing 
 
Twelve BALB/c mice in each group were dosed with 2x109 HU58 spores 
delivered intranasally, sublingually and orally. Mice (n=6) were culled at 6h and 
at 24h, since it was assumed that 6h would be representative of spores entering 
the cells (Section 4.2.2) and at 24h they should have been cleared. HU58 was 
used rather than DS127 spores because antibody was required to obtain 
adequate fluorescence (see Section 4.2.4) and HU58 was the strain that was 
used in the TB experiment presented in Chapter 3 and is more likely to be used 
as a vaccine adjuvant and is therefore more relevant. 
Lung and gut samples from one mouse per group were used for flow cytometric 
analysis, and the other lung and gut samples were fixed in 10% (v/v) NBF for 
histological analysis. The NALT was removed from all mice, but was pooled into 
three groups of two defined NALT tissues for each group because the number 
of cells isolated from the NALT was considered quite low for flow cytometric 
analysis. The lung, gut and NALT samples were next labelled for M cells, 
macrophages, DCs, neutrophils and spores using fluorescent antibody, and 
analysed on a BD Accuri C6 flow cytometer.  
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4.2.10. Distribution of live spores 
 
Using previous information about the size of spores as determined on the flow 
cytometer (Section 4.2.3) the correct forward and side scatter was identified on 
the flow cytometer and gated on. FITC positive events were then observed thus 
enabling the identification of free spores that had not associated with any 
murine cells. 
In the lung, spores were seen after nasal and oral dosing with spore numbers 
being reduced after 24h post-nasal dosing and completely cleared after oral 
administration (Figure 4-9). One explanation for spores being present following 
oral dosing is that the mice may have coughed after the gavage dosing and 
inadvertently inhaled spores into lungs via the nasopharyngeal route. In the 
NALT, again spores were seen after nasal and oral dosing, with a marked 
reduction observed after 24h. In the gut, spores were detectable following all 
dosing routes with concurrent decreases after 24h. The presence of spores 
after sublingual dosing suggests that the mice may have swallowed some of the 
administered dose, but that the spore numbers were very low.  
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Figure 4-9. Flow cytometric analysis of spores identified inside different tissues. BALB/c 
mice (n=5) were dosed with 2x10
9
 HU58 spores either intranasally (green), sublingually (red) or 
orally (blue) and samples were taken 6h (circles) or 24h (squares) after dosing. Lungs, gut and 
NALT tissues were removed and homogenised as described in the methods (see Sections 2.20 
and 2.21) and spores were labelled using anti-spore antibody and anti-rabbit IgG-FITC 
secondary antibody using intracellular staining. Spores were gated on using FSC and SSC (see 
Section 4.2.4) and FL1 (FITC fluorescence). Percentage of events from the whole population 
was used for calculations. Limit of detection = 0.1%. Dots indicate individual mice and median 
shown by the lines. Mann-Whitney was used to compare dosing routes at each time point. 
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4.2.11. Distribution of autoclaved spores 
 
When groups of mice were dosed orally, sublingually or nasally, live spores 
could not be readily detected in the tissues tested after sublingual dosing 
(Figure 4-9). In the experiment using autoclaved spores therefore, only oral and 
nasal dosing routes were examined. Autoclaved spores were tested since 
autoclaved spores were evaluated as a delivery system in Chapter 3. Inactive 
spores may be used as a vaccine in the future so investigating whether there 
are differences in the way spores are distributed and phagocytosed depending 
on whether they are live or autoclaved is important to examine. The experiment 
was a repeat of the experiment with live spores; BALB/c mice (n=10/group) 
were dosed with 2x109 autoclaved HU58 spores either orally or nasally, and 
then n=5 culled after 6h and 24h. The lungs, gut and NALT from four mice were 
processed to isolate single cells. M cells, DC, macrophages and neutrophils 
with and without spores were measured using antibodies. The lung and gut 
tissue from one mouse from each group was used for histological analysis. 
The results showed that the highest numbers of spores were delivered to the 
lungs after 6h but some were also delivered after oral dosing (Figure 4-10). 
Nasal and oral dosing delivered autoclaved spores to the gut, but the highest 
numbers of spores were observed after oral dosing at 6h. Nasal dosing 
delivered the most spores to the NALT in comparison to oral and sublingual 
dosing. The results are quite similar to dosing with live spores so it appears that 
the initial distribution of spores after oral and nasal dosing is the same 
regardless of whether the spores are alive or dead. However, spores do seem 
to be cleared more quickly from the lungs when they are autoclaved. 
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Figure 4-10. Distribution of autoclaved spores after nasal and oral dosing in the lungs, 
gut and NALT. BALB/c mice (n=4) were dosed with 2x10
9
 autoclaved spores either intranasally 
(green), sublingually (red) or orally (blue) and samples were taken 6h (circles) or 24h (squares) 
after dosing. Lungs, gut and NALT tissues were removed and homogenised as described in the 
methods (see Sections 2.20 and 2.21) and spores were labelled using anti-spore antibody and 
anti-rabbit IgG-FITC secondary antibody using intracellular staining. Spores were gated on 
using FSC and SSC (see Section 4.2.4) and FL1 (FITC fluorescence). Percentage of events 
from the whole population was used for calculations.The proportion of events that were positive 
for anti-spore and anti- FITC are in the whole populations. Limit of detection = 0.1%. Dots 
indicate individual mice and lines show the median. Mann-Whitney was used to compare dosing 
routes at each time point. 
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4.2.12. Immunofluorescence analysis of live spores in the lungs 
 
The lungs and gut from one mouse per group were immersed in 10% NBF for 
24h before embedding in paraffin wax and sectioning. Sections of lungs and gut 
from immunised mice were stained for spores, M cells and nuclei and examined 
using an EVOS microscope. After nasal dosing, there were a large number of 
spores seen in the lungs at the 6h time point. They were found clumped 
together around the airways, but individual spores could also be seen infiltrating 
the tissue (Figure 4-12 and Figure 4-13). At 24h, there was a reduction in the 
number of spores seen in the lungs, but there was still considerable clumping of 
spores. These results confirmed the integrity of flow cytometric analysis in that 
there were a large number of spores following nasal dosing in the lung tissue. 
The immunofluorescence adds useful information about the localisation of 
spores in tissue. Spores appear to be most concentrated around the airways, 
with single spores distributed through the lung tissue. There were also spores 
seen inside epithelial cells (Figure 4-13). 
After sublingual dosing, very few spores were identified at either time point in 
the lungs, and only single spores were observed rather than clumps (Figure 
4-12 and Figure 4-14). After oral dosing, there were more spores observed 
than after sublingual dosing, but again they were generally seen as single 
spores rather than clumps (Figure 4-12 and Figure 4-14).  
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Figure 4-11. Immunofluorescence images of lung sections at 20x magnification taken 
from mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice 
were dosed with 2x10
9
 HU58 spores nasally and lungs were removed 6h and 24h after dosing. 
Tissues were immersed in 10% NBF and embedded in paraffin wax before sectioning and 
immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary 
antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and 
anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 20x magnification using 
the EVOS fl microscope. 
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Figure 4-12. Immunofluorescence images of lung sections at 20x magnification taken 
from mice after different dosing regimens (sublingual and oral) after 6h and 24h. BALB/c 
mice were dosed with 2x10
9
 HU58 spores sublingually and orally and lungs were removed 6h 
and 24h after dosing. Tissues were immersed in 10% NBF and embedded in paraffin wax 
before sectioning and immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores 
(anti-spore primary antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell 
(NKM 16-2-4) and anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 20x 
magnification using the EVOS fl microscope. 
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Figure 4-13. Immunofluorescence images of lung sections at 60x magnification taken 
from mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice 
were dosed with 2x10
9
 HU58 spores nasally and lungs were removed 6h and 24h after dosing. 
Tissues were immersed in 10% NBF and embedded in paraffin wax before sectioning and 
immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary 
antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and 
anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 60x magnification using 
the EVOS fl microscope. 
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Figure 4-14. Immunofluorescence images of lung sections at 60x magnification taken 
from mice after different dosing regimens (sublingual and oral) after 6h and 24h. BALB/c 
mice were dosed with 2x10
9
 HU58 spores sublingually and orally and lungs were removed 6h 
and 24h after dosing. Tissues were immersed in 10% NBF and embedded in paraffin wax 
before sectioning and immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores 
(anti-spore primary antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell 
(NKM 16-2-4) and anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 60x 
magnification using the EVOS fl microscope. 
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4.2.13. Immunofluorescence analysis of autoclaved spores in the 
lungs 
 
After nasal dosing, at 6h there are autoclaved spores distributed throughout the 
lung tissue, but there appear to be fewer than after immunisation with live 
spores (Figure 4-15 and Figure 4-17). The distribution of autoclaved spores in 
the lung tissue is quite different to live spores as instead of grouping around the 
airways, there are clusters of spores inside individual cells (Figure 4-17).  After 
24h, the spores were still present, even though the flow cytometry indicated no 
spores, spores could be seen, but they were mostly inside cells whereas the 
flow cytometer was detecting free spores, which may account for the difference. 
The spores inside individual cells seem to be more densely packed at 24h. After 
oral dosing, there were fewer spores in the lung in comparison to nasal dosing 
and oral dosing of live spores but they were present. They also appear to be 
clustering inside certain cells (Figure 4-16 and Figure 4-18). 
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Figure 4-15. Immunofluorescence images of lung sections at 20x magnification taken 
from mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice 
were dosed with 2x10
9
 autoclaved HU58 spores nasally and lungs were removed 6h and 24h 
after dosing. Tissues were immersed in 10% NBF and embedded in paraffin wax before 
sectioning and immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore 
primary antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) 
and anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 20x magnification 
using the EVOS fl microscope. 
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Figure 4-16. Immunofluorescence images of lung sections at 20x magnification taken 
from mice after oral dosing regimen after 6h and 24h. BALB/c mice were dosed with 2x10
9
 
autoclaved HU58 spores orally and lungs were removed 6h and 24h after dosing. Tissues were 
immersed in 10% NBF and embedded in paraffin wax before sectioning and immunofluorescent 
staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary antibody followed by anti-
rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and anti-mouse IgG-TRITC 
(red)). Arrows indicate spores. Sections read at 20x magnification using the EVOS fl 
microscope. 
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Figure 4-17. Immunofluorescence images of lung sections at 60x magnification taken 
from mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice 
were dosed with autoclaved 2x10
9
 HU58 spores nasally and lungs were removed 6h and 24h 
after dosing. Tissues were immersed in 10% NBF and embedded in paraffin wax before 
sectioning and immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore 
primary antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) 
and anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 60x magnification 
using the EVOS fl microscope. 
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Figure 4-18. Immunofluorescence images of lung sections at 60x magnification taken 
from mice after oral dosing regimens after 6h and 24h. BALB/c mice were dosed with 2x10
9
 
autoclaved HU58 spores orally and lungs were removed 6h and 24h after dosing. Tissues were 
immersed in 10% NBF and embedded in paraffin wax before sectioning and immunofluorescent 
staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary antibody followed by anti-
rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and anti-mouse IgG-TRITC 
(red)). Arrows indicate spores. Sections read at 60x magnification using the EVOS fl 
microscope. 
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4.2.14. Immunofluorescence analysis of live spores in the gut 
 
The sections taken for immunofluorescence analysis were from the jejunum 
area, whereas the flow cytometric analysis corresponded to the duodenum, 
through to the cecum and so there could be a difference in the representation of 
spores between flow cytometry and immunofluorescence as the histology 
sample represented only a small section of the gut. In all of the gut samples, 
there appeared to be patches of M cell populations at the base of the villi 
(Figure 4-19, Figure 4-20, Figure 4-21, Figure 4-22). Following intranasal 
dosing, spores could be identified at 6h and 24n inside the villi of the gut and 
near the basal membrane. After sublingual and oral dosing, spores were seen 
predominately nearer the M cells and closer to the basement membrane 
(Figure 4-22).  
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Figure 4-19. Immunofluorescence images of gut sections at 20x magnification taken from 
mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice were 
dosed with 2x10
9
 HU58 spores nasally and the gut was removed 6h and 24h after dosing. 
Tissues were immersed in 10% NBF and embedded in paraffin wax before sectioning and 
immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary 
antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and 
anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 20x magnification using 
the EVOS fl microscope. Villi and basement membrane labelled on naïve sample. 
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Figure 4-20. Immunofluorescence images of gut sections at 20x magnification taken from 
mice after different dosing regimens (sublingual and oral) after 6h and 24h. BALB/c mice 
were dosed with 2x10
9
 HU58 spores sublingually and orally and the gut was removed 6h and 
24h after dosing. Tissues were immersed in 10% NBF and embedded in paraffin wax before 
sectioning and immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore 
primary antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) 
and anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 20x magnification 
using the EVOS fl microscope. 
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Figure 4-21. Immunofluorescence images of gut sections at 60x magnification taken from 
mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice were 
dosed with 2x10
9
 HU58 spores nasally and the gut was removed 6h and 24h after dosing. 
Tissues were immersed in 10% NBF and embedded in paraffin wax before sectioning and 
immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary 
antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and 
anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 60x magnification using 
the EVOS fl microscope. 
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Figure 4-22. Immunofluorescence images of gut sections at 60x magnification taken from 
mice after different dosing regimens (sublingual and oral) after 6h and 24 h. BALB/c mice 
were dosed with 2x10
9
 HU58 spores sublingually and orally and the gut was removed 6h and 
24h after dosing. Tissues were immersed in 10% NBF and embedded in paraffin wax before 
sectioning and immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore 
primary antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) 
and anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 60x magnification 
using the EVOS fl microscope. 
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4.2.15. Immunofluorescence analysis of autoclaved spores in 
the gut 
 
Autoclaved spores could be seen throughout the gut tissue after nasal dosing 
and were still present after 24h (Figure 4-23 and Figure 4-25). Following oral 
dosing of autoclaved spores, more spores could be seen in the gut in 
comparison to live spores (Figure 4-24 and Figure 4-26). Autoclaved spores 
appear to be mostly clustered at the basement membrane around the M cells 
(Figure 4-26).   
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Figure 4-23. Immunofluorescence images of gut sections at 20x magnification taken from 
mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice were 
dosed with 2x10
9
 autoclaved HU58 nasally and the gut was removed 6h and 24h after dosing. 
Tissues were immersed in 10% NBF and embedded in paraffin wax before sectioning and 
immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary 
antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and 
anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 20x magnification using 
the EVOS fl microscope. 
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Figure 4-24. Immunofluorescence images of gut sections at 20x magnification taken from 
mice after different dosing regimens (oral) after 6h and 24h. BALB/c mice were dosed with 
2x10
9
 autoclaved HU58 orally and the gut was removed 6h and 24h after dosing. Tissues were 
immersed in 10% NBF and embedded in paraffin wax before sectioning and immunofluorescent 
staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary antibody followed by anti-
rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and anti-mouse IgG-TRITC 
(red)). Arrows indicate spores. Sections read at 20x magnification using the EVOS fl 
microscope. 
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Figure 4-25. Immunofluorescence images of gut sections at 60x magnification taken from 
mice after different dosing regimens (naïve and nasal) after 6h and 24h. BALB/c mice were 
dosed with 2x10
9
 autoclaved HU58 nasally and the gut was removed 6h and 24h after dosing. 
Tissues were immersed in 10% NBF and embedded in paraffin wax before sectioning and 
immunofluorescent staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary 
antibody followed by anti-rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and 
anti-mouse IgG-TRITC (red)). Arrows indicate spores. Sections read at 60x magnification using 
the EVOS fl microscope. 
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Figure 4-26. Immunofluorescence images of gut sections at 60x magnification taken from 
mice after different dosing regimens (oral) after 6h and 24h. BALB/c mice were dosed with 
2x10
9
 autoclaved HU58 orally and the gut was removed 6h and 24h after dosing. Tissues were 
immersed in 10% NBF and embedded in paraffin wax before sectioning and immunofluorescent 
staining. Stained for nuclei (DAPI (blue)), spores (anti-spore primary antibody followed by anti-
rabbit IgG-FITC (green)) and M cells (anti M-cell (NKM 16-2-4) and anti-mouse IgG-TRITC 
(red)). Arrows indicate spores. Sections read at 60x magnification using the EVOS fl 
microscope. 
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4.2.16. Live spores infiltrating the lungs 
 
Spores inside cells were detected by first treating cells with saponin followed by 
the addition of anti-spore primary and anti-rabbit IgG-FITC secondary 
antibodies. Saponin perforates the cell membrane enabling intracellular access 
of antibodies. Populations that were positive for FITC labelled spores and either 
M cells, macrophages, neutrophils or dendritic cells were identified.  
The population of spores in M cells did not vary significantly following any of the 
dosing routes used.  Using the nasal dosing route most spores were found 
inside M cells at 6h, this reduced at 24h. After oral dosing, some spores were 
seen in the M cells at 6h (Figure 4-27). The DC populations in the lung were 
also consistent after nasal dosing showing the highest numbers of intracellular 
spores inside DCs. Spores were also seen after sublingual dosing at 6h (Figure 
4-28). In the macrophage populations, only nasal dosing showed a significant 
number of spores within cells, and there was an increase in macrophage 
numbers following nasal and oral dosing (Figure 4-29). The neutrophil 
population increased from 6h to 24h after nasal dosing, and the number of 
spores inside neutrophils also increased in line with this. Some spores were 
detected in neutrophils after sublingual and oral dosing at 6h (Figure 4-30).  
Based on these results, it appears that; i) nasal dosing delivered the highest 
number of spores to the lungs and ii) that all four cell types identified were 
involved in engulfment of spores by phagocytosis, iii) but DCs and neutrophils 
contained the highest numbers of spores. The neutrophils behaved differently to 
the other cells types as the population increased at 6h and again at 24h (Figure 
4-30). This may be a result of secretion of chemokines from other cells and/or 
Laura Sibley                                Chapter 4: Localisation of Spores after Dosing by Different Mucosal Routes 
 
161 
from damaged cells in the lung tissue, which recruited more neutrophils to the 
site later on.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-27. Flow cytometric analysis of M-cell populations in the lungs after dosing mice 
nasally, sublingually or orally with HU58 spores. BALB/c mice (n=5) were dosing with 2x10
9
 
HU58 spores nasally, sublingually or orally and lungs taken at 6h or 24h after dosing. Lungs 
were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained for 
spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and M cells (NKM 16-2-4-PE). 
Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) and 
24h (squares). Limit of detection = 0.1x10
4
. Dots indicate individual mice and bars represent the 
median. Mann-Whitney were used to compare the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-28. Flow cytometric analysis of DC populations in the lungs after dosing mice 
orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 2x10
9
 
HU58 spores nasally, sublingually or orally and lungs taken at 6h or 24h after dosing. Lungs 
were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained for 
spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and DCs (CD11c-APC).Black: 
naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) and 24h 
(squares). Limit of detection = 0.1x10
4
. Dots indicate individual mice and bars represent the 
median. Mann-Whitney were used to compare the dosing routes. 
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Figure 4-29. Flow cytometric analysis of macrophage populations in the lungs after 
dosing mice orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were 
dosing with 2x10
9
 HU58 spores nasally, sublingually or orally and lungs taken at 6h or 24h after 
dosing. Lungs were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells 
stained for spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and macrophages 
(F4/80-PerCP).Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h 
(circles) and 24h (squares). Limit of detection = 0.1x10
4
. Dots indicate individual mice and bars 
represent the median. Mann-Whitney were used to compare the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-30. Flow cytometric analysis of neutrophil populations in the lungs after dosing 
mice orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 
2x10
9
 HU58 spores nasally, sublingually or orally and lungs taken at 6h or 24h after dosing. 
Lungs were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained 
for spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and neutrophils (Ly6G-
APC).Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) 
and 24h (squares). Limit of detection = 0.1x10
4
. Dots indicate individual mice and bars 
represent the median. Mann-Whitney were used to compare the dosing routes. 
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4.2.17. Live spores infiltrating the gut 
 
The gut data showed spores apparently infiltrating all four types of cells 
identified, but mainly the M cells and neutrophils (Figure 4-31, Figure 4-32, 
Figure 4-33, Figure 4-34). Not all mice had detectable spores in the DCs and 
macrophages however. The nasal and oral dosing regimens exhibited the 
highest infiltration in M cells at 6 h and this reduced after 24h (Figure 4-31). 
There were very few spores identified after sublingual dosing in any of the cell 
types examined. It would have been predicted that oral dosing would have 
resulted in the highest number of spores in the gut because oral dosing enters 
the digestive system directly, but the nasal dosing seems to have generated the 
highest numbers.  
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Figure 4-31. Flow cytometric analysis of M cell populations in the gut after dosing mice 
orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 2x10
9
 
HU58 spores nasally, sublingually or orally and gut taken at 6h or 24h after dosing. The gut 
were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained for 
spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and M cells (NKM 16-2-4-PE). 
Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) and 
24h (squares). Limit of detection = 0.1x10
5
. Dots indicate individual mice and bars represent the 
median. Mann-Whitney were used to compare the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-32. Flow cytometric analysis of DC populations in the gut after dosing mice 
orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 2x10
9
 
HU58 spores nasally, sublingually or orally and gut taken at 6h or 24h after dosing. The gut 
were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained for 
spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and DCs (CD11c-APC). Black: 
naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) and 24h 
(squares). Limit of detection = 0.1x10
5
. Dots indicate individual mice and bars represent the 
median. Mann-Whitney were used to compare the dosing routes. 
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Figure 4-33. Flow cytometric analysis of macrophage populations in the gut after dosing 
mice orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 
2x10
9
 HU58 spores nasally, sublingually or orally and gut taken at 6h or 24h after dosing. The 
gut were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained for 
spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and macrophages (F4/80-
PerCP). Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h 
(circles) and 24h (squares). Limit of detection = 0.1x10
5
. Dots indicate individual mice and bars 
represent the median. Mann-Whitney were used to compare the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-34. Flow cytometric analysis of neutrophil populations in the gut after dosing 
mice orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 
2x10
9
 HU58 spores nasally, sublingually or orally and gut taken at 6h or 24h after dosing. The 
gut were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained for 
spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and neutrophils (Ly6G-APC). 
Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) and 
24h (squares). Limit of detection = 0.1x10
5
. Dots indicate individual mice and bars represent the 
median. Mann-Whitney were used to compare the dosing routes. 
Laura Sibley                                Chapter 4: Localisation of Spores after Dosing by Different Mucosal Routes 
 
166 
4.2.18. Live spores infiltrating the NALT 
 
In the NALT following nasal dosing, M cells were shown to carry the most 
spores, which was expected as their role is to translocate particles across the 
epithelial barrier and the NALT has a large amount of epithelium (Figure 4-35). 
There were a few spores seen in the DCs and macrophages after sublingual 
dosing, but at very low levels (Figure 4-37, Figure 4-36). Although very few 
spores were seen in the other cell types, the numbers of macrophages and 
neutrophils increased at 6h (Figure 4-37, Figure 4-38), which suggested that 
the dosing route has had an effect on the cell populations. It could be that an 
earlier time point would have provided more information about the NALT cell 
populations involved in spore uptake and by 6h spores were in the process of 
being cleared from the area. 
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Figure 4-35. Flow cytometric analysis of M cell populations in the NALT after dosing mice 
orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 2x10
9
 
HU58 spores nasally, sublingually or orally and the NALT taken at 6h or 24h after dosing. The 
NALT were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained 
for spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and M cells (NKM 16-2-4-
PE). Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) 
and 24h (squares). Limit of detection = 0.1x10
3
. Dots indicate individual mice and lines 
represent the median. Mann-Whitney were used to compare the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-36. Flow cytometric analysis of DC populations in the NALT after dosing mice 
orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 2x10
9
 
HU58 spores nasally, sublingually or orally and the NALT taken at 6h or 24h after dosing. The 
NALT were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells stained 
for spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and DCs (CD11c-APC). 
Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h (circles) and 
24h (squares). Limit of detection = 0.1x10
3
. Dots indicate individual mice and bars represent the 
median. Mann-Whitney were used to compare the dosing routes. 
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Figure 4-37. Flow cytometric analysis of macrophage populations in the NALT after 
dosing mice orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were 
dosing with 2x10
9
 HU58 spores nasally, sublingually or orally and the NALT taken at 6h or 24h 
after dosing. The NALT were homogenised as described in the methods (Section 2.21) and 
1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and 
macrophages(F4/80-PerCP). Black: naïve, green: nasal dosing, red: sublingual dosing, blue: 
oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
3
. Dots indicate 
individual mice and bars represent the median. Mann-Whitney were used to compare the 
dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-38. Flow cytometric analysis of neutrophil populations in the NALT after dosing 
mice orally, nasally or sublingually with HU58 spores. BALB/c mice (n=5) were dosing with 
2x10
9
 HU58 spores nasally, sublingually or orally and the NALT taken at 6h or 24h after dosing. 
The NALT were homogenised as described in the methods (Section 2.21) and 1x10
6
 cells 
stained for spores (anti-spore primary with anti-rabbit IgG-FITC secondary) and neutrophils 
(Ly6G-APC). Black: naïve, green: nasal dosing, red: sublingual dosing, blue: oral dosing at 6h 
(circles) and 24h (squares). Limit of detection = 0.1x10
3
. Dots indicate individual mice and bars 
represent the median. Mann-Whitney were used to compare the dosing routes. 
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4.2.19. Autoclaved spores infiltrating the lungs 
 
Autoclaved spores are only seen in the M cells following oral dosing at 6h 
(Figure 4-39), whereas spores were detected in M cells after administration of 
live spores via the intranasal route.  This could mean that in the lungs, M cells 
are better able to interact with live spores. Autoclaved spores were seen in the 
DCs and macrophages after nasal and oral administration (Figure 4-40, Figure 
4-41). The numbers of spores are highest at 6h so it would appear that the 
spores are starting to be cleared after 24h.  Spores were present only in 
neutrophils after oral administration of spores to the lungs at 6h (Figure 4-42).  
It would be expected that more spores would be inside host cells after nasal 
dosing, because a greater number of spores are delivered to the lungs (Figure 
4-10) but there appear to be more after oral dosing inside M cells, macrophages 
and neutrophils.  
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Figure 4-39. Flow cytometric analysis of M cell populations in the lungs after dosing mice 
orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the lung taken at 
6h or 24h after dosing. The lungs were homogenised as described in the methods (Section 
2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and M cells (NKM 16-2-4-PE). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
4
. Dots 
indicate individual mice and lines represent the median. Mann-Whitney were used to compare 
the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-40. Flow cytometric analysis of DC populations in the lungs after dosing mice 
orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the lung taken at 
6h or 24h after dosing. The lungs were homogenised as described in the methods (Section 
2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and DCs (CD11c-APC). Black: naïve, green: nasal dosing, red: sublingual dosing, 
blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
4
. Dots indicate 
individual mice and lines represent the median. Mann-Whitney were used to compare the 
dosing routes. 
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Figure 4-41. Flow cytometric analysis of macrophage populations in the lungs after 
dosing mice orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice 
(n=4) were dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the 
lung taken at 6h or 24h after dosing. The lungs were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and macrophages (F4/80-PerCP). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
4
. Dots 
indicate individual mice and lines represent the median. Mann-Whitney were used to compare 
the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-42. Flow cytometric analysis of neutrophil populations in the lungs after dosing 
mice orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the lung taken at 
6h or 24h after dosing. The lungs were homogenised as described in the methods (Section 
2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and neutrophils (Ly6G-APC). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
4
. Dots 
indicate individual mice and lines represent the median. Mann-Whitney were used to compare 
the dosing routes. 
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4.2.20. Autoclaved spores infiltrating in the gut 
 
The greatest numbers of spores were seen inside the M cells, dendritic cells, 
macrophages and neutrophils after oral dosing at 6h (Figure 4-43 – Figure 4-
46). This was expected because the spores were being delivered directly to the 
gut. Following administration of live spores, the numbers inside all of the host 
cells of the gut measured were lower in comparison to autoclaved spores, and 
this could be because the spores had germinated and so fewer were detectable 
as they were vegetative cells and the antibody detects spores only. All four host 
cell populations were responsible for spore uptake, but the DCs and 
macrophages were the dominant populations that contained spores, and spores 
were seen at 6h and 24h. In the gut, it appears that M cells and neutrophils 
phagocytose autoclaved spores better than in the lungs, but in both cases, 
macrophages and DCs were the dominant populations.  
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Figure 4-43. Flow cytometric analysis of M cell populations in the gut after dosing mice 
orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the gut taken at 
6h or 24h after dosing. The gut tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and M cells (NKM 6-2-4-PE). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
5
. Dots 
indicate individual mice and lines represent the median. Mann-Whitney was used to compare 
the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-44. Flow cytometric analysis of DC populations in the gut after dosing mice 
orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the gut taken at 
6h or 24h after dosing. The gut tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and DCs (CD11c-APC). Black: naïve, green: nasal dosing, red: sublingual dosing, 
blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
5
. Dots indicate 
individual mice and bars represent the median. Mann-Whitney was used to compare the dosing 
routes. 
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Figure 4-45. Flow cytometric analysis of macrophage populations in the gut after dosing 
mice orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the gut taken at 
6h or 24h after dosing. The gut tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and macrophages (F4/80-PerCP). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
5
. Dots 
indicate individual mice and lines represent the median. Mann-Whitney was used to compare 
the dosing routes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-46. Flow cytometric analysis of neutrophil populations in the gut after dosing 
mice orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the gut taken at 
6h or 24h after dosing. The gut tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and neutrophils (Ly6G-APC). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
5
. Dots 
indicate individual mice and lines represent the median. Mann-Whitney was used to compare 
the dosing routes. 
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4.2.21. Autoclaved spores infiltrating the NALT 
 
Spores were identified inside M cells after nasal and oral dosing (Figure 4-47) 
at 6h. After 24h they were cleared after nasal dosing but some were still 
observed after oral dosing (Figure 4-47). After nasal dosing at 24h, spores 
were observed inside DCs (Figure 4-48). There were some spores inside DCs 
6h after oral dosing, but the numbers were more variable. Spores were also 
detected inside macrophages after nasal and oral dosing, but this was also 
variable (Figure 4-49). More spores were seen in neutrophils after nasal dosing 
compared to oral dosing (Figure 4-50). A greater number of autoclaved spores 
appeared to enter the NALT in comparison to live spores, and enter all types of 
cells, whereas the live spores, only when dosed intranasally entered M cells. 
More repeats would be required to get a clearer picture of distribution of 
autoclaved spores in the NALT. 
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Figure 4-47. Flow cytometric analysis of M cell populations in the NALT after dosing mice 
orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the NALT taken at 
6h or 24h after dosing. The NALT tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and M cells (NKM 6-2-4-PE). Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
3
. Dots 
indicate individual mice and lines represent the median. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-48. Flow cytometric analysis of DC populations in the NALT after dosing mice 
orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the NALT taken at 
6h or 24h after dosing. The NALT tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and DCs (CD11c-APC).Black: naïve, green: nasal dosing, red: sublingual dosing, 
blue: oral dosing at 6h (light grey) and 24h (dark grey). Limit of detection = 0.1x10
3
. Dots 
indicate individual mice and bars represent the median. 
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Figure 4-49. Flow cytometric analysis of macrophage populations in the NALT after 
dosing mice orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice 
(n=4) were dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the 
NALT taken at 6h or 24h after dosing. The NALT tissues were homogenised as described in the 
methods (Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit 
IgG-FITC secondary) and macrophages (F4/80-PerCP).Black: naïve, green: nasal dosing, red: 
sublingual dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 
0.1x10
3
. Dots indicate individual mice and bars represent the median. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-50. Flow cytometric analysis of neutrophil populations in the NALT after dosing 
mice orally, nasally or sublingually with autoclaved HU58 spores. BALB/c mice (n=4) were 
dosing with 2x10
9
 autoclaved HU58 spores nasally, sublingually or orally and the NALT taken at 
6h or 24h after dosing. The NALT tissues were homogenised as described in the methods 
(Section 2.21) and 1x10
6
 cells stained for spores (anti-spore primary with anti-rabbit IgG-FITC 
secondary) and neutrophils (Ly6G-APC).Black: naïve, green: nasal dosing, red: sublingual 
dosing, blue: oral dosing at 6h (circles) and 24h (squares). Limit of detection = 0.1x10
3
. Dots 
indicate individual mice and bars represent the median. 
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4.3. Discussion 
 
Spores must be able to cross epithelial barriers and be presented to leukocytes 
in order to generate immune responses. In these experiments, it has been 
demonstrated that spores can cross the epithelial barriers of the lungs, gut and 
the NALT using flow cytometry, and confirmed in the lungs and gut using 
immunofluoresence.  
4.3.1. Optimisation of method for detecting spores on the flow cytometer 
 
The growth and sporulation of spores was studied using the flow cytometer to 
assess whether the technique was appropriate to use for detecting spores in 
tissues. Growth of bacilli could be distinguished from spores and two 
populations could be detected as the bacteria began to sporulate. The two 
populations were confirmed by phase-contrast microscopy, and the spores were 
also confirmed using anti-spore and anti-rabbit IgG-FITC antibody on the flow 
cytometer. Other spore forming microorganisms have been characterised using 
FSC and SSC (Tracy et al. 2010; Comas-Riu & Vives-Rego 2002) and using 
fluorescent dyes have been able to detect germinated cells (Tracy et al. 2010; 
Smelt et al. 2008). Monitoring spore growth could also be applied to investigate 
the roles of certain proteins in spore development or germination by using 
knock-outs of developmental genes and determining any differences in 
sporulation/germination. The role of BclA proteins in C. difficile germination is 
currently being investigated at RHUL by other lab members using flow 
cytometry (unpublished).  
Strain DS127 that has GFP fused to CotC exhibited fluorescence under the 
microscope, but when dosed to tissues, the spores could not be detected 
because they were not brighter than the autofluorescence of the tissue. The 
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spores were also not sufficiently detectable by flow cytometry so as to be able 
to truly identify them as DS127 spores. The results are supported by data from 
Zhou et al, who used CotC-TP22.3 expressing spores against C. sinesis and 
found on the flow cytometer than the antigen could be detected, but only 2,900 
events out of 10,000 were positive (Zhou et al. 2008). When the anti-spore 
antibody and anti-IgG FITC was used, there was a clear shift in fluorescence 
and the majority of spores were positive. It was important that the spores could 
be identifiable for the dosing experiment to be able to investigate the distribution 
of spores. The spores could be characterised by their FSC-A and SSC-A profile, 
but there are likely to be other commensal bacteria naturally present in the mice 
of a similar size and therefore an antibody based system was required.   
4.3.2. Sublingual dosing 
 
Very few spores were identified in any tissues after sublingual dosing. From this 
work it is difficult to determine the fate of the spores, but they could have either 
i) crossed into the bloodstream or ii) been degraded and soluble proteins 
crossed into the bloodstream. Amuguni et al showed that B. subtilis spores 
carrying TTFC delivered sublingually were able to generate humoral and 
cellular immune responses so although they were not detectable here, 
sublingual immunisation with spores has been demonstrated to elicit immune 
responses (Amuguni et al. 2011). Logistically identifying the localisation of 
spores would be difficult in the mouth but further work to characterise immune 
responses downstream of sublingual dosing could be carried out to discover 
how well spores delivered by this route can generate an immune response. 
Sublingual immunisation is a promising route of mucosal immunisation because 
it is easy to administer, has been reported to generate strong immune 
responses in the lungs and genital tract and lower doses can be used (10-50 
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fold less than oral dosing) (Czerkinsky et al. 2011). Sublingual administration of 
HPV VLPs were able to protect against genital challenged with HPV 
pseudovirons and they hypothesised that after sublingual vaccination, IgA 
antibody secreting cells (ASC) have a unique migratory pattern that let them 
target distant mucosal sites (Cuburu et al. 2009). 
4.3.3. Distribution of spores in the respiratory tract tissues 
 
The lungs and NALT would be the prime locations targeted by respiratory 
pathogens such as MTB, therefore this is where a vaccine stimulated immune 
response would be most useful. Work into the distribution of B. anthracis after 
inhalation has demonstrated that spores are predominately delivered to the 
lungs and nasopharynx, and that they germinate in the nasopharynx and NALT, 
but there is very little germination in the lungs (Glomski et al. 2007). The data 
here suggests a similar model for B. subtilis as spores were still detected after 
24h in the lungs whereas if they had germinated they would have not bound the 
anti-spore antibody. After influenza infection, it has been presented that the 
immune cells are increased in the NALT (Asanuma et al. 1997) and that when 
the NALT is injected with antigens, it has been demonstrated to elicit stronger 
immune responses in comparison to the nasal dosing route (Hou et al. 2002). 
Live spores were found in the NALT after nasal dosing in this experiment, and 
there were changes in the cell populations within 24h, mainly after nasal dosing 
so this is promising that spores are able to induce immune responses in the 
NALT, which could affect the ability of the MALT to respond to pathogens. A 
wider variety of cells were found to contain spores after administration of 
autoclaved spores, but a greater quantity were found in the M cells of the NALT 
after dosing with live spores.  
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4.3.4. Differences between cell types in different tissues 
 
The cells observed to engulf the most live spores in each tissue varied and may 
represent the different roles of each tissue. DC populations engulfed the 
greatest proportion of spores in the lungs, but not in the NALT and this could be 
due to the NALT physiology as it has been reported that few DCs accumulate 
under the M cells in the NALT and were not observed to sample the airways 
and therefore may not be involved in antigen capture here (Kim et al. 2011). M 
cells harboured the most spores in the NALT and other research has 
demonstrated that M cells in the NALT are key for the uptake of other bacteria 
such as Group A Streptococcus (Park et al. 2003). Neutrophils phagocytosed 
spores in the lungs and gut but not in the NALT, which may be because the 
NALT is a lymphoid tissue and not a general portal of entry for pathogens. The 
NALT is comprised mainly of T-cells, B-cells and APCs beneath the FAE 
containing M cells and therefore it could be less likely that granulocytes will 
arrive here (Zanvit et al. 2010). 
DCs in the lungs were dominant in engulfing spores along with neutrophils and 
may be indicative that in the lungs, DCs are known to extend their dendrites 
past the epithelial walls to sample the environment (Hasenberg et al. 2013). 
Therefore, it is expected that they would have a major role in antigen sampling 
of spores. Macrophages in the lungs have been hypothesised to be non-motile 
and have more of a regulatory role rather than phagocytic, and that bacterial 
clearance is dependent on neutrophils moving through the lung tissue 
(Hasenberg et al. 2013). M cells have been presented as a portal of entry for 
MTB in the lungs  (Teitelbaum et al. 1999) but in this study, low numbers of 
spores were found in M cells. This could be due to the lung having less 
epithelial cells than the other tissues and therefore less specialised epithelial M 
Laura Sibley                                Chapter 4: Localisation of Spores after Dosing by Different Mucosal Routes 
 
182 
cells. An alternative hypothesis is that there could be a difference between M 
cells in the lungs and the receptors they have as it has been reported that M 
cells in Peyer’s patches have a GP-2 (glycoprotein-2) receptor for FimH 
bacteria that is not found on villus M cells (Kim et al. 2011) and therefore there 
could be other receptors that affect M cell uptake that are tissue specific. 
Although DCs are known to sample the gut lumen (Rescigno & Di Sabatino 
2009), few spores were found in the gut DCs. This could be because the spores 
were non-pathogenic and therefore did not activate danger signals to stimulate 
DCs. Macrophages in the colon have also been reported to be regulatory and 
produce IL-10 (Hasenberg et al. 2013; Barnes & Powrie 2009) which could 
explain why little phagocytosis by macrophages was observed here. M cells 
were one of the dominant populations that engulfed spores in the gut and they 
are well known to sample antigens here and provide entry for some pathogens 
(Man et al. 2004).  
4.3.5. M cells 
 
M cells are a target in mucosal vaccine research, and there is a drive to 
increase the uptake by M cells through various mechanisms, so that the 
antigens have increased contact with immune cells. For example, by targeting 
the endocytosis receptor Claudin 4 found on M cells using C. perfringens 
enterotoxin, uptake of haemagglutanin antigen was increased and IgG and IgA 
in the serum, BAL and faeces were increased compared to antigen alone (Lo et 
al. 2012). It was previously presented that M cells transport B. subtilis in the 
appendix of rabbits (Rhee et al. 2004), and in the lung are able to transport 
MTB in mice (Teitelbaum et al. 1999). B. anthracis has also been investigated in 
vitro and it was discovered that adherence and translocation was higher in the 
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M cells in comparison to intestinal cell line Caco-2 cells and therefore suggests 
further that Bacillus species may use M cells to enter tissues (Tonry et al. 
2013). Here, it was demonstrated that M cells were able to transport live spores 
in the gut, lung and NALT of the mouse but had a more major role in transport 
in the NALT and gut. This is important because the gut is exposed to many 
foreign antigens so confirming that spores are taken up by M cells increases the 
likelihood of generating immune responses in the gut after both nasal and oral 
dosing.  
4.3.6. Comparison of live and autoclaved spores 
 
A greater quantity of live spores were seen in the gut after intranasal dosing 
whereas it would have been predicted that oral dosing would deliver most 
spores to the gut. There are a number of potential reasons for this; i) the spores 
administered to the gut was in a larger volume of solution, which may have 
passed rapidly through the gut with little opportunity for spores to dissociate 
from the liquid into the gut cells. Nasal dosing however, would likely have been 
more aerosolised and particulate, therefore spores may have passed through 
the gut more easily and been able to interact with the host cells better,  ii) the 
stomach environment is known to contain germinants (Paidhungat & Setlow 
2001) so spores could have germinated and therefore would not have been 
observed using anti-spore antibody, iii) in previous studies, the oral dose used 
to immunise mice was 5x1010 spores (Permpoonpattana et al. 2011), which is 
more than one log higher than that used here, so it could mean that at a higher 
dose, more spores would be able to cross the epithelium. A lower dose was 
used here to be able to make a direct comparison between the oral, nasal and 
sublingual dosing routes, iv) also to be taken into consideration is that transit 
through the gut of the mouse is thought to be around 3h (Huang, La Ragione, et 
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al. 2008) so the highest amount of uptake may have been missed and looking 
at other time points in the future could be useful. 
A greater number of spores were seen in the gut after oral delivery of 
autoclaved spores in comparison to live spores. This could be because the live 
spores germinated and so were not detectable using the anti-spore antibody. 
This could mean that for practical use as an oral vaccine, autoclaved spores 
may be better than live spores because more spores were able to enter the 
tissue, and would be able to present antigens to the immune cells. Another 
strategy that has been pioneered by iGEM in Munich is to use a technology 
called ‘germinationSTOP’, which inactivated germination genes and also had a 
suicide switch incorporated into the genome. This meant that spores were 
unable to germinate, but to ensure that only spores were present, if germination 
occurred the suicide switch would kill the bacterium. The technology in this case 
was used to display a laccase enzyme on the surface to degrade pollutants 
(Mascher et al. 2012). This strategy would have the advantage of prolonging 
antigen delivery because the bacteria would stay in the spore form, and would 
still be able to interact with cell receptors because the surface proteins would 
not be damaged. Another strategy for improving longevity of antigen 
presentation using live spores is discussed by Hinc et al, where as well as 
surface display of UreA, the antigen was also incorporated into the genome 
under germination transcriptional control so the gene would be expressed by 
the vegetative cell, therefore lengthening the time of antigen exposure (Hinc et 
al. 2010).      
Perkins et al studied the changes to B. subtilis after autoclaving and showed 
using electron microscopy, that the surface of the spores had a wrinkled 
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appearance (Perkins et al. 2004). They hypothesised that the spores burst 
during the autoclaving process so the contents were released and therefore the 
spores afterwards had a smaller volume and the surface was wrinkled. They 
also showed general differences in protein composition of whole autoclaved 
spores using Fourier Transform Infrared Reflectance (FT-IR) spectroscopy 
(Perkins et al. 2004). In this study, using light microscopy, a size change could 
also be detected and the alteration in phase-bright could be due to the lack of 
internal material. Damage to the coat proteins was also observed in this study 
because CotB and CotC could not be detected using Western blotting. It has 
been shown that the surface properties of nanoparticles can affect the 
mechanism by which they enter cells (Krishnendu Saha 2013) so it could be 
possible that the surface changes in the spores after autoclaving cause a 
difference in the way the spores enter cells. Work by Sirec et al also may 
support this theory as they tested the ability of different environmental Bacillus 
subtilis spores to bind antigen and found that they had different hydrophobicity 
that affected their ability to bind antigen (Sirec et al. 2014). Therefore, 
autoclaved spores would certainly have different surface properties to live 
spores that could affect their binding capabilities. It was suggested by Huang et 
al that spores that autoclaved spores do not interact with TLR2 or TLR4, but are 
able to elicit immune responses (Huang, La Ragione, et al. 2008). Work by 
Colenutt et al also confirmed that TLR2 expression was much reduced with 
autoclaved spores in comparison to live spores and germinated cells and 
suggested that the peptidoglycan present in the spore cortex was released 
when the spore germinated and could interact with TLR2, whereas autoclaved 
spores could not release the peptidoglycan (Colenutt & Cutting 2014). In this 
study, the cells that interacted with the spores when they were autoclaved 
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differed to live spores, which support the suggestion that there could be 
differences in interactions between cells and spores depending on their state.  
Using immunofluorescence, the distribution of live and autoclaved spores in the 
lungs was quite different. The live spores were predominately identified around 
the airways and scattered through the tissue. This data is similar to that 
reported by Jenkins et al with B. anthracis spores, that found spores around the 
alveolar and small airway epithelium (Jenkins & Xu 2013). In contrast, there 
were many autoclaved spores clustered inside individual round cells. From the 
flow cytometry analysis, it appears that live spores interact better with 
neutrophils and M cells in the lungs, but that DCs and macrophages can 
phagocytose both types of spores. If it is assumed that TLR2 and TLR4 are not 
involved with interactions with autoclaved spores, there must therefore be other 
mechanisms by which macrophages and DCs interact with the particles. 
Handley et al demonstrated that DCs do not rely of antigen capture to be able to 
phagocytose (Handley et al. 2005), which may explain why they are able to 
phagocytose autoclaved spores even though the surface proteins are damaged. 
Other evidence for this comes from comparing the uptake of latex beads, where 
the phagocytosis appears to be similar to spores in that they are clustered 
inside round cells (Byersdorfer & Chaplin 2001). It has been suggested that 
dendritic cells alternate their shape between dendritic and round, which 
correlates with their antigen capturing and antigen internalising roles 
respectively (Handley et al. 2005). Macrophages are also round when they are 
phagocytosing so the cells seen to internalise the autoclaved spores could be 
DCs and macrophages, which would be consistent with the flow cytometric 
analysis. It has been shown that macrophages in vitro can interact with latex 
beads and positively and negatively charged beads, which suggests that the 
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interactions are not due to electrostatic interactions (Seyrantepe et al. 2010). 
This could have been a possibility since Bacillus spores have been shown to be 
hydrophobic (McKenney et al. 2013) and proteins can be bound to the surface 
of spores using electrostatic and hydrophobic interactions (Song et al. 2012). 
There are several other mechanisms by which macrophages can interact with 
particles as they have many different receptors on the cell surface and uptake 
mechanisms. Fcγ receptors are involved in recognising opsonised particles 
(Seyrantepe et al. 2010), whereas scavenger receptors (SR) are another type of 
PRR of which there are several classes that can recognise different types of 
pathogen and there is also complement activated phagocytosis, where 
complement proteins deposited on bacteria act as opsonins (DeLoid et al. 
2009). DeLoid et al found that when SRs were blocked, uptake of beads was 
reduced, but uptake of S. aureus was not affected, so the uptake of different 
particles and pathogens is complex and variable (DeLoid et al. 2009). Further 
investigation into the interactions of live spores compared to autoclaved spores, 
using in vitro methods and blocking different pathways could be investigated. 
Microparticles are of interest in the adjuvant field and it has been demonstrated 
that particles of 1-10µM are preferentially taken up by macrophages and 
dendritic cells so therefore spores would the right size at 1µM for phagocytosis 
for these cells (Hafner et al. 2011).  
The mechanisms by which M cells and neutrophils phagocytose particles are 
different to macrophages and DCs and may explain why their ability to 
phagocytose autoclaved spores was poor in comparison to live spores. M cells 
use glycoconjugates to bind to microorganisms and have a variety of types that 
bind to a wide variety of different microbial peptides (Man et al. 2004). Because 
autoclaved spores will have damaged proteins on the surface, the 
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glycoconjugates may not bind as efficiently, leading to a reduction in uptake. 
TLR4 and α5β1 integrin was also found to be expressed more on M cells than 
other intestinal epithelial cells in the gut and when TLR4 and α5β1 integrin were 
blocked, uptake of Haemophilus influenzae was reduced (Tyrer et al. 2006). H. 
influenzae that was mutated to change the LPS structure showed a decrease in 
uptake, indicating that M cells are dependent on PAMPs for engulfing bacteria 
(Tyrer et al. 2006). Therefore the change in the surface of autoclaved spores 
may have altered their interactions with M cells. Neutrophils have opsonin 
dependent and independent mechanisms of uptake, similar to macrophages 
and dendritic cells and also have PRRs. In a study by Heinzelmann et al, the 
kinetics of uptake of fast growing S. aureus with slow growing K. pneumoniae 
was compared and uptake was found to be slower with K. pneumonia 
(Heinzelmann et al. 1999). So perhaps in the case of autoclaved B. subtilis, 
since they are inactive, the uptake by neutrophils may be decreased. There is 
also evidence that neutrophils recognise bacteria by sugar residues (Doolittle et 
al. 1983), therefore autoclaved spores that have damaged surface proteins and 
sugars, may be less well recognised and phagocytosed.  
4.4. Conclusions 
In this chapter, the distribution of spores in the lungs, gut and NALT after nasal, 
oral and sublingual immunisation using HU58 spores was investigated and it 
was found that nasal dosing distributes spores to all three tissues and that 
spores can cross epithelial barriers and enter the tissues. Live and autoclaved 
spores behaved similarly initially, but autoclaved spores were cleared faster 
from the lungs, and were at higher numbers in the gut, which is probably 
because they were unable to germinate. Further work could be carried out to 
directly compare adaptive immune responses stimulated by spores downstream 
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of nasal, oral and sublingual immunisation, similar to work by Cuburu et al, who 
used Ovalbumin (OVA) with cholera toxin adjuvant and saw that antibody 
responses were highest after sublingual and nasal dosing in comparison to oral 
(Cuburu et al. 2007). 
The types of cells involved with uptake also varied according to the dosing 
route, and by the tissue involved. After immunisation with live spores, all types 
of cells were involved in phagocytosis in the lungs, with DCs and neutrophils 
dominating, whereas in the gut, M cells and neutrophils harboured the most 
spores and in the NALT, M cells were dominant. After dosing with autoclaved 
spores, DCs and macrophages have the highest number of spores in the lungs, 
DCs in the gut and all cells in the NALT, albeit at very low levels.  
These results demonstrate that the spores enter the tissue and interact with 
cells that should lead to the generation of adaptive immune responses and may 
have implications for choosing which immunisation route to use with spores as 
a vaccine adjuvant. Whether the differences in the interactions between 
autoclaved spores with M cells, neutrophils, macrophages and DCs is due to 
surface changes or their lack of ability to germinate cannot be fully discerned in 
this project and further work could be done to look at the surface properties of 
autoclaved spores and their interactions with cells. 
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Chapter 5: Innate Immune Responses to Spores after Intranasal 
Dosing 
 
5.1. Introduction 
 
The innate immune response is becoming an increasingly important 
consideration in the development of mucosal vaccines because activation of 
innate immunity can directly influence the adaptive immune response (Neutra & 
Kozlowski 2006). Nasal dosing has been demonstrated to be able to elicit 
systemic immune responses that are comparable to injectable vaccines, as well 
as stimulating mucosal responses (Czerkinsky et al. 2011). This route therefore 
shows promise as a vaccination route since protection can be induced at the 
site of potential infection as well as generating circulating antibodies.  
BALB/c mice (n=30) were dosed intranasally with 2x109 HU58 spores and n=5 
mice were culled on days zero, one, two, three, four and seven. On each day, 
the numbers of NK cells, macrophages, DCs and neutrophils, as wells as TLR2 
and TLR4 expression were monitored in the lungs, gut, spleen and peripheral 
lymphoid tissues. Splenocytes and NALT tissue were incubated for 48h after 
removal and the supernatants used to measure cytokine production. Serum was 
also taken to measured complement activation.  
The cell populations examined were the professional phagocytes; neutrophils, 
macrophages, DCs and NK cells that directly kill infected cells.  Macrophages 
and DCs are particularly important because of their role as APCs, as they 
bridge the gap between the innate and adaptive immune responses. The 
primary role of neutrophils and NK cells is to eradicate pathogens (Dempsey et 
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al. 2003). NK cells also produce cytokines including IFNγ that stimulate other 
immune cells, such as macrophages (Welsh & Waggoner 2013). The 
information generated from the results from this chapter also implied how long it 
took for the spores to be cleared and the immune system to return to normal. 
The spores used in this chapter are inherently non-pathogenic, but if a large 
and protracted immune response were generated, this might generate 
inflammation and tissue damage, which would not be advantageous for a 
vaccine. The variations in cell numbers in the spleen provided information on 
whether nasal dosing of spores generated systemic immune responses and 
population changes in the lymphoid tissues provided evidence of activation of 
the adaptive immune response. 
TLRs are expressed on many cell types including DCs, macrophages, 
monocytes, B-cells, T-cells, Tregs and granulocytes among others (Dembic 
2000). TLR2 responds to ligands such as lipopeptides and peptidoglycan that 
are generally found on Gram-positive bacteria and TLR4 is activated by 
substances such as LPS, which are typical of Gram-negative bacteria 
(Christmas 2010). However, this classification is general and the ligands they 
are activated by are not strict for specific pathogen classes and depend on 
particular molecular interactions. For example, C. difficile has been shown to 
interact with TLR4 even though it is a Gram-positive organism because the 
surface layer proteins bind to TLR4 (Ryan et al. 2011) and MTB interacts with 
both TLR2 and TLR4 (Sánchez et al. 2010). Work by de Souza et al 
demonstrated that TLR2 knockout mice generated less antibody after dosing 
with B. subtilis spores carrying HIV antigens in comparison to wild-type mice (de 
Souza et al. 2014), therefore changes in TLR2 expression would be expected in 
response to administration of B. subtilis spores. However, there could be 
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ligands on spores that activate TLR4 as well as TLR2 because TLR2 and TLR4 
have both been shown to be activated by B. subtilis spores and germinating 
cells in vitro (Huang, La Ragione, et al. 2008). In this study the changes in TLR 
receptor expression on cells using flow cytometry was monitored to see whether 
stimulation was demonstrable in vivo. TLR activation is important because the 
interaction with PAMPs stimulates intracellular pathways that upregulate genes 
related to inflammation and activation of other immune cells. It has been 
demonstrated that TLR4 deficient mice were more susceptible and developed 
more severe disease to C. difficile (Ryan et al. 2011). Further to this, pre-
stimulation of TLR5 with purified Salmonella flagellin was able to provide 
protection against C. difficile infection (Jarchum et al. 2011).  
Cytokines and chemokines are effectors of the immune response and their 
production in the innate immune response is in part controlled by the TLR 
stimulation and downstream signalling to transcriptional activators of genes 
involved in cytokine production (Dempsey et al. 2003). A wide variety of 
cytokines and chemokines are involved in the innate immune response, and the 
ones monitored in the study were IL-6, IL-10, IL-12p70, IFNγ, TNFα and MCP-1 
(Table 5-1). The inflammatory cytokines; IL-6, IFNγ and TNFα are part of the 
innate and adaptive immune responses and activate macrophages (Murray & 
Wynn 2011). Inflammation induces migration of other immune cells to the 
infected area. IL-12p70 is the active heterodimer of IL-12 (Bette et al. 1994) and 
is produced by macrophages and DCs causing naïve T-cells to differentiate to 
Th1 cells and stimulate further production of IFNγ and TNFα (Kaiko et al. 2008). 
MCP-1 chemokine recruits monocytes, memory lymphocytes and NK cells to 
sites of inflammation and is primarily produced by monocytes and macrophages 
(Deshmane et al. 2009). IL-10 is important in anti-inflammatory responses and  
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Table 5-1. Summary table of a selection of immune cells and some of the cytokines they 
respond to and produce when activated. 
Cell type Activated by Produces 
Neutrophil TNF, IFNγ, IL-17 TNF 
NK cell IL-12, MCP-1 IFNγ 
M1 Macrophage TNF, IFNγ, MCP-1 TNF, IL-6, MCP-1 
M2 Macrophage IL-10, MCP-1 IL-10 
Dendritic cell MCP-1, IFNγ, IL-10 IL-12, IL-6, IL-33 
Epithelial cell IL-6 TNF, IL-6 
Th1 IL-6, IL-10, IL-12 TNF, IFNγ, IL-2 
Th2 IL-4, IL-33 IL-5, IL-10 
Tc IFNγ TNF, IFNγ 
Th17 IL-6 IL-17 
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enhances B-cell lifespans and is produced by M2 macrophages, Th2 cells and 
Tregs (Mauri & Bosma 2012). These cytokines were monitored over seven days 
and provided information about the functionality of the immune cells and the 
type of immune responses stimulated. 
Live spores were used in this experiment since the results from Chapter 4 
demonstrated that live spores had a more active role in uptake and interacted 
with a wider range of host immune cells than autoclaved spores. Also, in other 
studies, the adaptive immune responses have been ascertained to be higher 
with live rather than inactive spores (de Souza et al. 2014; Colenutt & Cutting 
2014). Therefore, using live spores should maximise the chances of detecting 
any changes in immune responses. 
5.1.1. Aims 
The primary aim of this chapter was to monitor the immune responses of mice 
after nasal dosing with spores. This provided information about how the spores 
acted as an immune-potentiator class of adjuvant, as well as a delivery vehicle 
when administered mucosally, which could affect the subsequent protective 
adaptive immune response. The second aim of monitoring the innate immune 
response was to explore their potential use for prophylaxis against certain 
infections, primarily respiratory diseases. This hypothesis is based on the work 
by Song et al that demonstrated that mice dosed with PY79 wild-type B. subtilis 
spores were able to provide protection against influenza infection (Song et al. 
2012). Following this experiment and monitoring the changes in immune cells, a 
time after dosing was chosen to infect the mice with multi-drug resistant MTB 
(MDR-TB) to determine whether as a therapy, autoclaved spores were able to 
reduce infection.  
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5.2. Results 
5.2.1. Changes in cell populations in the lungs 
The lungs are, predictably, the main site where spores were delivered following 
nasal dosing as discussed in Chapter 4, and it is here that we would expect to 
see the highest level of immunological activity. The NK cell population 
decreased during the seven day study period (Figure 5-1). The neutrophil 
population increased from day one to four, and declined at day seven. 
Neutrophils are vital in the acute phase of infections for bacterial clearance and 
their increase in numbers suggested that there was production of cytokines and 
chemokines that were attracting neutrophils to the site of infection. The 
decrease at day seven suggests that the spores had been mainly cleared from 
the lungs (Figure 5-1). The DCs increased steadily from day two to seven 
(Figure 5-1). DCs have an important role in phagocytosis and in presenting 
antigens to T-cells and it appeared that they were stimulated to proliferate or 
were attracted from other areas by the presence of spores. M1 macrophages 
showed a small increase at day four post-vaccination, and M2 macrophages 
show no change, suggesting that macrophages were not primarily involved with 
phagocytosis of spores in the lungs (Figure 5-1).  
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Figure 5-1. Populations of different cell types in the lungs of mice over seven days after 
intranasal dosing with HU58 spores (2x10
9
). BALB/c mice (n=6-9) were dosed intranasally 
with 2x10
9
 HU58 spores and culled on days 0, 1, 2, 3, 4 and 7. The lungs were homogenised as 
described in the methods (Section 2.21) cells were stained; NK cells (CD49b-PE), neutrophils 
(Ly6G-APC), DCs (CD11c-APC
+
, F4/80-PerCP
-
), M1 (CD11c-APC
+
, F4/80-PerCP
+
) and M2 
(CD11c-APC
-
, F4/80-PerCP
+
) macrophages. Median of the percentage of the population 
expressing each marker with interquartile range displayed. Left of the black dashed line 
indicates measured against left axis, right side corresponds to right axis. Mann-Whitney was 
used to compared each time point to day zero. Asterisks p=<0.05.   
 
 
 
 
 
 
 
 
Laura Sibley                                       Chapter 5: Innate Immune Responses to Spores after Intranasal Dosing 
197 
5.2.2. Changes in cell populations in the spleen 
The spleen is an indicator of the systemic immune response and is important 
because after immunisation, APCs move to the lymph nodes and spleen as well 
as secondary lymphoid organs to generate adaptive immune responses. The 
NK cells increased in general, up to day seven suggesting that they had been 
activated (Figure 5-2) and there was a small increase in neutrophils. NK cells 
have a role in the lymph nodes whereby they can stimulate DC maturation and 
affect T-cell differentiation. The DCs increased from day two to four and started 
decreasing at day seven (Figure 5-2). This suggests that they had been 
activated and could be stimulating an adaptive response. There was a small 
increase in M1 macrophages from day two to four so some inflammatory 
response appears to have been initiated here because M1 macrophages are 
characteristic of inflammation and produce inflammatory cytokines, and 
macrophages can also act as APCs to activate T-cells. Macrophages are 
generally tissue resident so the increase here could be due to differentiation of 
progenitor cells rather than migration. There was no observable change in the 
M2 macrophage population (Figure 5-2). 
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Figure 5-2. Populations of different cell types in the spleen of mice over seven days after 
intranasal dosing with HU58 spores (2x10
9
).  BALB/c mice (n=6) were dosed intranasally with 
2x10
9
 HU58 spores and culled on days 0, 1, 2, 3, 4 and 7. The spleens were homogenised as 
described in the methods (Section 2.20) cells were stained; NK cells (CD49b-PE), neutrophils 
(Ly6G-APC), DCs (CD11c-APC
+
, F4/80-PerCP
-
), M1 (CD11c-APC
+
, F4/80-PerCP
+
) and M2 
(CD11c-APC
-
, F4/80-PerCP
+
) macrophages. Median of the percentage of the population 
expressing each marker with interquartile range displayed. Left of the black dashed line 
indicates measured against left axis, right side corresponds to right axis. Mann-Whitney was 
used to compared each time point to day zero. Asterisks p=<0.05.   
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5.2.3. Changes in cell populations in the gut 
As discussed in Chapter 4, spores when delivered nasally disperse in the gut. 
There was a general decrease in NK cells in the gut, suggesting there was no 
pro-inflammatory response (Figure 5-3). In the neutrophil, DC and macrophage 
populations, there was an initial decrease, followed by an increase at day three 
(Figure 5-3). These results confirm those of Chapter 4, that these cells are all 
involved in the phagocytosis and removal of spores. The increase in APCs 
suggests that here as well as in the lungs, T-cell activation may take place and 
homing to the gut could occur. All three populations decrease by day seven so 
the response is short-lived and it appears that the spores are rapidly cleared 
from the gut. 
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Figure 5-3. Populations of different cell types and in the gut of mice over seven days after 
intranasal dosing with HU58 spores (2x10
9
).  BALB/c mice (n=6-9) were dosed intranasally 
with 2x10
9
 HU58 spores and culled on days 0, 1, 2, 3, 4 and 7. The gut was homogenised as 
described in the methods (Section 2.21) cells were stained; NK cells (CD49b-PE), neutrophils 
(Ly6G-APC), DCs (CD11c-APC
+
, F4/80-PerCP
-
), M1 (CD11c-APC
+
, F4/80-PerCP
+
) and M2 
(CD11c-APC
-
, F4/80-PerCP
+
) macrophages. Median of the percentage of the population 
expressing each marker with interquartile range displayed. Mann-Whitney was used to 
compared each time point to day zero. Asterisks p=<0.05.   
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5.2.4. Cell population changes in the peripheral lymph nodes 
After phagocytosis of the pathogens, DCs travel to lymph nodes to prime and 
activate T-cells and initiate the adaptive immune response. At days four and 
seven there was an increase in DCs, which could be an indication that the 
adaptive immune response was stimulated (Figure 5-4). There was a general 
increase in NK cells over the seven days, and NK cells could promote DC 
maturation and T-cell differentiation. Therefore, there appears to be some 
evidence that T-cell and B-cell activation could be occurring here. There is little 
change in neutrophil and M1 populations (Figure 5-4). Finally, there was a 
small increase in M2 macrophages at day two to four (Figure 5-4), where they 
could play a role in reducing inflammation.  
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Figure 5-4. Populations of different cell types in the lymph nodes of mice over seven 
days after intranasal dosing with HU58 spores (2x10
9
). BALB/c mice (n=6) were dosed 
intranasally with 2x10
9
 HU58 spores and culled on days 0, 1, 2, 3, 4 and 7. The peripheral 
lymph nodes were homogenised as described in the methods (Section 2.20) cells were stained; 
NK cells (CD49b-PE), neutrophils (Ly6G-APC), DCs (CD11c-APC
+
, F4/80-PerCP
-
), M1 (CD11c-
APC
+
, F4/80-PerCP
+
) and M2 (CD11c-APC
-
, F4/80-PerCP
+
) macrophages. Median of the 
percentage of the population expressing each marker with interquartile range displayed. Mann-
Whitney was used to compare each time point to day zero. Asterisks p=<0.05.   
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5.2.5. TLR expression  
Expression of TLR2 in the lungs increased from day one, peaked at day three 
and remained high for the duration of the experiment (Figure 5-6). TLR4 
expression was lower than TLR2 for the entire time course (Figure 5-6). In the 
spleen, both TLRs were at lower levels than in the lungs, but there was a small 
increase in TLR2 at day one (Figure 5-6). TLR expression was not expected to 
be high in the spleen because it is not the site of entry of the spores after nasal 
dosing. In the peripheral lymph nodes, TLR2 and TLR4 levels were both 
increased at day three, but TLR4 was higher. This may indicate that some 
bacteria had travelled to the lymph nodes, and may  have led to the increase in 
DCs seen at day four to seven (Figure 5-5). There was a peak in TLR2 
expression at day one in the gut, and TLR4 at day three. The levels decreased 
quickly and were not as high as in the gut in comparison to the lungs, which 
could suggest that bacteria already present in the gut were causing tolerance, 
even though there was a transient increase in neutrophil, macrophage and DC 
populations, these could have been activated by mechanisms other than TLRs.  
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Figure 5-5. Expression of TLR2 and TLR4 in cells from the lung, spleen, peripheral lymph 
nodes and gut from mice immunised nasally with 2x10
9
 HU58 spores. BALB/c mice (n=6) 
were dosed intranasally with 2x10
9
 HU58 spores and culled on days 0, 1, 2, 3, 4 and 7. The 
lungs, spleen, peripheral lymph nodes and gut were homogenised as described in the methods 
(Section 2.20 and 2.21) cells were stained; TLR2 (CD282-PE) (blue), TLR4 (CD284-APC) (red). 
Median of the percentage of the population expressing each marker with interquartile range 
displayed. Mann-Whitney was used to compare each time point to day zero. Asterisks p=<0.05.   
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5.2.6. Cytokine production in splenocyte supernatants 
 
Cytokines produced by isolated splenocytes give an indication of the effector 
functions of the systemic immune response. MCP-1 is a chemoattractant, which 
recruits immune cells to the organ that is infected/inflamed and is the first 
indicator of a systemic immune response in the spleen so this cytokine may be 
partly responsible for the influx of DCs and NK cells to the spleen (Figure 5-7). 
The proinflammatory cytokines IL-6, TNF and IFNγ increased at day seven. 
TNF and IFNγ production suggest that the Th1 response had been activated but 
there was a small increase in IFNγ and TNF before this at day two to three, 
which could be attributed to NK cells as they increased at this time (Figure 5-2). 
IL-10 also increased at day seven, which could counteract the proinflammatory 
cytokines and minimise tissue damage. Although the numbers of DCs increased 
in the spleen, IL-12p70 did not increase, which would be expected because IL-
12p70 is characteristically produced by activated DCs to stimulate differentiation 
of naïve T-cells to Th1 cells. 
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Figure 5-6. Cytokine production from splenocytes isolated from mice immunised with 
2x10
9
 HU58 spores. BALB/c mice (n=5) were dosed intranasally with 2x10
9
 HU58 spores and 
culled on days 0, 1, 2, 3, 4 and 7. Splenocytes were isolated and 5x10
5
 cells were cultured for 
48h at 37°C and supernatants collected to measure cytokines using the cytokine bead array on 
the flow cytometer. Data shown shows the median pg/ml and interquartile range. Left of the 
black dashed line indicates measured against left axis, right side corresponds to right axis. 
Mann-Whitney was used to compare each time point to day zero. Asterisks p=<0.05.   
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5.2.7. Cytokine production in the NALT 
Measuring cytokine production in the NALT is way of measuring the immune 
responses in the nasopharynx, which is where the aim is to generate protective 
immune responses. IL-6 is a proinflammatory cytokine associated with infection 
and tissue damage. The levels of this cytokine are high throughout the time 
course, which suggested that this cytokine was produced due to the tissue 
damage incurred when removing the NALT (Figure 5-8). MCP-1 increased at 
day one, but remained above baseline levels until day four and this 
chemoattractant protein may play a role in attracting immune cells including 
DCs, macrophages and NK cells to the area. The characteristic Th1 cytokines 
TNF and IFNγ increased at day one and day four. TNF and IFNγ were both 
produced by NK cells, macrophages and Th1 cells suggesting a localised 
proinflammatory reaction. There was also a decrease in these cytokines at day 
seven, so T-cells may not be activated in the NALT, but could indicate that 
activated cells have migrated from the NALT.  
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Figure 5-7. Cytokine production from NALT tissue isolated from mice immunised with 
2x10
9
 HU58 spores. BALB/c mice (n=5) were dosed intranasally with 2x10
9
 HU58 spores and 
culled on days 0, 1, 2, 3, 4 and 7..NALT tissue was cultured for 48h at 37°C and supernatants 
collected to measure cytokines using the cytokine bead array on the flow cytometer. Data 
shown shows the median pg/ml and interquartile range. Left of the black dashed line indicates 
measured against left axis, right side corresponds to right axis. Mann-Whitney was used to 
compare each time point to day zero. Asterisks p=<0.05.   
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5.2.8. Complement killing assay 
On each day after intranasal dosing with 2x109 HU58 spores, serum was taken 
from terminal heart bleeds. Serum from two mice from each time point used in a 
complement killing assay, where sera was incubated with spores and after 90 
min was plated out onto agar. Viable count was used to calculate percentage 
viability from a control sample that had no sera and therefore no complement 
mediated death. From the viable count results, complement in the sera 
appeared to be activated at day one and two (Figure 5-10). The assay needs 
repeating with more samples for serious conclusions to be drawn from the data. 
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Figure 5-8. Percentage of dead spores when spores were incubated with serum from two 
mice dosed with HU58 spores (2x10
9
) intranasally as measured using viable count. 
BALB/c mice were immunised intranasally with 2x10
9
 HU8 spores and n=5 were culled on days 
0, 1, 2, 3, 4 and 7 and serum taken by terminal heart bleeds. 1x10
6
 spores were incubated with 
20µl of sera from mice from each time point and incubated at 37°C for 90 min. Spores were 
then serially diluted and plated out onto DSM agar plates and incubated at 37°C overnight and 
the viable count calculated. % of dead spores was calculated by number of colonies in sample 
with sera/number of colonies in sample without sera x 100. Dashed line indicates the baseline 
level of complement activation in naïve mice (Day 0).  
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5.2.10. Challenge with MDR-TB 
BALB/c mice (n=10) were challenged with MDR-TB three days after nasal 
administration of autoclaved HU58 spores because an increase in DCs and 
neutrophils were seen in the lungs in the previous experiment (Figure 5-1). The 
work was carried out by Gil Reynolds Diogo and Dr Rajko Reljic at SGUL, who 
also tested the IL-4D2 cytokine, and IL-4D2 with HU58 spores together. After 
challenge, the mice were given three further doses over the course of seven 
days, and four weeks after treatment, the mice were culled and the lungs plated 
out on 7H11 agar plates to examine bacterial burden (Figure 5-9). The results 
showed that autoclaved HU58 spores alone had little effect on bacterial burden 
in comparison to PBS (Figure 5-10).  
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Figure 5-9. CFU of MDR-TB in the lungs of mice treated three days prior to infection and 7 
days post-infection with either 2x10
9
 autoclaved HU58 spores, IL-4D2 or both agents. 
BALB/c mice (n=10/group) were dosed intranasally with either 2x10
9
 autoclaved HU58 spores, 
IL-4D2 or both agents. Three days later, they were challenged with MDR-TB (5x10
5
 CFU) and 
received four further doses of 2x10
9
 autoclaved HU58 spores, IL-4D2 or both agents. Four 
weeks following infection, the mice were culled and the lungs were homogenised and plated out 
onto 7H11 agar plates and incubated at 37°C for 8 weeks to examine bacterial burden. ANOVA 
used to compare groups. Those mice that had no recoverable MTB were removed from analysis 
because they may not have been successfully challenged with MTB. 
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5.3. Discussion 
Generation of an innate immune response has been shown to be important in 
vaccine development. Vaccine adjuvants that work as immune-potentiators, 
such as attenuated pathogens or killed pathogens, that activate the immune 
response via TLR activation, have been shown to be effective adjuvants. Some 
vaccines have TLR agonists added to improve their performance. For example, 
Monophosphoryl Lipid A (MPL), which is a TLR4 agonist has been included in 
Human Papillomavirus (HPV) vaccines that also contain Alum and has 
improved vaccine immunogenicity (‘Cervarix’) (Rappuoli et al. 2013).  
5.3.1. Responses in mucosal tissues 
In this study, TLR2 expression was increased in the lung, as this was the site of 
delivery of the spores following nasal dosing. The data implies that ligands on 
B. subtilis interact with TLR2 more dominantly than TLR4, which is in 
contradiction to the in vitro work by Huang et al that suggested that TLR2 and 
TLR4 were activated equally (Huang, La Ragione, et al. 2008). However, this 
could be due to the lung environment as there was some expression of TLR4 
detected in the lymph nodes and gut. In MTB infection, is has been shown that 
TLRs are important for protection, as MyD88, TLR2, TLR4 and TLR9 knock-out 
mice are far more susceptible to MTB infection, which is hypothesised to be due 
to a deficiency in stimulation of macrophage effector mechanisms (Korbel et al. 
2008). Therefore, stimulating proliferation of TLR2 expressing cells could be an 
advantage against pathogens including MTB.  
The main populations that altered in the lungs were neutrophils and DCs. DCs 
phagocytosed live HU58 spores in the lungs and this data agrees with that from 
Shreton-Rama et al that demonstrated phagocytosis of B. anthracis spores by 
DCs (Shetron-Rama et al. 2010), therefore there may be a common element 
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between these Bacillus species that stimulates uptake by DCs. In relation to TB, 
the innate immune response is important for controlling disease and formation 
of the granuloma. MTB is phagocytosed by macrophages and DCs, DCs 
produce IL-12, which stimulate NK cells and Th1 cells to produce IFNγ which 
activates the phagocytic activity of macrophages (Andersen & Woodworth 
2014). In this study, demonstrating phagocytosis of B. subtilis spores by DCs 
and proliferation of DCs in the lungs could imply that this is a relevant immune 
response that could protect against TB infection. DC stimulation and maturation 
also increases the presentation of antigens to T-cells; therefore spores carrying 
TB antigens should be able to generate memory cells.  
Neutrophils appear to be involved in clearing B. subtilis from the lungs and their 
decrease at day seven probably correlates with the complete clearance of 
spores. This hypothesis is supported by work from Jenkins et al, who compared 
the persistence of B. subtilis and B. anthracis after inhalation, to discover 
whether the persistence of B. anthracis for weeks/months was due to the spore 
in general, or something specific to B. anthracis. They found that B. subtilis 
spores did not persist and could not be detected in tissues after two weeks and 
hypothesised that some component of the exosporium of B. anthracis was 
responsible for its persistence (Jenkins & Xu 2013). Therefore it was expected 
that B. subtilis spores would be cleared as implied here. Neutrophils have been 
implicated in the killing of B. anthracis because it is hypothesised that 
cutaneous B. anthracis infection is less lethal than inhalation or ingestion 
because more neutrophils are present in the skin than in the lung and gut 
(Mayer-Scholl et al. 2005). In the lungs, neutrophils have been demonstrated to 
be recruited after B. anthracis infection and that IL-17 knock-out mice, were 
more susceptible to infection because IL-17 recruits neutrophils (Garraud et al. 
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2012). Anthrax toxins however reduce recruitment and neutrophil priming 
(Wright 1986) so once B. anthracis has germinated it can evade killing by 
neutrophils. Therefore, it is unsurprising that B. subtilis spores induce neutrophil 
recruitment because they are related to B. anthracis, but as they are non-
pathogenic and do not produce toxins; the neutrophils persist until the spores 
are removed. An explanation for the decrease seen of NK cells could be that 
neutrophils are thought to interact with NK cells to inhibit their proliferation but 
promote their cytotoxic activity and therefore the increase in neutrophils may 
have inhibited NK cells (Costantini & Cassatella 2011).  
In the case of TB, DCs that acquire antigens via phagocytosis of infected 
neutrophils are considered to be more effective at activating T-cells in 
comparison to those that phagocytose MTB directly. Neutrophils are known to 
enhance DC maturation (Alemán et al. 2007) and therefore are able to 
modulate DCs and ultimately antigen presentation. It has been demonstrated 
that neutrophils increase first in the lungs after MTB infection, followed by 
migration of DC to the lungs (Blomgran & Ernst 2011).  
There was no change in the macrophage populations in the lungs in this 
experiment (Figure 5-1), which was not expected and conflicts with information 
on B. anthracis where B. anthracis spores survive and germinate in 
macrophages (Guidi-Rontani 2002) as well as in vitro data demonstrating B. 
subtilis germination inside macrophages (Duc et al. 2004). There are four 
possible reasons for this; i) that lung macrophages are not the primary 
phagocyte in the lung that engulf B. subtilis spores and infers a difference 
between B. subtilis and B. anthracis, especially as B. subtilis is thought to be a 
gut resident rather than lung (Huynh A Hong et al. 2009) whereas B. anthracis 
can cause infection here ii) the number of macrophages was low in the lungs 
Laura Sibley                                       Chapter 5: Innate Immune Responses to Spores after Intranasal Dosing 
216 
and because macrophages are predominately tissue resident and an influx from 
the bloodstream is less likely, iii) Kirby et al suggested that macrophages 
undergo apoptosis after phagocytosis so the numbers may not significantly 
change until later on (Kirby et al. 2006) or, iv) Kirby et al also suggested that 
pulmonary DCs and alveolar macrophages were compartmentalised differently 
(Kirby et al. 2006) and therefore BAL washes could have provided more 
information about macrophage activity. Macrophages are important in the 
chronic phase of infection and clearing debris (Silva 2009) so they may be 
increased after seven days and so monitoring the responses for longer could be 
useful to garner more information about the macrophage involvement. 
Measurements of macrophage activity (cytokines, reactive oxygen species 
(ROS) (Mosser & Zhang 2008)) may also be relevant to measure in future 
experiments because the numbers of macrophages may not alter but their 
activation status could.  
In Chapter 4, spores were revealed to be able to cross the gut epithelium when 
dosed nasally. The neutrophils, macrophages and DCs, all show a transient 
increase at day three after dosing. In Chapter 4, all of these cell types were 
shown to phagocytose spores, consequently it correlates that there is an effect 
on the levels of these cells over time; although the increase was three days 
after dosing (Figure 5-3). There were also increases in the TLR2 and TLR4 
expression in the gut, but they were both low level and short-lived in 
comparison to the lungs (Figure 5-6). The transient increase in cell populations 
and low TLR expression could represent that the gut is more likely to be tolerant 
of antigens in comparison to the lungs because of the high number of 
commensal bacteria present (Barnes & Powrie 2009). The alternative 
explanation is that the activated cells migrated to local lymph nodes. In practice, 
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oral dosing would be used to target the gut, and would use a higher dose than 
used in this experiment, and therefore may overcome any issues of tolerance. 
This was demonstrated by Permpoonpattana et al who used 5x1010 spores 
delivered orally and observed protection against C. difficile infection 
(Permpoonpattana et al. 2011).     
5.3.2. Responses in lymphoid tissues 
The importance of looking at the immune responses in the lymphoid tissues of 
the peripheral lymph nodes (thymus, axillary and inguinal), NALT and spleen is 
because this is where T-cell and B-cell maturation occurs. DCs in the lymph 
nodes present the antigen to naïve T-cells so that they differentiate and 
proliferate and become Th cells, which can then leave the lymph nodes and 
travel to other tissues. T-cells can also differentiate into T follicular helper cells 
(Tfh) that interact with B-cells to stimulate antibody production.  
Cytokine production in the NALT tissue was used to monitor lymphoid activity in 
the mucosal immune system. The secretion of MCP-1 may be from 
macrophages and monocytes in the tissue and attracted other immune cells to 
the tissue. The increase in the pro-inflammatory cytokines IFNγ and TNF at day 
one and four (Figure 8) could be attributed to NK cells, neutrophils or 
macrophages because due to the timing of production they are unlikely to be 
produced by Th1 cells. Observation of immune responses in the NALT was 
found to be  as previous work has shown that inducing immune responses in 
the NALT can lead to protection against infection, for example against influenza 
(Matsuo et al. 2000). Therefore, to use spores as a mucosal vaccine, it is 
important to induce responses in the NALT that can activate mucosal immunity. 
Previous research by Glomski et al demonstrated the NALT as a site of entry of 
B. anthracis when aerosolised (Glomski et al. 2007) so there could be some 
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common component between these Bacillus species that interact with the NALT 
M cells. 
The spleen is a lymphoid tissue that is able to filter blood and remove bacteria 
from circulation and contains large numbers of lymphocytes (Mebius & Kraal 
2005). Overall, there was an increase in NK cells, DCs and a small increase in 
neutrophils and M1 macrophages, indicating that a systemic immune response 
had been mounted (Figure 5-2). NK cells have been demonstrated to be able to 
interact with DCs by the production of IFNγ (Bajénoff et al. 2006), which can 
stimulate DC maturation and also influence T-cell differentiation. Therefore, the 
increase in NK cells (Figure 5-2) in the spleen could be due to an influx from 
the bloodstream, attracted by the increase in MCP-1 (Figure 5-7) where they 
can then interact with DCs. MCP-1, which could be produced by monocytes and 
be responsible for the increase in DCs as well as NK cells. The presence of pro-
inflammatory cytokines IL-6, IFNγ and TNF all increased at day seven after 
dosing with spores, suggests differentiation of naïve T-cells to Th1 cells. 
However, the anti-inflammatory cytokine IL-10 also increased at day seven, 
which could have been produced to counteract the pro-inflammatory cytokines 
and so prevent inflammation and potential damage by Th2 or Tregs. MCP-1 
also has an effect on the polarisation of naïve T-cells to Th2 cells and secretion 
of IL-4 (Deshmane et al. 2009) and therefore may support evidence that an 
adaptive immune response has been stimulated and indicate that a Th2 
response had been mounted. In a study by Qu et al, B. subtilis spores carrying 
C. sinensis antigens were dosed orally to mice, and IL-6, IFNγ, IL-10 and TNF 
levels were also measured and found to be elevated in splenocyte supernatants 
and so, regardless of mucosal immunisation route these could be the set of 
cytokines that are stimulated by spores (Qu et al. 2014). There was a lack of IL-
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12p70 produced, which is typically produced by DCs to stimulate naïve T-cells 
to differentiate to Th1 cells. Because there was an increase in DCs, it would be 
expected that there would be an increase in IL-12p70 as it is produced by DCs, 
and data from de Souza et al demonstrated production of IL-12 from bone 
marrow derived DCs in vitro after incubation with B. subtilis spores (de Souza et 
al. 2014). One reason why there was a lack of IL-12p70 production could be 
because DCs require co-stimulation with IFNγ from T-cells to produce IL-12, so 
that DCs activate T-cells, which in turn signal to DCs to produce IL-12 (Lenz et 
al. 2001). Therefore, if the time course of the experiment were increased and T-
cells were activated, as we hypothesise by the increase in IFNγ and TNF at day 
seven, an increase in IL-12p70 may follow. A second hypothesis could be a 
problem with the assay (e.g. not adding the IL-12p70 beads), but the IL-12p70 
standard curve was present so this is unlikely. A third reason is that MCP-1 has 
been demonstrated to inhibit IL-12 (Deshmane et al. 2009) and there is 
production of MCP-1 in the spleen. The final hypothesis is that there are 
different types of effector DCs that can produce a wide variety of cytokines. 
Some DCs produce IL-6 that can stimulate Th17 cells, which are antimicrobial 
and produce cytokines that can attract neutrophils (Perona-Wright et al. 2009). 
Other DCs are able to produce IL-33, which activates differentiation to Th2 cells 
(Rank et al. 2009). The increase in IL-6 observed in the splenocyte 
supernatants therefore could be attributed to DCs inducing anti-bacterial 
mechanisms to clear spores by activating Th17 cells. Support for this theory 
comes from Qu et al, who demonstrated that IL-17 was produced in response to 
oral immunisation with spores carrying antigens for C. sinensis (Qu et al. 2014). 
From this set of cytokine data from the spleen, the type of Th response cannot 
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be definitively proven and further work to characterise the T-cell phenotypes 
should be carried out.  
There was an increase in TLR2 and TLR4 expression in the lymph nodes at day 
three following intranasal dosing with spores, which was interesting because it 
was prior to an increase in DCs suggesting that spores migrated to the 
peripheral lymph nodes and were able to activate DCs, which could later 
influence T-cell development. The increase in DCs could also be DCs that have 
travelled from the lungs and gut. Changes in the populations of DCs and NK 
cells in the lymph nodes was evidence that the spores were having an impact 
here, and the NK cells could be influencing the DCs, as similarly described in 
the spleen, which would then lead to initiation of the adaptive immune response.  
To further investigate the link between the innate and adaptive immune 
responses, the events in the lymphoid tissue could be examined further. 
Immunohistochemistry of the lymph nodes could provide information about the 
germinal centre reaction and show interactions between the spores and DCs, T-
cells and B-cells in different regions in the lymph nodes, as described by Moon 
et al who examined delivery of nanoparticles carrying malaria antigens (Moon et 
al. 2012). The data as it stands could be interpreted to support that naïve T-
cells could be differentiated to; Th1, Th2 or Th17 cells, and so more work could 
be done to elucidate the types of T-cells that were stimulated using 
immunophenotyping and measuring more cytokines.  
5.3.3. Responses in the blood 
Complement is an important innate mechanism for removing pathogens from 
circulation by either opsonisation or lysis. In this study, bacterial killing after 
addition of sera from immunised mice was used as an indicator of complement 
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activation. The highest numbers of bacteria were killed using sera from mice 
one day after dosing with spores and that serum from after day two or three, the 
effect had reduced. This data confirmed the cytokine and cell population data 
from the spleen that a systemic immune response had been activated following 
intranasal dosing. There is evidence that B. anthracis binds C3 complement 
protein and that phagocytosis is dependent on complement binding (Gu et al. 
2012). The complement killing assay infers that complement is able to bind and 
kill B. subtilis spores and may also aid phagocytosis.  
5.3.4. Spores as an immunotherapeutic 
After nasal dosing with autoclaved HU58 spores, mice were challenged with 
MDR-TB and given further HU58 doses but succumbed to infection (Figure 5-
11). Higher levels of the IL-4 antagonist, IL-4D2 have been seen in individuals 
that are infected but are controlling the TB disease in comparison to those with 
active TB, and is associated with promotion of Th1 responses and suppression 
of Th2 responses (Demissie et al. 2004). It is hypothesised that MTB stimulates 
IL-4 production which increases the M2 phenotype of macrophages that 
enhances uptake of MTB by increasing expression of the mannose binding 
receptor and also decreases the oxidative burst inside macrophages to 
enhance MTB survival (Buccheri et al. 2007). Therefore, by increasing the 
levels of IL-4D2, the disease control could be improved which is why Dr Rajko 
Reljic and Gil Reynolds Diogo were interested in testing IL-D42 as a therapeutic 
against MTB infection. Dr Rajko Reljic has also previously investigated blocking 
IL-4 activity using anti-IL-4 antibodies and demonstrated a reduction in bacterial 
burden (Buccheri et al. 2007). There appeared to be no difference in bacterial 
burden between different treatment groups. As demonstrated in Chapter 4, the 
interactions with host cells differ between live and autoclaved spores and 
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therefore the innate immune responses may also be different. Colenutt et al 
compared live and autoclaved spores as a therapeutic against C. difficile when 
delivered orally and found that live spores provided greater protection (Colenutt 
& Cutting 2014). Therefore autoclaved spores may be less useful therapeutic 
agents and live spores may perform better against MTB, and this should be 
investigated in future work. To improve the spores as a treatment for TB, 
perhaps substances could be added to the preparations that stimulate 
macrophage activity, for example IFNγ, as macrophages are essential for MTB 
killing. Immunotherapy for TB is important because of the increasing numbers of 
people who are succumbing to MDR-TB (85,085 cases globally in 2012, in 
comparison to 11,988 in 2005 (WHO 2013)), even in patients that have not 
received drug treatment (Kumar 2012). Therefore, a therapy avoiding drugs 
would avoid the development of drug resistance altogether. There are two main 
post-exposure therapies in development for TB; RUTI which contains semi-
purified MTB fragments, and another that contains inactivated M. vaccae (Stop 
TB Partnership Working Vaccines New T B 2009). RUTI has been tested after a 
short course of antibiotics and has shown to induce Th1/Th2/Th3 responses, 
increase the number of CD8+ cells and enhance control of TB infection 
(Cardona 2006). Reducing the antibiotic therapy from nine months to one month 
has huge advantages for improving patient treatment compliance and reducing 
the development of MDR-TB.  
It has been shown that virus-like nanoparticles stimulated neutrophil migration 
to the lungs and an increase in TNFα and IL-6 in the spleen and were able to 
protect against influenza and S. pneumoniae challenge (Mathieu et al. 2013). 
TNFα and IL-6 cytokines and neutrophil migration to the lungs were observed in 
this study with administration of HU58 spores so perhaps spores could be used 
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for other respiratory pathogens where neutrophil and DC infiltration to the lungs 
could be protective, and so spores could be tested as a therapy/prevention 
against S. pneumoniae and B. anthracis infections. 
5.4. Conclusions 
In this chapter, B. subtilis spores dosed nasally were able to induce innate 
immune responses in both the mucosal and systemic immune compartments 
(Figure 5-13). This initiation of the innate immune response confirms that B. 
subtilis is an immune-potentiator, which has now been demonstrated when 
used mucosally and therefore this should increase the ability of the spores to 
generate adaptive immune responses. In the future, it would be interesting to 
test the level of protection that this innate immune response could deliver 
against different diseases. A more thorough analysis of the innate immune 
response consequences on the adaptive immune response could be conducted 
to examine generation of memory cells. Other experiments could study the 
bronchoalveloar lavage (BAL) to see immune cells including DCs, in the airways 
as demonstrated in other studies (Kalsdorf et al. 2009; Kirby et al. 2006) and 
more complex flow cytometry could be used to determine cell subsets. For 
example, CD11c is highly expressed on DCs, but is also weakly expressed on 
other cells including granulocytes and NK cells and so using other markers 
would be more specific (B D Pharmingen 2014). DC maturation markers such 
as MHC II, CD40 and CD86 could also be included.  
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Chapter 6: General Discussion 
 
6.1. B. subtilis spores as a vaccine against tuberculosis 
B. subtilis spores have previously been demonstrated to adsorb antigen on the 
spore surface (Song et al. 2012) and in this work, this was developed further by 
testing their capacity to carry more than one antigen. This attribute has 
implications for the design of multivalent spore-based vaccines by improving 
immunogenicity and versatility of this platform technology. Recombinant spores 
were also examined and a method for spore inactivation was tested; a method 
that is currently being further optimised in the Cutting laboratory for a C. difficile 
vaccine to be taken to a human clinical trial (CDVAX 2014). Spores carrying the 
TB antigens MPT64 and Ag85B-Acr were shown to elicit some Th1 immune 
responses when delivered nasally to mice, and demonstrated a reduction in 
bacterial burden when challenged with MTB in the lungs and spleen compared 
to PBS, which was equivalent to BCG. The limitations of this study are that only 
two animals were used for the immunogenicity studies, and that no MTB was 
recoverable from some animals, so although the results suggest that spores 
were able to elicit Th1 responses and showed a reduction in bacterial burden, 
strong conclusions cannot be drawn.  
The main model for initial testing of the immunogenicity of novel TB vaccines is 
to use the mouse model, and therefore this study sits alongside other studies 
that have explored nanoparticle and DNA TB vaccines (Stylianou et al. 2013, J. 
Vipond et al. 2006). Due to the lead candidate TB vaccine, MVA85A showing no 
significant benefit in recent clinical trials (Tameris et al. 2013), this highlights 
that research into novel TB vaccines is still required. Spores show potential as a 
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TB vaccine adjuvant because they are heat stable, easily transportable, safe 
and relatively cheap to manufacture. TB is a disease that is most prevalent in 
developing countries therefore a cost effective vaccine with no cold chain is 
essential.  
6.2. Distribution of spores in the lung, gut and NALT after nasal, 
sublingual and oral dosing 
Nasal, sublingual and oral are the main routes under investigation for 
administration of mucosal vaccines and they were compared in this thesis to 
understand how the route affected the distribution of spores. The method for 
identifying spores inside tissues and cells using the flow cytometer was 
optimised and could provide a useful tool in the future for exploring spore 
interactions with host cells and antigen delivery. Characterising spore 
development using the flow cytometer has also proved informative and is being 
used by other lab members to characterise germination of C. difficile and 
comparing the physiological states of B. subtilis.  
Nasal and oral dosing distributed the spores to the lung, gut and NALT, but the 
nasal route delivered the highest proportion of spores, most probably because 
the spores were aerosolised. It proved difficult to identify where spores were 
dispersed after sublingual dosing, and this will require further investigation by 
examining other tissues. The distribution of spores is important because it 
proves that spores can cross epithelial barriers, and implies that spores will be 
able to generate immune responses, especially as it is known that the strongest 
immune responses are generated at the site of administration (Holmgren & 
Czerkinsky 2005). The NALT is a prime inductive site for the MALT and it is 
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important that spores can infiltrate the NALT where they can promote immune 
responses against respiratory pathogens.  
The alternative method for examining dissemination of bacteria to different 
tissues is to use viable count from homogenised tissue and this could be used 
to validate the results of the spores distribution is tissues, but could not be used 
to examine autoclaved spores. Hoa et al used viable count to observe 
dissemination of B. subtilis after oral dosing and detected spores in the lungs, 
spleen, mesenteric lymph nodes as well as the gut (Hoa et al. 2001). Viable 
counting is a traditional method for quantifying bacteria, but there are problems 
associated with reliability and contamination from other bacteria, especially as 
tissues are not sterile and therefore flow cytometry is a more sensitive method 
because the bacteria of interest are specifically stained using antibodies. The 
other method that is becoming more popular for investigating dissemination of 
pathogens is whole body imaging, where the infectious agent is tagged with 
luciferase which can be detected through the tissue, and the development of the 
infection can be observed. The major advantage of this method is that it is non-
invasive and the whole time course of infection can be observed. However, 
individual bacteria cannot be detected so infection has to be established to be 
visible and for non-pathogenic bacteria such as B. subtilis it is probably 
unsuitable because these bacteria are expected to be cleared and not establish 
themselves in the host. An interesting study could be to use in vivo imaging of 
an infection after vaccination or treatment with spores to see whether the 
disease development was different to unvaccinated animals. 
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6.3. Cell interactions with spores in different tissues after nasal, 
sublingual and oral dosing 
Neutrophils, dendritic cells, macrophages, along with epithelial M cells were 
investigated for their ability to phagocytose spores after nasal, oral and 
sublingual administration in the lungs, gut and NALT. This provided information 
on i) how the spores were cleared from the system, ii) the cells that were likely 
to induce immune responses and iii) the differences in the partiality of particular 
phagocytes depending on location. The lungs showed that neutrophils and DCs 
preferentially phagocytosed spores, whereas in the gut, M cells and neutrophils 
were dominant and the highest numbers of spores were observed in the M cells 
localised in the NALT. This information supports data from Rhee et al that 
revealed uptake of spores by M cells in the appendix of rabbits (Rhee et al. 
2004), but here the data demonstrated that M cells in the NALT also played a 
significant role in the uptake of spores. In vitro, data has shown that 
macrophages phagocytose spores, but in this research, they appeared to play a 
minor role in uptake, and DCs and neutrophils were more dominant, which 
agrees with data demonstrating that spores enhance DC maturation (de Souza 
et al. 2014) and the close relative of B. subtilis, B. anthracis, has also been 
shown to be phagocytosed by DCs (Shetron-Rama et al. 2010). These results 
were interesting because it revealed that certain cells favour phagocytosis of 
spores in different tissues, which could have downstream effects on the immune 
response. For example, in the gut, if a pathogen specifically targets M cells, 
such as Shigella, spores could be used as a therapeutic because the M cells 
and underlying immune cells would be primed and rendered able to clear the 
pathogen. Spores may be more readily adaptable for some diseases than 
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others, but due to their antigen carrying properties, they could be modified 
genetically or non-genetically to carry activators of other cell types.  
There are published studies that examine cellular interactions with bacteria in 
vitro, for example Trouillet et al examined the adhesion and invasion of S. 
aureus using flow cytometry intracellular staining (Trouillet et al. 2011). In vitro 
assays have the advantage of being more controllable and can offer useful 
information about individual interactions but cannot always be translated in vivo 
or provide details about relative contributions by certain populations. In vivo 
studies that have examined particle distribution using flow cytometry include 
those that demonstrated migration of DCs carrying OVA or latex beads from the 
lungs to the lymph nodes (Vermaelen 2000, Byersdorfer & Chaplin 2001). Work 
by Reljic et al identified DCs and macrophages in the lungs that had internalised 
BCG expressing GFP (Reljic et al. 2005) and a study by Geddes et al 
demonstrated Salmonella expressing red fluorescence could be observed 
inside CD4+, CD8+, B-cells, macrophages, monocytes, neutrophils and DCs in 
the spleen after injection (Geddes et al. 2007). Using intracellular staining of B. 
subtilis in more than one tissue is a novel application of this technology and has 
provided information about phagocytosis in three different tissues and two 
different physiological states of the spores.  
6.4. Cell interactions with live and autoclaved spores 
Spores, whether inactivated by autoclaving or by formaldehyde treatment could 
be a form used as a vaccine adjuvant since i) spores with antigen on the spore 
surface will lose the antigenic determinant when they germinate and, ii) if the 
spores are genetically modified they require inactivation for safety reasons. 
However, the differences in the interactions of live and inactivated spores with 
host cells could affect their immunogenicity. In this study, the initial distribution 
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of spores was similar after nasal and oral dosing, but the cells they interacted 
with were different. The denatured proteins on the autoclaved spores, as 
demonstrated by Western blotting, appear to prohibit spore interaction with 
neutrophils and M cells but they were still phagocytosed by antigen presenting 
cells; macrophages and DCs. Data from Huang et al  indicated that autoclaved 
spores could not activate TLRs in vitro (Huang, La Ragione, et al. 2008), which 
probably partially accounts for the lack of interaction with neutrophils and M 
cells, whereas DCs and macrophages, can phagocytose independently of 
antigen presence. Autoclaved spores were able to generate immune responses 
as shown in Chapter 3 but in the literature, inactivated spores were found to be 
less immunogenic than live spores (de Souza et al. 2014). Further to this, 
Colenutt et al found inactive spores to be less protective than live spores 
against C. difficile infection (Colenutt & Cutting 2014). Autoclaved spores could 
therefore be used as a vaccine adjuvant in the future as they are still processed 
by APCs and could present their antigens and stimulate adaptive immune 
responses, but live spores appear to be more immunogenic and interact with a 
wider array of immune cells. Future work could examine the interactions 
between cells and formaldehyde treated spores, and to also compare the 
downstream adaptive immune responses between live and inactivated spores 
after mucosal immunisation. If live spores are more immunogenic, other 
strategies could be utilised to prevent germination (e.g. using 
‘germinationSTOP’ technology (Mascher et al. 2012)) whilst maintaining the 
surface proteins for cell interactions.  
6.5. Innate immune responses after nasal dosing with spores 
The innate immune responses to spores after nasal dosing were investigated 
because there has been shown to be a link between activation of the innate 
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immune response affecting the adaptive immune response, which could have 
important implications for designing spore-based vaccines. There are also 
consequences for using the spores as a therapy for respiratory diseases as 
protection against influenza has been demonstrated a few days after dosing 
with nanoparticles (Mathieu et al. 2013) and with wild-type inactive B. subtilis 
spores (Song et al. 2012).  
Following nasal dosing of HU58 spores to mice, it was demonstrated that 
immune responses in the mucosal tissues (lungs, gut), lymphoid tissues 
(peripheral lymph nodes, NALT) and systemic compartments (spleen, serum 
complement activation) could be stimulated. DCs were found to be stimulated in 
all tissues measured, which is positive because DCs bridge the gap between 
the innate and adaptive immune systems. Neutrophils numbers increased in the 
lungs, which confirmed the results from Chapter 4 that discovered spores 
internalised by neutrophils. This finding could have consequences for 
enhancing antigen presentation because apoptotic neutrophils are 
phagocytosed by DCs and the antigens presented by DCs, as well as spore 
clearance to prevent pathogenic immune responses. NK cells increased in the 
secondary lymphoid tissues, and have a role in enhancing DC antigen 
presentation and T-cell differentiation. Therefore, the data implies that DCs are 
indeed stimulated to present antigens carried by spores to the lymphoid tissues 
to activate T-cells. Further work could be carried out to investigate the pattern of 
events in the lymphoid tissue, and correlate the involvement of DCs with 
numbers of T and B-cells and investigate how the adaptive immune responses 
could be enhanced.  
The innate immune responses to spores has been previously been examined in 
vivo by de Souza et al, but the major difference is that they investigated the 
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immune responses after injection rather than by mucosal dosing, and did not 
track the distribution of spores as described here (de Souza et al. 2014). The 
data from de Souza et al demonstrated that spores enhanced maturation of 
DCs (de Souza et al. 2014), which corresponds to the data generated in this 
work because mature DCs migrate to lymphoid tissue to deliver antigens Hill et 
al. 1990.  
After nasal dosing of autoclaved spores, mice were challenged with MDR-TB, 
and the mice still succumbed to infection indicating that the innate immune 
response initiated was either not strong enough or the relevant cells required to 
combat TB were not activated. However, it must be noted that autoclaved 
spores were examined in Chapter 4 and indicated that neutrophils were not 
activated, and numbers of DCs phagocytosing spores were lower so this should 
be repeated with live spores to see whether the outcome could be improved. 
Spores could be further investigated as a therapy against other respiratory 
pathogens, where neutrophils and DCs are known to be important. The 
implications of these results are that live spores delivered nasally were able to 
stimulate mucosal and systemic immune responses and thus are immune-
potentiators, and therefore as an adjuvant could enhance vaccines against 
respiratory pathogens.  
6.6. Final Remarks 
In conclusion, it has been demonstrated that spores can act as an immune-
potentiator when used as a mucosal vaccine and that their distribution and 
phagocytosis by certain cells depends on i) their dosing route, ii) the tissue and 
iii) whether the spores were live or autoclaved. Most previous work testing B. 
subtilis as a vaccine adjuvant delivered mucosally has focused on protection 
and adaptive immune responses; therefore this work adds to the field by 
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suggesting initial mechanisms and cell interactions that have implications for the 
downstream adaptive immune response. The spores have the potential to be a 
successful vaccine adjuvant and immunotherapeutic because of their safety 
profile and their ability to stimulate immune responses. The addition of different 
antigens or other components could be utilised to further enhance the 
immunogenicity or targeting towards specific tissues or pathogens. 
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Chapter 9 : Appendix 
 
Recipes: 
 
10x Tris-buffered saline 
(TBS) 
Tris 24.2g 
NaCl 84g 
pH7.6, 1L dH2O 
 
Acrylamide 
Acrylamide 30g 
Bis-Acrylamide 0.8g 
100ml dH2O 
 
 
Up to 10ml with dH2O 
 
Spore coat extraction buffer 
Tris-HCl 0.5M 0.1ml 
10% SDS 0.1ml 
dH2O 0.75ml 
1M DTT 0.5ml 
 
 
10x Running Buffer 
Tris 30g 
Glycine 142g 
SDS 5g 
1L dH2O 
 
Stacking gel buffer 
Tris-HCl 0.5M ph6.8  
 
 
Resolving gel buffer 
Tris-HCl 1.5M 
pH8.8 
 
 
 
10x Transfer buffer 
Tris 30.3g 
Glycine 144g 
1L dH2O 
5x Sample buffer 
Glycerol 1ml 
SDS 1g 
Tris-Hcl 0.5M pH6.8 6.5ml 
2-mercaptoethanol 2.5ml 
0.5% bromophenol 1ml 
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1x Transfer buffer 
10x Transfer buffer 100ml 
Methanol 200ml 
dH2O 700ml 
 
 
Stain 
R250 Coomassie 
blue 
1g 
Methanol 400ml 
Glacial acetic acid 100ml 
dH2O 500ml 
 
 
Destain 
Methanol 100ml 
Glacial acetic acid 100ml 
dH2O 800ml 
 
 
12% Resolving gel 
dH20 1.75ml 
Resolving gel buffer 1.25ml 
Acrylamide 2ml 
10% AMPS 25µl 
20% SDS 25µl 
TEMED 2.5µl 
 
 
Stacking gel 
dH2O 1.2ml 
Stacking gel buffer 0.5ml 
Acrylamide 0.3ml 
10% AMPS 10µl 
20% SDS 10µl 
TEMED 4µl 
 
TMB stock 
TMB 6mg/ml 
Dissolve in ethanol 
 
TMB 
dH2O 9ml 
Sodium acetate 
pH5.5 
1ml 
H2O2 2µl 
TMB stock 167µl 
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A1 binding buffer (AKTA) 
Sodium phosphate 20mM 
NaCl 0.5M 
Imidazole 10mM 
pH 7.4. dH2O 
 
A3 buffer (AKTA) 
NiSO4 100mM 
dH20 
 
B elution buffer (AKTA) 
Sodium phosphate 20mM 
NaCl 0.5M 
Imidazole 0.5M 
pH 7.4. dH2O 
 
Difco Sporulation Media 
(DSM) 
Oxoid Nutrient 
Broth 
8g 
KCl 1g 
MgSO4.7H20 0.25g 
NaOH 1N 0.7ml 
dH20 1L 
 
DSM Supplements (add after 
autoclaving) 
Ca(NO3) 1M 1ml/1L 
MnCl2 10mM 1ml/1L 
FeSO4 1mM 1ml/1L 
 
 
LB (Luria Bertani) media 
Oxoid Tryptone 10g 
Yeast extract 5g 
NaCl 10g 
NaOH 1N 0.7ml 
 
 
10% Neutral Buffered 
Formalin (NBF) 
37% formaldehyde 10% 
dH20 90% 
NaH2PO4 4g/L 
Na2HPO4 6.5g/L 
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10x Phosphate buffered 
saline (PBS) 
Na2HPO4 0.1M 800ml 
NaH2PO4 0.1M 200ml 
pH7.4  
NaCl 85g 
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Chapter 4 flow cytometry example gating plots 
Lungs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laura Sibley                                                                                                             Chapter 9: Appendix 
258 
Gut 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laura Sibley                                                                                                             Chapter 9: Appendix 
259 
NALT 
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Chapter 5 Flow cytometry example gating plots 
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Lymph nodes 
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Spleen 
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